

(A Component Unit of the State of Oregon)

Financial Statements and Supplementary Information; Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

Year Ended June 30, 2021

(With Independent Auditors' Report Thereon)

Year ended June 30, 2021

Table of Contents

	Page
Independent Auditors' Report	1–2
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards	3–4
Management Discussion and Analysis	5–30
Financial Statements:	
Statements of Net Position	31–32
Statements of Revenues, Expenses, and Changes in net Position	33
Statements of Cash Flows	34–35
Nongovernmental Discretely Presented Component Units – Consolidated Balance Sheets	36–37
Nongovernmental Discretely Presented Component Units – Consolidated Statements of Operations	38
Nongovernmental Discretely Presented Component Units – Consolidated Statements of Changes in Net Assets	39
Notes to Financial Statements	40–105
Required Supplementary Information (Unaudited)	106
Combining Schedules of Net Position, Year ended June 30, 2021 with comparative totals for June 30, 2020	107-108
Combining Schedules of Revenues, Expenses, and Changes in Net Position, Year ended June 30, 2021 and comparative totals for June 30, 2020	109
Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance	110–111
Schedule of Expenditures of Federal Awards	112–129
Notes to Schedule of Expenditures of Federal Awards	130–131
Schedule of Findings and Questioned Costs	132



KPMG LLP Suite 3800 1300 South West Fifth Avenue Portland, OR 97201

Independent Auditors' Report

The Board of Directors Oregon Health & Science University:

Report on the Financial Statements

We have audited the accompanying financial statements of the business-type activities and discretely presented component units of Oregon Health & Science University (OHSU), as of and for the years ended June 30, 2021 and 2020, and the related notes to the financial statements, which collectively comprise OHSU's basic financial statements for the years then ended as listed in the table of contents.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express opinions on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.

Opinions

In our opinion, the financial statements referred to above present fairly, in all material respects, the respective financial position of the business-type activities and the discretely presented component units of the Oregon Health & Science University as of June 30, 2021 and 2020 and the respective changes in its financial position and, where applicable, its cash flows thereof for the years then ended in accordance with U.S. generally accepted accounting principles.



Other Matters

Required Supplementary Information

U.S. generally accepted accounting principles require that the management's discussion and analysis on pages 5 through 30 and the supplementary pension information on page 106, be presented to supplement the basic financial statements. Such information, although not a part of the basic financial statements, is required by the Government Accounting Standards Board who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information, in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audit of the basic financial statements. We do not express an opinion or provide any assurance on the information because the limited procedures do not provide us with sufficient evidence to express an opinion or provide any assurance.

Supplementary and Other Information

Our audits were conducted for the purpose of forming opinions on the financial statements that collectively comprise OHSU's basic financial statements. The supplemental information included in schedules 1, 2, 3, 4, and 5 on pages 107 through 113 is presented for purposes of additional analysis and is not a required part of the basic financial statements. Such information has been subjected to the auditing procedures applied in the audit of the basic financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the basic financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary information included in schedules 1 through 5 is fairly stated, in all material respects, in relation to the basic financial statements as a whole.



Portland, Oregon October 29, 2021



KPMG LLP Suite 3800 1300 South West Fifth Avenue Portland, OR 97201

Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

Board of Directors Oregon Health & Science University:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the financial statements of the business-type activities and discretely presented component units of Oregon Health & Science University (OHSU), which comprise the Oregon Health & Science University statement of financial position and the Nongovernmental Discretely Presented Component Units combined balance sheet as of June 30, 2021, and the related Oregon Health & Science University statements of revenues, expenses, and changes in net position, and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated October 29, 2021.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered OHSU's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of OHSU's internal control. Accordingly, we do not express an opinion on the effectiveness of OHSU's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether OHSU's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of OHSU's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering OHSU's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.



Portland, Oregon October 29, 2021

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

Introduction

Oregon Health & Science University (OHSU or the University) is Oregon's only public health sciences university and major academic health center. It is a national leader in education of health professionals and scientists, advanced biomedical and healthcare research, leading edge patient care, and outreach. As part of its multifaceted public mission, OHSU strives for excellence in education, research and scholarship, clinical practice, and community service. Through its dynamic interdisciplinary environment, OHSU stimulates the spirit of inquiry, initiative, and collaboration among students, faculty, and staff.

The following discussion and analysis provides an overview of the financial activities of OHSU for the year ended June 30, 2021 and should be read in conjunction with the financial statements and related note disclosures. This discussion was prepared by management and is designed to focus on current activities, resulting changes, and current known facts with selective comparative information for the years ended June 30, 2020 and June 30, 2019.

Financial Highlights

The broadest measure of OHSU's financial strength is net position, which increased by \$493 million or 13.7% in fiscal year 2021, to \$4.1 billion, compared to a small decrease in net position of \$14 million in fiscal year 2020. Very strong investment returns of \$440 million, \$73 million in additional federal grants from the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), and increased recovery of operations from the initial impacts of Coronavirus or COVID-19, were partially offset by accrued pension expense.

Accrued pension expense in fiscal year 2021 and 2020 reflects cumulative 2018 and 2019 investment returns on pension assets that were less than assumed, generating actuarial investment losses in Oregon's Public Employees Retirement System (PERS) that covers certain OHSU employees. PERS results affect OHSU financial statements with a lag.

OHSU's debt service coverage ratio was 6.92 times maximum annual debt service in fiscal year 2021, up from 2.93 in fiscal year 2020. Unrestricted days cash on hand, post GASB 68, were 256 on June 30, 2021, which include \$130 million of Medicare Accelerated and Advance Payments and \$62 million of OHSU's share of deferred FICA payroll taxes that were part of the federal response to COVID-19. Excluding these one time cash receipts, days cash on hand were 233.

For management purposes, OHSU prepares internal financial statements using the single line "equity method" of reporting results of OHSU Foundation. This method follows the "Total University" column on the combining financial statements included at the end of these financial statements, with gifts recorded when transferred from the Foundation to the University for use and State appropriations included within operating revenues.

The State grant to the Knight Cancer Challenge, the recording then spending of large gifts, and accrued expenses for PERS pension have caused large swings in OHSU's revenues and expenses over the past several years. Management uses the analysis of adjusted operating income on the following table to track underlying performance on a consistent basis: revenue from the State grant and gifts to the Knight Cancer Challenge that funded the Knight Cancer Research Building are removed, and expenses for pension benefits are recorded on a cash basis, rather than an accrual basis, as they were prior to adoption of GASB 68.

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

On this basis, adjusted operating revenues increased by 8.1% and adjusted operating income recovered to a gain of \$72 million in fiscal year 2021, compared to revenue growth of only 4.2% and a loss of \$(28) million in fiscal year 2020. This pattern reflects recovery from deferral of non-urgent cases and other impacts to operations during the first months of COVID-19 in the spring of 2020. Increased complexity of cases, stable payer mix, strong pharmacy growth, and tight control of services and supplies also contributed to improved year-over-year performance. Nonoperating gains were much higher in fiscal year 2021 as well, from investment returns and CARES Act funding.

Analysis of Total University Column of Combining Statements of Revenues, Expense, and Changes in Net Position

Years Ended June 30, 2021, 2020 and 2019

(Dollars in thousands)

	 2021	2020	2019
Adjusted operating revenues before Knight Cancer Research Building funding	\$ 3,663,867	3,390,562	3,254,385
Salaries, benefits, services, and supplies, net of accrual adjustments for pension Depreciation, amortization, and interest	 3,379,530 211,878	3,205,607 213,273	2,859,985 217,921
Adjusted operating expenses	 3,591,408	3,418,880	3,077,906
Adjusted operating income (loss) Knight Cancer Research Building funding Accrual adjustments for pension benefits	 72,459 (67,092)	(28,318) (58,521)	176,479 30,393 (34,336)
Total University operating income (loss)	5,367	(86,839)	172,536
CARES Act funding Investment and other nonoperating income	 72,593 147,994	37,859 49,845	70,849
Total University net income	225,954	865	243,385
Contributions for capital and other Change in interest in the Foundations	 5,965 260,807	7,088 (21,810)	32,816 (24,293)
Total increase (decrease) in net position	\$ 492,726	(13,857)	251,908

Although risks from COVID-19 remain, management believes that OHSU has preserved its underlying financial position, providing a firm platform to build back to where revenues cover both operations and robust investment in people, programs and places on a sustainable basis.

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

COVID-19 Funding

Significant federal and state COVID-19 financial and liquidity support was provided to OHSU in the form of grants and loans in both fiscal year 2021 and 2020. The key programs included:

Medicare Advance Payment Program. In response to the COVID-19 public health emergency, the Centers for Medicare & Medicaid Services (CMS) expanded its Medicare Accelerated and Advance Payment Program (AAPP) to allow Medicare providers to receive advances on future Medicare reimbursement. OHSU received \$145 million in federal Medicare advances in fiscal year 2020. Medicare began recovering advance payments by offsetting claims for services starting in April 2021 and recovered \$15 million in fiscal year 2021. OHSU estimates the recoupment period will extend into 2022. The remaining \$130 million is recorded in the accompanying Statements of Net Position: \$118 million as Unearned/Medicare advance payment current liability and \$12 million as long-term liability.

CARES Act FICA Deferral. Under the CARES Act employers are allowed to defer the deposit and payment of the employer's share of Social Security taxes. OHSU deferred \$62 million of applicable payroll taxes from the date the Act was signed into law through June 30, 2021. The deferred amounts will be due in two equal installments on December 31, 2021 and December 31, 2022. The portion due December 31, 2021 of \$31 million is reflected on the Statements of Net Position as accrued salaries, wages and benefits current liability while the remaining is shown as long-term liability.

CARES Act Provider Relief Fund. Under the CARES Act, enacted in March 2020, the Provider Relief Fund payments are intended to provide financial support to healthcare providers who diagnose, test, or care for individuals with possible or actual cases of COVID-19, and have health care related expenses and lost revenues attributable to COVID-19. OHSU received \$109.9 million under the "General" and "Targeted" distributions. OHSU recognized as CARES Act grants under other nonoperating revenues \$72.6 million and \$37.3 million for fiscal years 2021 and 2020, respectively.

Higher Education Emergency Relief Fund (HEERF) Grants. OHSU was awarded funding from HEERF I, II and III grants for Postsecondary Education. Each grant has specific criteria defined as the use of funds and eligibility. The provided funding comes in the form of emergency financial aid grants for students (Student Portion) and supplemental grant funds for institutional costs (Institutional Portion) to defray expenses associated with coronavirus. As of fiscal year end June 30, 2021, OHSU has applied the Institutional Portion to cover lost tuition and fees incurred in spring term 2020. OHSU recognized as CARES Act grants under other nonoperating revenues \$1.1 million and \$0.5 million for fiscal years 2021 and 2020, respectively.

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

Results of Operations

The statements of revenues, expenses, and changes in net position present OHSU's results of operations, including the Foundation. In accordance with generally accepted accounting principles (GAAP) for a government entity, revenues and expenses are classified as either operating or nonoperating.

The programs and operations of the University and the Foundation are funded from a broad range of sources, some of which are classified as operating and others as nonoperating. Thus on the combined GAAP statements summarized below, management believes that the net income/(loss) before contributions for capital and other line, which includes both operating and nonoperating revenues, provides the most useful indicator of financial performance, for several reasons. First, State appropriations and federal CARES Act grants are reported as nonoperating revenues although they support operating expenses and lost operating revenues. Second, Foundation operating expenses include transfers to the University as well as fundraising and other costs that are funded in part by endowment investment income, also reported as nonoperating. Third, a large factor impacting defined-benefit pension expense on a GASB 68 accrual basis is prior-year investment returns in Oregon's PERS pension system, while other investment returns are reported on a current year basis within nonoperating revenues.

	 2021	202	20	\$ Change
Patient service revenue, net	\$ 2,595,048	2,37	75,275	219,773
Gifts, grants, and contracts	703,065	66	64,646	38,419
All other operating revenues	 308,161	2	73,200	34,961
Total operating revenues	 3,606,274	3,3	13,121	293,153
Salaries, wages, and benefits	2,166,014	2,04	41,677	124,337
Defined-benefit pension	113,695	1(09,907	3,788
All other operating expenses	 1,406,739	1,34	47,970	58,769
Total operating expenses	 3,686,448	3,49	99,554	186,894
Operating income	(80,174)	(18	36,433)	106,259
Other nonoperating revenues (expenses)	443,932	-	70,343	373,589
State appropriations	44,243	:	39,581	4,662
CARES Act Grants	 72,593		37,859	34,734
Net income/(loss) before				
contributions for capital and other	480,594	(3	38,650)	519,244
Other changes in net position	 12,132	2	24,793	(12,661)
Total change in net position	\$ 492,726	(*	13,857)	506,583

Condensed Statements of Revenues, Expenses, and Changes in Net Position


(Dollars in thousands)


(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

OHSU's consolidated operating income increased in fiscal year 2021 by \$106 million compared to fiscal year 2020. The resuming of essential services, non-urgent and elective procedures, resulted in revenues rising, offset in part by PERS pension impacts and additional expenses associated with pandemic management. While the CARES Act grants, reported as nonoperating revenue, provided additional relief, they did not close the gap fully. However, significant investment returns, endowment gains and philanthropy did, resulting in positive consolidated net income before contributions for capital and other of \$481 million in fiscal year 2021, an increase of \$519 million from the loss of \$(39) million recorded in fiscal year 2020.

Revenues Supporting Core Activities

OHSU's operating revenues for fiscal year 2021 total \$3.60 billion, an increase of 8.9% from fiscal year 2020 at \$3.31 billion. The increase was driven by patient service revenue, grants, gifts and contracts and pharmaceutical services.





(Dollars in millions)

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

Patient service revenue increases stemmed from complexity of cases and stable payer mix. The following table of admissions and surgeries by month for fiscal years 2021 and 2020, shows the initial impact of the pandemic in March and April 2020 followed by recovery since then. Demand for OHSU's tertiary and quaternary services remains strong, however capacity has been constrained by beds in double rooms not used due to COVID-19, nurse staffing shortages limiting some ICU, OR and procedural capacity, and an increase in behavioral health cases that has increased average length of stay.

	Admi	issions	Surgica	lCases
_	FY21	FY20	FY21	FY20
July	2,227	2,633	2,745	3,270
August	2,168	2,422	2,697	3,247
September	2,135	2,368	2,675	2,995
October	2,194	2,524	2,956	3,287
November	1,995	2,342	2,561	3,006
December	2,053	2,413	2,782	3,081
January	2,012	2,439	2,516	3,162
February	1,867	2,257	2,496	2,828
March	2,228	2,030	2,939	2,163
April	2,318	1,542	3,041	965
May	2,216	2,000	2,829	2,045
June	2,199	2,085	2,887	2,623
Total	25,612	27,055	33,124	32,672

Hospital Patient Volume Count Detail and Hospital and Clinics Surgical Cases

Grants, gifts, and contracts remained strong in fiscal year 2021 at \$703 million, compared to \$665 million in 2020, despite the restricted research environment due to modified operations as a result of COVID-19. The University continues to report consistent growth in federal government and industry grants, an indicator of the success of OHSU's research and other programs, along with steady increases in medical contracts over the last three fiscal years, reflecting partnerships that extend OHSU programs across the region.

Gifts are recorded at the OHSU Foundation when pledged, and at the University when transferred from the Foundations and applied to program expenditures. The receipt of large gifts pledged in one year, received in cash over time, then spent during subsequent periods, results in significant fluctuation in the gift component of OHSU revenues on a combined basis. Gifts from the Foundations continue to provide critical funding to faculty, programs, and academic initiatives.

The Bill and Melinda Gates Foundation provided two grants in fiscal year 2021 totaling \$14.2 million to support HIV and TB vaccine using the CMV (Cytomegalovirus) platform. Several gifts were made in support of the pandemic response in fiscal year 2020, including: a \$7 million joint donation by Nike leaders and spouses John and Eileen Donahoe, Mark and Kathy Parker, and Phil and Penny Knight, to accelerate statewide efforts to contain, diagnose and treat COVID-19; \$1.6 million from the Andrew and Corey Morris-Singer Foundation to

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020

(Dollars in thousands)

expand access to healthcare professionals through a new phone hotline and telemedicine services; and \$1.5 million from an Oregon couple moved by the heroic work of frontline clinicians and healthcare workers during the COVID-19 crisis.

		Fiscal year ending June 30			
		2021	2020	2019	
			(Dollars in thousands)		
University grants and contracts, direct portion University grants and contracts, indirect cost	\$	534,952	492,818	457,088	
recovery		105,887	102,882	97,974	
State grant to the Knight Cancer Challenge Foundation gifts, net of eliminations, transferred		—	—	8,332	
to the University	_	62,226	68,946	47,686	
Total gifts, grants, and contracts	\$_	703,065	664,646	611,080	

Student tuition and fees were \$83 million and \$77 million in fiscal year 2021 and 2020, respectively. Fiscal year 2021 marks the eighth year of the OHSU Tuition Promise. Under this initiative, students enrolled in eligible clinical degree programs pay a tuition rate that is fixed for the remainder of their studies, as long as they complete the degree within the normal timeframe specified by the program. In 2020, OHSU refunded \$2.4 million in tuition to students that were unable to participate in clinical rotations during spring term as a result of the COVID-19 pandemic.

Other revenue increased in fiscal year 2021 by \$29 million, or 15.1%, from fiscal year 2020 in part from increases in outpatient pharmaceutical sales. OHSU provides drug treatment to patients through normal retail sales, as well as a specialty pharmacy where patients are able to obtain specialty drugs delivered to their homes for complex conditions such as autoimmune diseases and organ transplants.

Investment income and gain in fair value of investments, reported in other nonoperating revenues (expenses), totaled \$440 million in fiscal year 2021 compared to \$83 million in fiscal year 2020, largely reflecting the financial market response to the COVID-19 pandemic and unprecedented levels of federal fiscal and monetary support.

Certain revenues relied upon and budgeted for in operational support of education and service programs of the University are required to be recorded as nonoperating revenues. For management purposes, OHSU measures operating results including state appropriations. State appropriations totaled \$44 million in fiscal year 2021 and \$40 million in 2020. State appropriations support education in the Schools of Nursing, Dentistry and Medicine, as well as operations of the Child Development and Rehabilitation Center, the Office of Rural Health, and the Poison Center. In fiscal year 2021, state appropriations includes a \$5 million match from the State of Oregon Employer Incentive Fund (EIF), a program introduced to match PERS pension employer side account deposits.

As noted previously, OHSU received \$108 million under the "General" and "Targeted" distributions of the CARES Act Provider Relief Fund. OHSU recognized as CARES Act grants under other nonoperating revenues

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)


\$73 million and \$38 million for fiscal years 2021 and 2020, respectively, which also includes the institution portion of the HEERF grants for Postsecondary Education.

Expenses Associated with Core Activities

\$179

\$1,195

OHSU's total operating expenses on a combined basis increased by \$187 million, or 5.3%, in fiscal year 2021, and \$367 million, or 11.7%, in fiscal year 2020. In fiscal year 2021, expense growth is related to salaries, wages, and benefits, defined-benefit pension expense, services, supplies and other.



Salaries, wages.

and benefits*

supplies, and

Depreciation and

amortization

Services,

other

Interest


2,279

\$177 _

\$1,135

\$37

\$2,151



* Salaries, wages, and benefits figures include OHSU's proportionate share of the Oregon PERS's net pension liability of \$114 million and \$110 million expensed in fiscal years 2021 and 2020, respectively.

Salaries, wages, and benefits (excluding the impact of defined-benefit pension expense) comprised approximately 58.8% of total expenses, increasing by \$124 million, or 6.1%, in 2021 and \$183 million, or 9.8%, in 2020, respectively. In fiscal year 2021, expenses reflects additional staffing required to maintain operations in a COVID-19 pandemic environment and in fiscal year 2020 reflects OHSU's commitment to maintaining a full workforce with pay and benefits in March through June 30, 2020, during which elective and non-urgent procedures were restricted in order to conserve and redirect personal protective equipment for Oregon's COVID-19 emergency response.

Salaries, wages,

and benefits*

supplies, and

amortization

Depreciation and

Services,

other

Interest

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

OHSU's proportionate share of the Oregon Public Employees Retirement System (PERS) defined-benefit pension expense increased in fiscal year 2021 and 2020 as a result of cumulative 2018 and 2019 asset returns that were less than assumed, generating actuarial investment losses. Partially offsetting are provisions from Senate Bill 1049 that re-amortized the unfunded actuarial liability over 22 years and limited certain annual salary benefits to \$195,000 (indexed) starting in fiscal year 2020.

Services, supplies, and other expenses increased \$60 million or 5.3% in fiscal year 2021 and \$151 million, or 15.4%, in 2020, representing the non-labor costs associated with program growth, spending on pharmaceuticals and medical supplies, along with new expenses required to operate in a COVID-19 pandemic environment, such as technology used to support telemedicine.

Fiscal year 2021 and 2020 also included integrated clinical operations support/(benefit) for Adventist Health Portland at \$(4.2) million and \$10 million, respectively, an affiliate since January 2018, and Tuality (Hillsboro Medical Center) at \$0 million and \$25 million, respectively, a partner since February 2016.

Depreciation and amortization represents the reduction in value of capital assets with the passage of time. In fiscal year 2021, depreciation and amortization increased by \$2 million, or 1.3%, compared to a decrease of \$(10) million, or 5.4%, in 2020. After a decrease in annual depreciation in fiscal 2020 due to the change in capital threshold in fiscal 2019, fiscal year 2021 saw a modest increase in depreciation. The increase reflects overall reduced capital and routine equipment expenditures related to the sharp reduction of capital activity in the last quarter of fiscal year 2020 as a result of COVID-19 which led to a slower resumption of capital activities in fiscal year 2021.

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

Interest expense decreased by \$3.7 million, or 10.0%, in fiscal year 2021. Interest expense in the prior fiscal year was elevated due to costs of issuance of \$2.7 million for the Series 2019 Bonds. These costs of issuance were considered as a one-time expense in the prior year. The remaining difference year over year is the result of scheduled repayment of principal, interest savings from refinancing, and other amortization.

Operating Expenses by Functional Classification

Ŷ	,		
	 2021	2020	2019
Instruction, research, and public service	\$ 565,922	541,954	507,049
Clinical activity	2,333,445	2,251,293	1,986,762
Auxiliary activities	6,528	8,220	7,498
Internal service centers	15,746	16,049	10,327
Student services	18,260	16,772	14,800
Academic support	108,619	92,708	82,662
Institutional support	205,433	169,228	146,093
Operations, maintenance, and other	144,736	133,926	118,943
Direct foundation expenditures	41,695	34,183	37,499
Depreciation and amortization	178,972	176,700	186,719
Defined pension benefit, net of contribution	 67,092	58,521	34,336
Total operating expenses	\$ 3,686,448	3,499,554	3,132,688

(Dollars in thousands)

Financial Position

The statements of net position present the assets and liabilities, deferred inflows of resources and deferred outflows of resources, and net position of OHSU as of a point in time. Net position, the difference between total assets and deferred outflows as compared to total liabilities and deferred inflows, presents the financial position at the end of the fiscal year and is one of the broadest measures of the financial condition of OHSU, while the change in net position is an indication of whether the overall financial condition has improved or worsened during the year.

(A Component Unit of the State of Oregon)

Management Discussion and Analysis

June 30, 2021 and 2020

(Dollars in thousands)

The following table summarizes OHSU's statements of net position for the past three years by major category of assets, liabilities, deferred inflows and outflows, and net position.

Condensed Statements of Net Position

(Dollars in thousands)

	_	2021	2020	2019
Assets:				
Current assets	\$	1,401,359	1,410,015	1,125,847
Capital assets		2,055,987	2,103,591	2,072,996
Other noncurrent assets	_	2,894,624	2,231,465	2,371,988
Total assets		6,351,970	5,745,071	5,570,831
Deferred outflows	_	234,013	206,985	205,752
Total assets and deferred outflows	\$_	6,585,983	5,952,056	5,776,583
Liabilities:				
Current liabilities	\$	634,898	612,056	460,019
Noncurrent liabilities	_	1,699,451	1,593,396	1,503,847
Total liabilities	_	2,334,349	2,205,452	1,963,866
Deferred inflows		153,566	141,262	193,518
Net position:				
Net investment in capital assets		1,232,802	1,254,205	1,239,304
Restricted, expendable		801,921	683,114	717,100
Restricted, nonexpendable		304,696	295,926	274,762
Unrestricted	_	1,758,649	1,372,097	1,388,033
Total net position	_	4,098,068	3,605,342	3,619,199
Total liabilities, deferred outflows,				
and net position – end of year	\$_	6,585,983	5,952,056	5,776,583

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

Assets

The largest components of OHSU's assets are cash and investments and capital assets, or physical plant.

Cash and Investments. During fiscal year 2021, OHSU's unrestricted and restricted cash and investments increased from \$2.5 billion to \$3.1 billion attributable to operating and investment performance and Foundation activity. Policies set by OHSU and the Foundations dictate how investments are allocated and what risk profiles are assumed. Working capital is primarily invested in short duration, liquid fixed-income assets. Long-term investment strategy, including the investment of endowment funds and the associated spending distribution policy at the OHSU Foundation, is equity oriented, aiming to maximize total return, promote diversification, preserve capital, and provide for cash flow needs of the University.

Consolidated Asset Allocation of Unrestricted and Restricted Cash and Investments

		2021	2020	2019
Unrestricted cash and investments:				
Cash and cash equivalents	\$	433,534	427,991	96,419
Fixed income		942,161	855,547	1,035,482
Public Equity		366,662	191,761	243,920
Private Equity, Marketable Alt., and Other		524,907	389,588	300,800
Subtotal		2,267,264	1,864,887	1,676,621
Restricted cash and investments:				
Cash and cash equivalents		33,364	43,305	16,480
Fixed income		158,260	133,778	166,309
Public Equity		172,478	135,443	214,597
Private Equity, Marketable Alt., and Other	-	502,081	366,687	294,389
Subtotal		866,183	679,213	691,775
Totals	\$	3,133,447	2,544,100	2,368,396

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

The unrestricted portion of cash and investments is represented in the calculation of days cash on hand for OHSU. Days cash on hand increased from 222 days in 2020 to 256 days in 2021, the effect of a 20.9% increase in unrestricted operating cash and investments compared to a 4.9% increase in net unrestricted operating expenses.

Days Unrestricted Cash and Investments on Hand

	,		
	 2021	2020	2019
OHSU without OHSU Foundation: Unrestricted cash and investments Less nonoperating cash and investments	\$ 1,616,669 (80,132)	1,356,421 (55,319)	1,171,106 (45,297)
Operating cash and investments	\$ 1,536,537	1,301,102	1,125,809
Unrestricted operating expenses: Total operating expenses Less depreciation and amortization	\$ 3,269,674 (178,888)	3,128,200 (176,617)	2,777,553 (186,621)
Net unrestricted operating expenses	\$ 3,090,786	2,951,583	2,590,932
Daily expense Days cash on hand	\$ 8,468 181	8,087 161	7,098 159
OHSU plus OHSU Foundation: Unrestricted cash and investments Less nonoperating cash and investments	\$ 2,267,264 (80,132)	1,864,887 (55,319)	1,676,621 (45,297)
Operating cash and investments	\$ 2,187,132	1,809,568	1,631,324
Unrestricted operating expenses: Total operating expenses Less depreciation and amortization	\$ 3,297,622 (178,972)	3,150,353 (176,700)	2,797,999 (186,720)
Net unrestricted operating expenses	\$ 3,118,650	2,973,653	2,611,279
Daily expense Days cash on hand	\$ 8,544 256	8,147 222	7,154 228

(Dollars in thousands)

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

The following table presents the days unrestricted cash on hand for OHSU as of fiscal year ended June 30, 2021, 2020, and 2019, calculated with the removal of pension adjustments due to the adoption of GASB 68.

Days Unrestricted Cash and Investments on Hand Pre-GASB 68 Adjustment

(Dollars in thousands)					
		2021	2020	2019	
OHSU plus OHSU Foundation: Operating cash and investments	\$	2,187,132	1,809,568	1,631,324	
Net unrestricted operating expenses Pension adjustment GASB 68	\$	3,118,650 (67,092)	2,973,653 (58,521)	2,611,279 (34,336)	
Adjusted net unrestricted operating expenses	\$	3,051,558	2,915,132	2,576,943	
Daily expense Days cash on hand (pre-GASB 68)	\$	8,360 262	7,987 227	7,060 231	

Capital Assets. Capital investments in patient care, research, education, and outreach are scaled and paced to available funding from operating earnings and philanthropy. Capital assets, net of accumulated depreciation, decreased by \$48 million and increased by \$31 million, respectively, during fiscal years 2021 and 2020. In 2021 and 2020, capital expenditures included the continued construction of the Elks Children's Eye Clinic/Casey Eye Institute expansion, the design of OHSU Hospital Expansion Project (OHEP), and the purchase of the Physician's Pavilion building (PPV) along with annual capital for replacement, infrastructure, and new capacities. In response to the COVID-19 pandemic and financial challenges, the start of construction for the OHEP was deferred and overall capital spending was curtailed resulting in a decrease in capital assets net of accumulated depreciation.

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

Liabilities

Total liabilities increased by \$129 million, or 5.8%, in fiscal year 2021 and \$242 million, or 12.3% in fiscal year 2020. In fiscal year 2021, the increases were primarily related to accounts payable and accrued expenses, accrued salaries, wages, and benefits, and PERS pension liability. In fiscal year 2020, the increases were related to several activities including the current portion of CARES Act Medicare Advance Payment, CARES Act deferral of OHSU's share of Social Security payroll taxes, PERS pension liability, long-term debt and other noncurrent liabilities.

Current liabilities consist of the current portion of long-term debt, capital leases, and self-funded insurance, accounts payable and accrued expenses, salaries, wages, and benefits payable and unearned revenue. In fiscal year 2021 and 2020, current liabilities also reflect the CARES Act Medicare Advance Payment of \$118 million and \$146 million, respectively, and OHSU's share of deferred Social Security payroll taxes of \$62 million and \$24 million, respectively.

Noncurrent liabilities increased \$106 million or 6.7% in fiscal year 2021 due to an increase in the pension liability and the long-term portion of CARES Act Medicare Advance Payment in other noncurrent liabilities.

Debt Management. At the close of fiscal years 2021 and 2020, OHSU had a total of approximately \$970 million and \$997 million in long-term debt and capital leases outstanding, respectively. Of the total \$970 million in long-term debt and capital leases outstanding at the end of 2021, \$946 million is considered noncurrent and \$24 million is considered current and due within one year. OHSU continues to maintain its Standard & Poor's and Fitch ratings of AA-, and Moody's rating of Aa3.

One measure of the degree of leverage on the University's statements of net position is the ratio of total longterm debt to net position, shown below. Leverage, according to this metric, decreased from 0.28 in 2020 to 0.24 in 2021. In prior fiscal year 2020, this metric was slightly higher as OHSU issued long-term debt for the refunding of previous debt and the acquisition of Physicians Pavilion.

	 2021	2020 (Dollars in millions)	2019
Total debt and capital leases Net position	\$ 970 4,098	997 3,605	979 3,619
Total debt and capital leases to net position	\$ 0.24	0.28	0.27

Maximum Annual Debt Service Coverage. The maximum annual debt service coverage ratio for an entity represents the amount of cash flow available to meet the maximum annual interest and principal payment on debt. Per bond covenants, OHSU's credit group must maintain a debt coverage ratio of 1.10 times or greater. The University continues to exceed this minimum requirement with ratios of 6.92 in fiscal year 2021, 2.93 in 2020, and 6.65 in 2019.

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020

Sunc 30, 2021 and 2020

(Dollars in thousands)

Calculation of Maximum Annual Debt Service Coverage Ratio - Unrestricted

(Dollars in thousands)					
		2021	2020	2019	
Total excess of revenues over expenses Add/subtract restricted net loss/gain	\$	480,594 (132,947)	(38,650) 21,581	219,827 51,905	
Unrestricted excess of revenue over expenses	\$	347,647	(17,069)	271,732	
Adjustments: Net unrealized (gain) loss in fair value	•	(400 500)	(1.4.070)	(50.000)	
of investments Loss on disposal of assets	\$	(129,506) 193	(14,276) 419	(58,639) 411	
Interest expense ⁽¹⁾ Depreciation and amortization		32,990 178,972	36,331 176,700	30,965 186,720	
	\$	82,649	199,174	159,457	
Income available for debt service Maximum annual debt service Maximum annual debt service coverage	\$	430,296 62,147 6.92	182,105 62,180 2.93	431,189 64,879 6.65	

⁽¹⁾ Interest expense is decreased by investment income on trust accounts.

The following table presents the maximum annual debt service coverage ratio for the last three fiscal years, calculated with the removal of pension adjustments due to the adoption of GASB 68.

Calculation of Maximum Annual Debt Service Coverage Ratio – Unrestricted Pre-GASB 68 Adjustment

(Dollars in thousands)

	 2021	2020	2019
Income available for debt service Pension adjustment GASB 68	\$ 430,296 67,092	182,105 58,521	431,189 34,336
Adjusted income available for debt service	\$ 497,388	240,626	465,525
Maximum annual debt service Maximum annual debt service coverage	\$ 62,147	62,180	64,879
(pre-GASB 68)	8.00	3.87	7.18

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

Deferred Inflows and Outflows

Under GASB Statement No. 65, *Items Previously Reported as Assets and Liabilities*, certain deferred outflows are presented below assets and certain deferred inflows are presented below liabilities.

In fiscal year 2021, the deferred outflows increased by \$27 million and deferred inflows increased by \$12 million due to several items, including deferred amortization of derivative instruments, losses and gains on refunding of debt, pension activities, life income agreements and pending funds. In fiscal year 2020, the deferred outflows increased by \$1 million and the deferred inflows decreased by \$52 million due to several items of significance, including deferred amortization of derivative instruments, losses on refunding debt, pension amounts and pending funds.

Within the deferred outflows section of the statements of net position is the deferred amortization of derivative instruments. OHSU currently holds one interest rate swap agreement. The balance of the deferred outflow for amortization of derivative instruments was \$6.1 million in 2021 and \$7.3 million in 2020.

Losses and gains on refunding of debt are amortized over the shorter of the life of the new debt or the remaining life of the old debt. Absent any refunding activity, these numbers will slowly decline. OHSU has both deferred gains and losses. The deferred loss on refunding of debt of \$27.8 million in 2021 and \$30.2 million in 2020 is reported in the deferred outflows section below assets. The deferred gain on refunding of debt of \$1.3 million in 2021 and \$1.5 million in 2020 is reported in the deferred inflows section below liabilities.

In fiscal year 2021 and 2020, the deferred outflows related to the Oregon PERS pension obligation were \$190 million and \$160 million, respectively, primarily representing assumption changes. Contributions made post measurement date are also reflected in deferred outflows. In fiscal year 2021, OHSU's contributions were \$58 million, which included an additional \$10 million in excess contribution above the contractually required \$48 million. In fiscal year 2020, OHSU's contributions made post measurement date were \$61 million, which included an additional \$10 million in excess contribution above the contractually required \$48 million. In fiscal year 2020, OHSU's contributions made post measurement date were \$61 million, which included an additional \$10 million in excess contribution above the contractually required \$51 million. Deferred inflows related to pension activities for fiscal years 2021 and 2020 were \$46 million and \$56 million, respectively, representing a decrease in proportionate share.

Finally, deferred inflows included an increase in life income agreements of \$6 million and an increase of \$17 million in pending funds.

Net Position

As noted earlier, total net position increased \$493 million in fiscal year 2021, as compared to a decrease of \$14 million in fiscal year 2020. In fiscal year 2021, the increase in net position occurred within unrestricted and restricted, offset by net investment in capital assets, which decreased by \$21 million. Unrestricted net position, which is 42.9% of OHSU's total net position, increased by \$387 million in 2021 as compared to a decrease of \$16 million in 2020 which was primarily due to the losses associated with the COVID-19 pandemic. Restricted net position, which is 27.0% of OHSU's total net position, increased by \$128 million in 2021 primarily driven by programmatic spending on research and academic programs.

When evaluating OHSU's net position, it is important to note that OHSU's Marquam Hill property is leased from the State for renewable 99-year periods, at a lease payment equal to the debt service on bonds outstanding at

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

the time of OHSU's separation from the Oregon University System. As that debt service is relatively low, the capitalized net present value of those lease payments is significantly less than the fair value of the included land and buildings.

OHSU Missions

OHSU's strategic plan, called OHSU 2025, is built around the OHSU's vision: "OHSU will partner to make Oregon a national leader in health and science innovation for the purpose of improving the health and wellbeing of all Oregonians and beyond."

Six goals - timeless aspirations - form the basis of the plan:

- 1. Building a diverse, equitable environment where all can thrive and excel.
- 2. Being the destination for transformational learning.
- 3. Enhancing health and healthcare in every community.
- 4. Discovering and innovating to advance science and optimize health worldwide.
- 5. Partnering with communities for a better world.
- 6. Ensuring a sustainable foundational infrastructure.

The plan was developed through a crowdsourcing process to tap into OHSU member aspirations and develop a shared future vision.

These goals span OHSU's missions, supported by objectives that are focused on identifying new ways to understand disease, treat illness and train the next generation of scientists and health professionals. They begin with our commitment to listen to what communities — across Oregon and around the world — need from OHSU, and end with our commitment to the people who will respond to those needs and make this work a reality.

With 42 objectives and hundreds of tactics, OHSU 2025 reflects not only the breadth and complexity of the state's only academic health center, but also the challenges in health and science that OHSU must address. OHSU's scale and scope, our profound connection to Oregonians, and our decades of experience at the leading edge of innovation have already laid the foundation for this plan's success.

The following sections highlight achievements for each of our missions.

OHSU Education

A foundation of OHSU's mission is the education and training of dentists, nurses, physicians, physician assistants, other health professionals, biomedical scientists, and engineers, through a broad range of undergraduate and graduate programs that provide healthcare and biomedical workforce for Oregon and beyond. Educational programs are conducted on the OHSU campus in Portland, online, and at various locations throughout the State. Collaborative programs enable OHSU to offer a joint Doctor of Pharmacy

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

degree through an affiliation with Oregon State University (OSU) as well as a joint Ph.D. degree and a joint Master of Science degree in Medical Physics. In partnership with Oregon Institute of Technology (OIT), OHSU offers a joint B.S. degree in Medical Laboratory Science, a joint B.S. degree in Emergency Medical Services Management and a joint Associate of Applied Science degree in Emergency Medical Technology–Paramedic. OHSU also offers a joint Master of Business Administration in Health Care Management with Portland State University (PSU) and has also established a joint School of Public Health with PSU comprising several undergraduate and graduate programs including Bachelor degrees, Graduate Certificates, Master of Science, Master of Public Health, and Ph.D. programs.

As of the fall 2020 term, OHSU had 3,035 students enrolled in its various programs (excluding students enrolled in the joint Pharm.D. degree program with OSU, the joint undergraduate programs with OIT and the School of Public Health joint degree students registered by PSU). The following table sets forth the number of students enrolled in OHSU's programs for each of the past three academic years.

	_	2020/2021	2019/2020	2018/2019
School of Dentistry:				
Graduate	\$	27	26	27
Professional	_	291	297	296
Subtotal	_	318	323	323
School of Medicine:				
Undergraduate		17	17	18
Graduate		753	780	812
Professional	_	617	630	603
Subtotal	_	1,387	1,427	1,433
School of Nursing:				
Undergraduate		792	759	764
Graduate		87	177	222
Professional		189	100	44
Subtotal		1,068	1,036	1,030
School of Public Health:				
Graduate		262	231	213
Total	\$	3,035	3,017	2,999

Fall Headcount Enrollment ^(a) For Programs in the Years Indicated

(a) This table excludes interns, residents, and trainees. This table also excludes students enrolled in the joint Pharm.D. degree program with OSU, the joint undergraduate programs with OIT and the School of Public Health joint degree students registered by PSU.

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

OHSU Research

OHSU is a national leader in neuroscience; cancer research; hearing; microbiology; ophthalmology; infectious disease and immunology in many fields of research, including: reproductive biology; atomic, molecular, cellular, and tissue imaging; and evidence-based medicine. OHSU research projects received 72% of the grants made by the National Institutes of Health (NIH) in the state of Oregon, with the next largest recipient receiving 11%. OHSU was ranked 29th out of the 2,416 entities that received funding from the NIH. Faculty members include five members of the National Academy of Sciences and nine members of the National Academy of Medicine. Researchers at OHSU have developed many of the leading advances in medicine, including the first artificial heart valve, pioneering use of optical coherence tomography, the first percutaneous angioplasty procedure, and the first molecularly targeted cancer therapy (Gleevec®).

OHSU's many institutes are nationally and internationally recognized, including the Knight Cancer Institute, the only National Cancer Institute designated Comprehensive Cancer Center in Oregon; the Vollum Institute, privately endowed and dedicated to basic science research that has led to new treatments for neurological and psychiatric diseases; and the Casey Eye Institute, a world-recognized academic regional eye center that attracts top specialists from around the globe. OHSU's West Campus is home to the Vaccine and Gene Therapy Institute, which-focuses on serious viral disease threats and programs intended to span the continuum between basic and clinical science, where discoveries are rapidly advanced from the level of molecular and cellular biology through animal models and ultimately into clinical testing, and the Oregon National Primate Research Center, one of the seven National Primate Research Centers supported by the National Institutes of Health. Their world-class translational research programs focus on current, developing, and projected high-priority human medical needs that are projected to increase in importance over the coming decades.

OHSU actively pursues private and public partnerships on important and innovative research projects to supplement federal funding, with corporate partners such as Thermo Fisher Scientific's Analytical Instrumentals Segment, a leading electronic microscopy company, and other major information technology and life sciences companies, and with academic partners such as PSU, OSU, University of Oregon, Pacific Northwest National Laboratory, and Lawrence Berkeley National Laboratory.

Although the COVID-19 pandemic disrupted science at OHSU, the institution continued to strive in many areas and accomplished many extraordinary things. Despite the many challenges, OHSU had another record year; receiving nearly \$586 million in externally sponsored awards for fiscal year 2021.

In June 2021, OHSU was the first institution in the Pacific Northwest to install a new type of scanner that will advance both patient care and clinical research. The 3-Tesla magnet for the GE Signa Positron Emission Tomography/Magnetic Resonance Imaging scanner will be delivered and installed in the Lamfrom Biomedical Research Building on OHSU's Marquam Hill campus. The \$11.7 million project includes the cost of the scanner and renovations needed to accommodate it in the building. The device will be especially useful for organs and diseases that are better imaged with MRI rather than a different type of scanner called PET CT, for computed tomography. These include neurological conditions such as epilepsy and brain tumors, head and neck cancers, heart conditions such as cardiac sarcoidosis and myocarditis, in addition to different types of cancer such as prostate cancer, rectal cancer and cervical cancer.

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

In May 2021, Scientists have for the first time revealed the structure surrounding important receptors in the brain's hippocampus, the seat of memory and learning. The study, carried out at OHSU, published in the journal *Nature*. Working with a mouse model, the OHSU researchers made the breakthrough by developing monoclonal antibodies to isolate the receptor and the complex of subunits surrounding it. They then imaged the entire collection using state-of-the-art cryo-electron microscopy at the Pacific Northwest Cryo-EM Center, housed in OHSU's South Waterfront campus in Portland. The findings may be immediately useful in drug development for conditions such as epilepsy.

About two decades after first devising a new kind of vaccine, OHSU researchers are unlocking why it stops and ultimately clears the monkey form of HIV, called SIV, in about half of nonhuman primates – and why it's a promising candidate to stop HIV in people. In scientific papers that were simultaneously published in the journals *Science and Science Immunology* during 2021, creators of the cytomegalovirus, or CMV, vaccine platform describe the unusual biological mechanisms through which it works. The findings also helped fine-tune VIR-1111, the CMV-based experimental vaccine against HIV that was developed at OHSU and is now being evaluated in a Phase 1 clinical trial. The trial is being conducted by Vir Biotechnology, which licensed the CMV vaccine platform technology from OHSU.

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

OHSU Healthcare

OHSU is home to Oregon's only major academic health center, which serves a multistate area with tertiary and quaternary healthcare services from its campus in Portland, Oregon, where it operates two hospitals, OHSU Hospital and OHSU Doernbecher Children's Hospital (OHSU Hospital or the Hospital), with 576 licensed beds. During 2021, the OHSU Hospital represented 8.2% of the available beds and 11.1% of the filled beds for the entire State. The OHSU Hospital had an 80% occupancy rate for available beds in 2021, compared to the Oregon statewide average of 59% according to the Oregon Association of Hospitals and Health Systems' Oregon DataBank. As an academic health center, OHSU's professional staff is composed primarily of the faculty of OHSU's School of Medicine. The OHSU Practice Plan (OPP) is the largest organized clinical practice in Oregon. As of June 30, 2021, there were over 1,713 active faculty practice plan members, including physicians, nurse practitioners, physician assistants, and other licensed independent practitioners from across all medical specialties.

	Fiscal year ending June 30			Variance		
OHSU Patient Activity	2021	2020	2019	2021 v 2020	2020 v 2019	
Inpatient admissions	25,612	27,055	29,174	(5.3)%	(7.3)%	
Average length of stay	6.66	6.32	6.12	5.4	3.3	
Average daily census	448	453	476	(1.1)	(4.8)	
Day/observation patients	41,327	38,643	42,320	6.9 %	(8.7)%	
Emergency visits	41,997	44,965	47,856	(6.6)	(6.0)	
Ambulatory visits	1,103,642	978,492	987,024	12.8	(0.9)	
Surgical cases	33,124	32,672	37,080	1.4	(11.9)	
Casemix index	2.49	2.43	2.26	2.5 %	7.5 %	
Outpatient share of activity	55.4 %	53.6 %	52.3 %	3.4	2.5	
CMI/OP adjusted admissions	142,945	141,644	137,995	0.9	2.6	

In addition to its tertiary care focus in Portland, OHSU is working with other healthcare providers noted below to leverage expertise and resources throughout Oregon.

Adventist Health. Adventist Health Portland and OHSU finalized an agreement to integrate their clinical activities and services in the Portland metropolitan area through an affiliation effective January 1, 2018. This agreement makes OHSU and Adventist Health Portland part of the same Portland metropolitan health system, bringing together Adventist's healthcare enterprise that includes a 302-licensed bed medical center, 25 medical clinics and home care and hospice services in the Portland-Vancouver metro area. Under this affiliation, OHSU and Adventist Health will share a bottom line and operate as a unified system. The agreement does not include OHSU's research and education missions. The other twenty Adventist Health hospitals in the western United States are also excluded from the agreement. Each organization will retain its existing hospital licenses, capital assets, and employees. Each entity will continue to maintain its own mission and culture but together will seek to transform access and the delivery of health to Oregonians through a unified clinical enterprise and shared brand experience.

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

Tuality Healthcare. On February 1, 2016, OHSU affiliated with Tuality through the execution of a management agreement (the Tuality Agreement) between the organizations. Tuality owns and operates Tuality Community Hospital, a 215-licensed-bed acute care hospital located in Hillsboro, Oregon. Under the Tuality Agreement, OHSU agrees to oversee the unified and integrated clinical enterprises of OHSU and Tuality as a single, integrated economic unit. OHSU and Tuality remain as separate entities, own their own assets and continue to be the licensed operators of their own facilities. Under the Tuality Agreement, OHSU agrees to be responsible for Tuality's operating income and loss, including making cash payments to Tuality in an amount equal to any Tuality operating loss, in the manner specified in the Tuality Agreement. Tuality is a component unit of OHSU as OHSU approves Tuality's annual operating budget. Since Tuality has a separate board of directors and they do not provide services exclusively to OHSU, they are presented as a discretely presented component unit of OHSU. In November 2019, Tuality adopted a new public-facing name, Hillsboro Medical Center.

Columbia Memorial Hospital. OHSU and Columbia Memorial Hospital (CMH) in Astoria, Oregon, have collaborated on programs, including cardiology and cancer, offering chemotherapy, imaging, pharmacy, and other services for individuals on the North Oregon Coast. OHSU and CMH jointly organize and operate an Oncology Collaboration, including a 18,000-square-foot comprehensive cancer treatment center and specialty clinic, with radiation therapy. CMH owns and operates the cancer treatment center, opened in October 2017, under its license while OHSU has provided the professional services and medical direction through OHSU-employed physicians.

OHSU Foundation

OHSU has one designated independent nonprofit foundation – the Oregon Health and Science University Foundation (OHSU Foundation, the Foundation). The Foundation exists to secure private philanthropic support to advance OHSU's vital missions and to invest and manage gifts responsibly to honor donors' wishes.

The Foundation is an Oregon nonprofit corporation promoting the charitable, scientific, and educational purposes of OHSU. The Foundation is a component unit of OHSU for financial reporting purposes, but is not part of the OHSU Obligated Group established pursuant to the Master Indenture, which currently consists solely of OHSU. The Foundation has a self-perpetuating board trustees, on which the OHSU president sits as an ex officio voting member.

Doernbecher Children's Hospital Foundation, an Oregon nonprofit corporation originally established in 1944 promoting an interest in and support for Doernbecher Children's Hospital, a functional unit of OHSU specializing in healthcare services to children, merged on January 1, 2021 with OHSU Foundation. OHSU Foundation continued as the surviving corporation following the merger. OHSU Foundation is tax-exempt under Section 501(c)(3) of the Internal Revenue Code.

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)


As OHSU's designated foundation, all development activities conducted by the Foundation must be coordinated with OHSU. In accepting gifts, the Foundation must obtain OHSU approval for all endowments and any gifts that result in new programs. In addition, if the Foundation was dissolved or if the OHSU president were to revoke recognition of the Foundation as an OHSU-designated foundation, the assets of such foundation would, within the limits of legal and fiduciary rights, be distributed to OHSU, its successor in interest, or to another entity recognized by OHSU as an institution foundation. These interrelated functions and requirements have been further confirmed and implemented in the articles and bylaws of the Foundation. The table below identifies major gifts, which are reported as required under the Council for Advancement and Support of Education (CASE) Reporting Standards and Management Guidelines, which may differ from recognition rules under governmental accounting standards.

Amount	OHSU major gifts description	Fiscal year
\$14.2 million	HIV and TB vaccine using CMV platform grant	2020–21
\$10 million	OHSU-UO Center for Biomedical Data Science gift	2019–20
\$25 million	OHSU and Doernbecher Children's Hospital gift	2017–18
\$14.7 million	SMMART Trials grant	2017–18
\$15 million	Center for Pancreatic Health gift	2016–17
\$15 million	Casey Eye Institute gift	2015–16
\$12 million	Gary and Christine Rood Family Pavilion gift	2015–16
\$500 million	Knight Cancer Institute gift	2014–15
\$100 million	Knight Cancer Institute gift	2014–15
\$38.8 million	Vaccine and Gene Therapy Institute, Oregon National Primate	
	Research Center, and Behavioral Neuroscience grant	2014–15
\$28.9 million	Knight Cancer Institute and OHSU Parkinson Center gift	2013–14
\$25 million	Center for Pancreatic Health gift	2013–14
\$10 million	Knight Cancer Institute gift	2013–14
\$125 million	Gift to create a Cardiovascular Institute at OHSU	2012–13
\$25 million	Bob and Charlee Moore Institute for Nutrition gift	2011–12
\$10 million	New School of Dentistry gift	2010–11
\$100 million	Knight Cancer Institute gift	2008–09

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

Economic Outlook

Fiscal year 2021 saw continued capital market and economic volatility as the global economy continued to be impacted by COVID-19. During fiscal year 2021, the U.S. economy began exhibiting signs of more substantive recovery as reflected in the improving labor market, as well as most recent strong year over year real gross domestic product (GDP) growth rate of 12.2% according to the U.S. Bureau of Economic Analysis. The below chart illustrates the federal and Oregon state unemployment levels over the previous two fiscal years for fuller context.



Source: Bureau of Labor Statistics

Post fiscal year-end 2021, the federal and Oregon employment picture continued to be strong with Oregon posting a preliminary unempoloyment rate figure of 5.6%, while the federal level stood at 5.9%. There is still substantial uncertainty of the impact the Delta variant will have on the Oregon, U.S. and world economies moving into fall and winter.

In financial markets, fiscal year 2021 saw the continued rally from the March 2020 lows in risk assets as COVID-19 concerns gave way to more optimistic economic and corporate profitability outlooks. On the fixed income side, coincident with more optimistic growth projections, the markets saw rates increase during the fiscal year on higher expectations related to both growth and inflation. Towards the end of fiscal year 2021 and into the beginning of fiscal year 2022, market focus has shifted to the timing and pace of modifications to the Federal Reserve's asset purchase program and expected Fed Funds Rate path. Additionally, with respect to

(A Component Unit of the State of Oregon) Management Discussion and Analysis June 30, 2021 and 2020 (Dollars in thousands)

fiscal policy, markets are awaiting the outcome of the Biden administration's proposed \$1 billion and \$3.5 billion infrastructure bills, as well as the fiscal year 2022 budget resolution. The healthcare regulatory environment also continues to exhibit substantial policy uncertainty as federal and state regulators attempt to mitigate COVID-19 impacts. The passage of the CARES Act in March 2020 provided major financial support to the healthcare industry and OHSU. The prospect of further federal aid is uncertain. As a consequence, the University is preparing for a range of possible outcomes.

Although many specific investments in the OHSU 2025 strategic plan have been paused due to the pandemic, the University continues to be guided by its "people first" approach to deliver breakthroughs for better health. This includes responding to COVID-19 by tightening first to loosen later, reducing salaries to avoid widespread layoffs where possible, and acting as one University even though different missions and units are impacted to different extents and at different times.

Results over the past several fiscal years show that OHSU's financial position remains strong, with net position increasing 32% from \$3.1 billion at July 1, 2017 to \$4.1 billion for the year ending June 30, 2021. OHSU's financial strength is further recognized by its credit ratings, Aa3 / AA- / AA- confirmed by Moody's, S&P, in early 2021, and by Fitch, in late 2020, respectively. The University's financial planning and budget process is designed to support ongoing investment in faculty and staff, programs, technology and facilities consistent with a nationally ranked health sciences university. On this path, OHSU has received unwavering public and philanthropic support.

(A Component Unit of the State of Oregon)

Statements of Net Position

As of June 30, 2021 and 2020

(Dollars in thousands)

_		2020
Assets:		
Current assets:		
Cash and cash equivalents \$	435,574	422,742
Short-term investments	104,421	253,989
Current portion of funds held by trustee	36,759	38,062
Patients accounts receivable, net of bad debt allowances of		
\$2,518 and \$1,528 – in 2021 and 2020	459,884	390,926
Student receivables	27,025	28,644
Grant and contract receivable	62,900	61,970
Current portion of pledges and estates receivable, net	121,502	85,605
Other receivables, net	54,235	46,087
Inventories, at cost	58,290	49,223
Prepaid expenses	40,769	32,767
Total current assets	1,401,359	1,410,015
Noncurrent assets:		
Capital assets, net of accumulated depreciation	2,055,987	2,103,591
Funds held by trustee – less current portion	10,182	13,252
Other long-term receivables, net of reserves	33,500	33,500
Long-term investments:		
Long-term investments, restricted	846,679	652,633
Long-term investments, unrestricted	1,746,773	1,214,736
Total long-term investments	2,593,452	1,867,369
Prepaid financing costs, net	1,484	1,705
Pledges and Estates Receivable, net – Less Current Portion	248,218	306,862
Restricted postemployment benefit asset	4,328	6,200
Other noncurrent assets	3,460	2,577
Interest in the foundations		
Total noncurrent assets	4,950,611	4,335,056
Total assets	6,351,970	5,745,071
Deferred outflows:		
Deferred amortization of derivative instruments	6,091	7,342
Loss on refunding of debt	27,794	30,197
Pension obligation	189,745	160,050
Goodwill	348	435
Other Postemployment Benefits (OPEB) obligation	10,035	8,961
Total deferred outflows	234,013	206,985
Total assets and deferred outflows $\$$	6,585,983	5,952,056

(A Component Unit of the State of Oregon)

Statements of Net Position

As of June 30, 2021 and 2020

(Dollars in thousands)

_	2021	2020
Liabilities:		
Current liabilities:		
Current portion of long-term debt \$	22,848	22,476
Current portion of long-term capital leases	1,234	943
Current portion of self-funded insurance programs liability	40,868	33,935
Accounts payable and accrued expenses	171,743	154,540
Accrued salaries, wages, and benefits	119,248	106,188
Compensated absences payable	76,432	68,996
Unearned revenue	81,831	74,543
Unearned/Medicare Advance Payment	118,420	145,975
Other current liabilities	2,274	4,460
Total current liabilities	634,898	612,056
Noncurrent liabilities:		
Long-term debt – less current portion	944,908	972,932
Long-term capital leases – less current portion	968	1,044
Liability for self-funded insurance programs – less current portion	46,639	39,861
Liability for life income agreements	23,492	20,741
Net pension liability	595,311	503,720
Other noncurrent liabilities	88,133	55,098
Total noncurrent liabilities	1,699,451	1,593,396
Total liabilities	2,334,349	2,205,452
Deferred inflows:		
Deferred amortization of derivative instruments	_	_
Gain on refunding of debt	1,291	1,546
Life income agreements	39,087	33,269
Pending Funds	65,455	48,135
Pension obligation	46,214	56,018
Other Postemployment Benefits (OPEB) amounts	1,519	2,294
Total deferred inflows	153,566	141,262
Net position:		
Investments in capital assets	1,232,802	1,254,205
Restricted, expendable	801,921	683,114
Restricted, nonexpendable	304,696	295,926
Unrestricted	1,758,649	1,372,097
Total net position	4,098,068	3,605,342
Total liabilities, deferred inflows, and net position $\$$	6,585,983	5,952,056

See accompanying notes to financial statements.

(A Component Unit of the State of Oregon)

Statements of Revenues, Expenses, and Changes in Net Position

Years ended June 30, 2021 and 2020

(Dollars in thousands)

_	2020	2020
Operating revenues:		
Patient service revenue, net of bad debt adjustments of \$6,310		
and \$12,112 – in 2021 and 2020, respectively \$	2,595,048	2,375,275
Student tuition and fees, net	82,770	77,305
Gifts, grants, and contracts	703,065	664,646
Other	225,391	195,895
Total operating revenues	3,606,274	3,313,121
Operating expenses:		
Salaries, wages, and benefits	2,166,014	2,041,677
Defined benefit pension	113,695	109,907
Services, supplies, and other	1,194,777	1,134,614
Depreciation and amortization	178,972	176,700
Interest	32,990	36,656
Total operating expenses	3,686,448	3,499,554
Operating (loss)	(80,174)	(186,433)
Nonoperating revenues, incl. state appropriations:		
Investment income and gain on fair value of investments	439,799	82,878
State appropriations	44,243	39,581
CARES Act grants	72,593	37,859
Other	4,133	(12,535)
Total nonoperating revenues (expenses), net	560,768	147,783
Net income (loss) before contributions for capital and other	480,594	(38,650)
Other changes in net position:		
Contributions for capital and other	783	3,361
Nonexpendable donations	11,349	21,432
- Total other changes in net position	12,132	24,793
- Total increase (decrease) in net position	492,726	(13,857)
Net position – beginning of year	3,605,342	3,619,199
Net position – end of year \$	4,098,068	3,605,342

See accompanying notes to financial statements.

(A Component Unit of the State of Oregon)

Statements of Cash Flows

Years ended June 30, 2021 and 2020

(Dollars in thousands)

	202 ²	<u> </u>	2020
Cash flows from operating activities:			
Receipts for patient services \$	2,523	.904	2,373,521
Receipts from students		,389	74,845
Receipts of gifts, grants, and contracts	780	,530	671,361
Other receipts	193	,344	331,142
Payments to employees for services	(2,193	,410)	(2,091,099)
Payments to suppliers	(1,194	,643)	(1,156,398)
Net cash provided by operating activities	194	,114	203,372
Cash flows from noncapital financing activities:			
Federal direct loan proceeds	75	,344	72,396
Federal direct loan disbursements	•	,724)	(61,081)
State appropriations		,243	39,581
CARES Act grants		,593	37,859
Nonexpendable donations and life income agreements	(2	.,627)	(5,732)
Net cash provided by noncapital financing activities	113	,829	83,023
Cash flows from capital and related financing activities:			
Scheduled principal payments on long-term debt	(12	,536)	(14,836)
Interest payments on long-term debt	(49	,061)	(50,057)
Proceeds from issuance of long-term debt		928	355,558
Repayment on debt		(7)	(305,480)
Acquisition of capital assets	(131	,368)	(207,295)
Proceeds from sale of capital assets		(193)	(419)
Net capital lease activity		215	(3,838)
Contributions for capital and other		783	3,361
Net cash used in capital and related financing activities	(191	,239)	(223,006)
Cash flows from investing activities:			
Purchases of investments	(1,215	,753)	(3,355,739)
Proceeds from sales and maturities of investments	1,079	,180	3,573,115
Interest on investments and cash balances	32	.,701	54,962
Net cash provided (used) by investing activities	(103	,872)	272,338
Net increase in cash and cash equivalents	12	,832	335,727
Cash and cash equivalents, beginning of year	422	.,742	87,015
Cash and cash equivalents, end of year \$	435	,574	422,742

(A Component Unit of the State of Oregon)

Statements of Cash Flows

Years ended June 30, 2021 and 2020

(Dollars in thousands)

	 2021	2020
Reconciliation of operating income (loss) to net cash provided by		
operating activities:		
Operating (loss)	\$ (80,174)	(186,433)
Adjustments to reconcile operating (loss) net cash provided	. ,	
by operating activities:		
Depreciation and amortization	178,972	176,700
Provision for bad debts	6,310	12,112
Interest expense reported as operating expense	32,990	36,656
Noncash contribution	(10,169)	(9,363)
Defined-benefit pension	52,092	48,521
Net changes in assets and liabilities:		
Patient accounts receivable	(75,268)	(12,789)
Student receivables	1,619	(2,460)
Grant and contracts receivable	(550)	(10,735)
Pledges and estates receivable	22,747	33,025
Other receivables, assets, and deferred outflows	(4,492)	(10,728)
Inventories	(9,067)	(4,802)
Prepaid expenses	(8,002)	(2,829)
Accounts payable and accrued expenses	17,203	(14,153)
Accrued salaries, wages, and benefits	13,060	4,413
Compensated absences payable	7,436	6,658
Other current liabilities	(2,186)	(1,077)
Liability for life income agreements	2,751	(2,494)
Unearned revenue	7,288	13,978
Medicare Advance Payment	(27,555)	145,975
Liability for self-funded insurance programs	13,711	893
Other noncurrent liabilities and deferred inflows	 55,398	(17,696)
Net cash provided by operating activities	\$ 194,114	203,372
Supplemental schedule of noncash capital and related financing and investing activities:		
Unrealized change in fair value of investments	\$ 38,537	9,529
Loss on disposal capital assets	(193)	(419)

See accompanying notes to financial statements

Nongovernmental Discretely Presented Component Units

Combined Balance Sheets

As of June 30, 2021 and 2020

(Dollars in thousands)

Assets	_	2021	2020
Current assets:			
Cash and cash equivalents	\$	38,819	6,148
Short-term investments		3,734	911
Patient accounts receivable, net of allowance for uncollectible			
accounts of \$1,405,178 as of June 30, 2020		38,936	29,341
Due from related party		—	20,950
Other receivables		18,158	3,484
Supplies inventory		4,903	3,842
Prepaid expenses and other		2,442	2,153
Current portion of assets whose use is limited	-	1,010	992
Total current assets	_	108,002	67,821
Assets whose use is limited:			
Board-designated funds		41,246	34,706
Under bond indenture agreement – held by Trustee		1	1
Donor-restricted – specific purpose		6,888	4,049
Donor-restricted – endowment		2,761	2,812
Required for current liabilities	_	(1,010)	(991)
Total assets whose use is limited	_	49,886	40,577
Property and equipment:			
Property and equipment, net of accumulated depreciation and			
amortization		62,752	62,332
Other assets:			
Other receivables – noncurrent		1,307	1,379
Investments in unconsolidated affiliates		1,104	1,521
Deferred compensation plan		2,814	2,358
Cash value of life insurance		727	565
Deferred costs and other		230	230
Intangible assets		1,550	1,610
Goodwill	-	319	319
Total other assets	_	8,051	7,982
Total assets	\$_	228,691	178,712

Nongovernmental Discretely Presented Component Units

Combined Balance Sheets

As of June 30, 2021 and 2020

(Dollars in thousands)

Current liabilities:		
Accounts payable \$	44,532	14,762
Accrued payroll and employee benefits	13,476	12,864
Due to related party	2,316	_
Deferred revenue	13,107	16,590
Estimated liabilities for Medicare and Medicaid settlements	423	450
Long-term debt due within one year	1,052	1,021
Accrued bond interest payable	86	92
Total current liabilities	74,992	45,779
Long-term liabilities:		
Long-term debt, net of amount due within one year	11,034	12,073
Liability for pension benefits	42,224	66,444
Other long-term liabilities	26,093	23,885
Total long-term liabilities	79,351	102,402
Total liabilities	154,343	148,181
Net assets:		
Net assets without donor restrictions	64,594	23,265
Net assets with donor restrictions	9,754	7,266
Total net assets	74,348	30,531
Total liabilities and net assets =	228,691	178,712

See accompanying notes to financial statements.

Nongovernmental Discretely Presented Component Units

Combined Statements of Operations

For the years ended June 30, 2021 and 2020

(Dollars in thousands)

	2021	2020
Net patient service revenue: Patient service revenue (net of contractual allowances and		
discounts) ¹ Provision for bad debts		\$ 199,410 (5,266)
Total net patient service revenue	226,775	194,144
Other revenue:	740	05.004
OHSU support Other revenue	746 202,931	25,321 11,793
Total other revenue	203,677	37,114
Total revenue	430,452	231,258
Operating expenses: Salaries and wages Employee benefits	91,704 23,271	88,626 25,264
Supplies and other expenses	262,590	81,625
Professional fees	31,947	26,803
Depreciation and amortization Interest	8,291 718	8,498 782
Total operating expenses	418,521	231,598
Income (loss) from operations	11,931	(340)
Other non-operating income: Realized income on investments whose use is limited by board		
designation	222	1,060
Gain on investments in affiliated companies Gain/(loss) on disposal of property and equipment	2,303 18	3,242 (35)
Change in net unrealized gains (losses) on investments	6,133	(317)
Other operating revenue	(600)	302
Total other income	8,076	4,252
Excess of revenue over expenses	20,007	3,912
Contributions for property and equipment acquisition Pension-related changes	506 20,815	909 (20,099)
Increase (decrease) in net assets without donor restrictions	6 41,328	(15,278)

¹ 2021 presentation reflect adoption of ASC 606, Revenue from Contracts with Customers

See accompanying notes to combined financial statements.

Nongovernmental Discretely Presented Component Units

Combined Statements of Changes in Net Assets

For the years ended June 30, 2021 and 2020

(Dollars in thousands)

	2021	2020
Net assets without donor restrictions: Excess of revenue over expenses Contributions for property and equipment acquisition Pension-related changes	\$ 20,007 506 20,815	3,912 909 (20,099)
Increase (decrease) in net assets without donor restrictions	41,328	(15,278)
Net assets with donor restrictions: Gifts, grants, and bequests Investment (loss) income Net assets released from restrictions Contributions for endowment funds	2,233 1,793 (1,539) 2	1,809 (190) (2,112) 2
Increase (decrease) in net assets with donor restrictions	2,489	(491)
Change in net assets	43,817	(15,769)
Net assets, beginning of year	30,531	46,300
Net assets, end of year	\$ 74,348	30,531

See accompanying notes to combined financial statements.

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

(1) Organization and Summary of Significant Accounting Policies

(a) Organization

As the only health sciences university and major academic health center in the state of Oregon (the State), Oregon Health & Science University (OHSU or the University) is dedicated to the education and training of healthcare professionals, research, patient care, outreach, and public service. In addition to the School of Medicine, School of Nursing, School of Dentistry, the joint College of Pharmacy with Oregon State University, and the joint School of Public Health with Portland State University, OHSU comprises several other academic and research units, including the Vollum Institute, the Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, OHSU Brain Institute, Oregon Institute of Occupational Health Science, Oregon Clinical and Translational Research Institute, and the Pacific Northwest Center for Cryo-EM. OHSU also comprises several clinical units, including OHSU Hospital (the Hospital), the OHSU Practice Plan (OPP), and the Institute on Development and Disability (IDD). Doernbecher Children's Hospital is a unit of the Hospital serving pediatric patients. The Knight Cancer Institute is the only National Cancer Institute designated cancer center in the State, and the Knight Cardiovascular Institute provides the State's most comprehensive clinical and research heart program. In addition, OHSU operates a captive insurance company domiciled in Arizona for self-insurance purposes, OHSU Insurance Company (INSCO), which is blended in the accompanying financial statements.

Pursuant to an act of the Oregon Legislature (the Act), on July 1, 1995, OHSU was restructured from one of seven component units of the Oregon University System (OUS) to an independent public corporation. OHSU remains a component unit of the State.

The majority of the real property that constitutes OHSU's main campus on Marquam Hill (and certain off-campus properties) in Portland is owned by the State. Pursuant to the Act, the State retained title of such real property and OHSU was granted exclusive care, custody, and control of such real property. To evidence this condition, the State and OHSU entered into a 99-year lease, dated July 1, 1995 (the State Lease), under which the State leased to OHSU all of the State's leasable interest in such real property. Under the terms of the State Lease, the State may terminate the State Lease if, prior to such termination, the State causes the defeasance or discharge of all then-outstanding obligations of OHSU that were issued to finance improvements on the property subject to the State Lease or to refinance obligations of OHSU to the State. Under the State Lease, improvements include completed and partially completed buildings, fixtures, structures, and other improvements constructed on the property subject to the State Lease. In addition, OHSU was granted ownership of all personal property of the University, as it existed prior to the enactment of the Act.

Oregon Health & Science University Foundation is a separately incorporated nonprofit Foundation affiliated with OHSU. The primary purpose of the Foundation is to raise money for OHSU research, scientific, charitable, and educational purposes and to promote support for Doernbecher Children's Hospital. Doernbecher Children's Hospital Foundation, an Oregon nonprofit corporation, merged on January 1, 2021 with OHSU Foundation. Consequently, the financial position and the changes in financial position of the Foundation is blended in the accompanying financial statements.

OREGON HEALTH & SCIENCE UNIVERSITY (A Component Unit of the State of Oregon) Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

On June 30, 2021, the University Medical Group (UMG), which was previously included as a blended component unit of OHSU, was dissolved.

On February 1, 2016, OHSU affiliated with Tuality Healthcare and subsidiaries (Tuality), doing business as Hillsboro Medical Center, through the execution of a management agreement (the Tuality Agreement) between the organizations. Tuality owns and operates Tuality Community Hospital, a 215-licensed-bed acute care hospital located in Hillsboro, Oregon. Under the Tuality Agreement, OHSU agrees to oversee the unified and integrated clinical enterprises of OHSU and Tuality as a single, integrated economic unit. OHSU and Tuality remain as separate legal entities, own their own assets, and continue to be the licensed operators of their respective facilities. Tuality is a component unit of OHSU as OHSU approves Tuality's annual operating budget. Since Tuality has a separate board of directors and they do not provide services exclusively to OHSU, they are presented as a discretely presented component unit of OHSU.

On January 1, 2020, OHSU partnered with ODS Community Health, Inc. to form OHSU Health IDS, LLC (OHI). OHI is owned 60% by OHSU and 40% by ODS Community Health, Inc. OHI operates as an Integrated Delivery System (IDS) under Health Share of Oregon, a Coordinated Care Organization (CCO) certified by the Oregon Health Authority (OHA) to serve OHP (Medicaid) enrollees in the Portland-metro area. OHI remains a separate legal entity, own their own assets, and maintains its own direct contract with Health Share of Oregon. OHI is a component unit of OHSU as OHSU approves OHI's annual operating budget. Since OHI has a separate board of directors and they do not provide services exclusively to OHSU, they are presented as a discretely presented component unit of OHSU.

(b) Accounting Standards

The accompanying financial statements are prepared in accordance with accounting principles generally accepted in the United States of America using the accrual basis of accounting. OHSU's financial statements and note disclosures are based on all applicable Governmental Accounting Standards Board (GASB) pronouncements and interpretations. OHSU uses proprietary fund accounting.

OHSU prepares and presents its financial information in accordance with GASB Statement No. 34, *Basic Financial Statements – and Management's Discussion and Analysis – for State and Local Governments* (GASB 34), known as the "Reporting Model" statement. GASB 34 established the requirements and reporting model for annual financial statements. GASB 34 requires that financial statements be accompanied by a narrative introduction and analytical overview of the reporting entity in the form of "management's discussion and analysis." This reporting model also requires the use of a direct-method cash flow statement.

OHSU has also adopted GASB Statement No. 35, *Basic Financial Statements – and Management's Discussion and Analysis – for Public Colleges and Universities – an amendment of GASB Statement No. 34*. This statement establishes accounting and financial reporting standards for public colleges and universities within the financial reporting guidelines of GASB 34.

(A Component Unit of the State of Oregon) Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

(c) Accounting Standards Impacting the Future

On April 15, 2020, the GASB proposed to postpone the effective dates of provisions in almost all Statements and Implementation Guides due to be implemented by state and local governments for fiscal years 2019 and later. In light of the COVID-19 pandemic, *the Exposure Draft, Postponement of the Effective Dates of Certain Authoritative Guidance*, would postpone by one year the effective dates of provisions in the pronouncements noted below. OHSU has elected to postpone the adoption of the noted pronouncements accordingly, and, the date of adoption noted includes the one-year deferral period.

In June 2017, GASB issued Statement No. 87, *Leases* (GASB 87), which is effective for reporting periods beginning after December 15, 2020. The objective of GASB 87 is to better meet the information needs of financial statement users by improving accounting and financial reporting for leases by governments. GASB 87 increases the usefulness of governments' financial statements by requiring recognition of certain lease assets and liabilities for leases that previously were classified as operating leases and recognized as deferred inflows of resources or deferred outflows of resources based on the payment provisions of the contract. It establishes a single model for lease accounting based on the principle that leases are financings of the right to use an underlying asset. Under GASB 87, a lessee is required to recognize a lease liability and an intangible right to use lease asset, and a lessor is required to recognize a lease receivable and a deferred inflow of resources, thereby enhancing the relevance and consistency of information about governments' leasing activities. The University is currently analyzing the impact of this statement.

In June 2018, GASB issued Statement No. 89, *Accounting for Interest Cost Incurred Before the End of a Construction Period* (GASB 89), which is effective for reporting periods beginning after December 15, 2020. The objectives of GASB 89 are to (1) enhance the relevance and comparability of information about capital assets and the cost of borrowing for a reported period and (2) simplify accounting for interest cost incurred before the end of a construction period. GASB 89 requires that interest cost incurred before the end of a construction period be recognized as an expense in the period in which the cost is incurred for financial statements prepared using the economic resources measurement focus. As a result, interest cost incurred before the end of a construction period will not be included in the historical cost of a capital asset reported in a business-type activity or enterprise fund. GASB 89 also reiterates that in financial statements prepared using the current financial resources measurement focus, interest cost incurred before the end of a construction period should be recognized as an expensite of a capital asset reported in a business-type activity or enterprise fund. GASB 89 also reiterates that in financial statements prepared using the current financial resources measurement focus, interest cost incurred before the end of a construction period should be recognized as an expenditure on a basis consistent with governmental fund accounting principles. The University is currently analyzing the impact of this statement.

(A Component Unit of the State of Oregon) Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

In May 2020, the GASB issued Statement No. 96, *Subscription-Based Information Technology Arrangements*, which will be effective for the fiscal year ending June 30, 2023. This statement provides guidance on the accounting and financial reporting for subscription-based information technology arrangements (SBITAs). This Statement defines an SBITA, establishes that an SBITA results in a rightto-use subscription asset (an intangible asset) and a corresponding subscription liability, provides the capitalization criteria for outlays other than subscription payments (including implementation costs of an SBITA), and requires note disclosures regarding an SBITA. The University is currently analyzing the impact of this statement.

In June 2020, the GASB issued Statement No. 97, Certain Component Unit Criteria, and Accounting and Financial Reporting for Internal Revenue Code Section 457 Deferred Compensation Plans-an amendment of GASB Statements No. 14 and No. 84, and a supersession of GASB Statement No. 32. Some requirements of the statement related to defined contribution post employment benefit plans and fiduciary defined benefit post-employment benefit plans are effective immediately. Management has concluded that these requirements have no material impact on OHSU. The remaining requirements are effective for the fiscal year ending June 30, 2022. This statement provides guidance intended to increase consistency and comparability related to reporting of fiduciary component units in situations where a potential component unit does not have a governing board and the primary government performs the duties that a governing board would typically perform. The Statement also intends to mitigate costs associated with the reporting of certain defined contribution pension plans, defined contribution other post-employment benefit (OPEB) plans, and employee benefit plans other than pension plans or OPEB plans (other employee benefit plans) as fiduciary component units in fiduciary fund financial statements. Lastly, the Statement seeks to enhance the relevance, consistency, and comparability of the accounting and financial reporting for Internal Revenue Code Section 457 deferred compensation plans that meet the definition of a pension plan, and for benefits provided through those plans. While management continues to assess the impact of implementation of this Statement, it is not currently expected the implementation to have a material impact on the financial statements.

(d) Financial Reporting Entity

As defined by generally accepted accounting principles, the financial reporting entity consists of OHSU as the primary government and its component units, which are legally separate organizations for which the primary government is financially accountable. Financial accountability is defined as a) appointment of the voting majority of the component units' board, and either (1) the ability to impose will by the primary government or (2) the possibility that the component unit will provide a financial benefit to or impose a financial burden on the primary government, or (b) the component unit is financially dependent on and there is potential for the component unit to provide specific financial benefits to, or impose specific burdens on, the primary government.

Component units are reported as part of the reporting entity under the blended or discrete method of presentation. Blending involves merging the component unit data with the primary government. There are three situations when blending is allowed: (1) when the board of the component unit is substantially the same as that of the primary government and there is a financial benefit or burden relationship between the primary government and the component unit or management of the primary government has operational responsibility for the component unit, (2) when the component unit provides services

(A Component Unit of the State of Oregon) Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

entirely, or almost entirely, to the primary government or otherwise exclusively, or almost exclusively, benefits the primary government even though it does not provide services directly to it, or (3) the component unit's total debt outstanding, including leases, is expected to be repaid entirely or almost entirely with resources of the primary government. OHSU Foundation and INSCO are considered to be blended component units as they serve the primary government exclusively. All transactions between OHSU and its blended component units are eliminated upon consolidation. Tuality and OHI are presented discretely since they have a separate board of directors and they do not provide services exclusively to OHSU. They are both considered a nonmajor component unit as there are no significant transactions with OHSU and there is not a significant financial benefit/burden relationship with OHSU.

Financial reports for INSCO and OHSU Foundation that include financial statements and required supplementary information are publicly available. These reports, and those of Tuality and OHI are, may be obtained by contacting the management of OHSU.

(e) Basis of Accounting

Basis of accounting refers to the timing of when revenues and expenses are recognized in the accounts and reported in the financial statements. OHSU reports as a proprietary fund within the governmental model. OHSU's financial statements have been prepared using the accrual basis of accounting with the economic resources measurement focus. Under this method of accounting, revenue is recognized when earned and expenses are recorded when liabilities are incurred without regard to receipt or disbursement of cash.

(f) Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in OHSU's financial statements include patient accounts receivable allowances, liabilities related to self-insurance programs, the fair value of interest rate swap agreements, and valuation of pension liabilities.

(g) Cash and Cash Equivalents

OHSU held no cash equivalents within cash and cash equivalents at June 30, 2021 or 2020.

(h) Investments

Investments are carried at fair value. Fair values are determined based on quoted market prices, where available. Investments in joint ventures are recorded using the equity method of accounting. Alternative investments, which are not readily marketable, are carried at estimated fair values as provided by investment managers. OHSU reviews and evaluates the values provided by the investment managers and agrees with the valuation methods and assumptions used in determining the fair value of the alternative investments. These estimated fair values may differ from the values that would have been used had a ready market for those securities existed.

(A Component Unit of the State of Oregon) Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

Net unrealized gains and losses are included in the net unrealized gain (loss) in fair value of investments in nonoperating revenues in the statements of revenues, expenses, and changes in net position. Interest, dividends, and realized gains and losses on investments are included in nonoperating revenues as investment income when earned.

(i) Inventories

Inventories consist primarily of supplies and pharmaceutical supplies in organized stores at various locations across the campus and in the Hospital. Inventories are recorded using several different methodologies dependent upon the operational use of the supplies and system capabilities. OHSU utilizes standard-cost and average-cost methodologies to record and report inventory value.

(j) Capital Assets

Capital asset acquisitions are stated at cost. Donated items are recorded on the basis of fair market value at the date of donation. OHSU capitalizes equipment additions greater than \$5 and capital projects greater than \$25. Maintenance, repairs, and minor replacements are expensed as incurred. When properties are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss on disposition is recorded as other in nonoperating revenue.

Interest on borrowed amounts during major construction is capitalized and amortized over the depreciable life of the related asset. During fiscal years 2021 and 2020, OHSU capitalized interest expense of approximately \$2,375 and \$2,377, respectively.

The provision for depreciation is determined by the straight-line method at rates calculated to amortize the cost of assets over the shorter of their estimated useful lives or the related lease term as follows: buildings and other improvements, 10 to 40 years; and equipment, 3 to 20 years.

(k) Net Position Classifications

Net position is classified into four net asset categories, in accordance with donor-imposed restrictions:

- Net investment in capital assets represents the depreciated value of capital purchases, net of related debt.
- Net position restricted, expendable, carries externally imposed time or purpose restrictions that expire in the future.
- Net position restricted, nonexpendable, carries externally imposed restrictions that never expire.
- Net position unrestricted carries no externally imposed restrictions.

Investment income earned on donor-restricted endowment funds in excess of the annual spending distribution is accounted for in the expendable restricted net position category.

The Foundation first apply restricted resources to an expense where an expense is incurred for a purpose for which both restricted and unrestricted funds are available.

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

A summary of restricted funds by restriction category for fiscal years ended June 30, 2021 and 2020 is as follows:

	 2021	2020
Restricted expendable:		
Research	\$ 488,399	481,238
Academic support	87,327	47,757
Instruction	69,368	37,666
Capital projects and planning	20,360	24,296
Student aid	70,631	51,193
Clinical support	19,877	10,193
Institutional support	5,875	3,537
Defined-benefit OPEB	4,328	6,200
Other	 35,756	21,034
	\$ 801,921	683,114
Restricted nonexpendable:		
Research	\$ 42,307	40,865
Instruction	82,527	77,077
Clinical support	_	1,469
Public service		4,800
Academic support	101,133	102,700
Student aid	48,485	46,430
Other	 30,244	22,585
	\$ 304,696	295,926

(I) Endowments

The endowment corpus is accounted for in the restricted, nonexpendable net position category and reported on the statements of net position as restricted long-term investments. The Foundation's spending policy for endowment funds is determined by the Executive Committee of the Board of Trustees (Executive Committee) and is calculated using a weighted average methodology comprised of an eight quarter moving average of the fair value of the endowment fund adjusted for inflation, and of the previous year's actual spending distribution adjusted for inflation. The resulting effective spending rate payout is then banded to be between 4.0% and 5.5% each year. The Executive Committee authorized a 4.5% distribution rate to calculate the effective spending rate for the years ended June 30, 2021 and 2020.

The Foundation's management and investment of donor-restricted endowment funds are subject to the provisions of the Uniform Prudent Management of Institutional Funds Act enacted by the State in January 2008.

(A Component Unit of the State of Oregon) Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

The endowment fund investment pool (endowment fund) held by the Foundation is the repository for funds from restricted, nonexpendable contributions where the principal amount cannot be used, but a spending distribution, described below, can be used for the designated purpose. The endowment fund also holds quasi-endowment funds, which have been designated as endowment by the Foundation's board of trustees. All interest, dividends, and changes in fair value on the endowment fund are allocated to the appropriate unrestricted or restricted net position classification as specified by the donor at the time of receipt. Endowment accounts receive spending distributions subject to the Foundation's board of trustees approved spending policy, which provides a predetermined amount of total return that can be spent for purposes designated by the donor. All expendable income restricted by the donor is carried as restricted, expendable net position until such time as the restriction has been met. At June 30, 2021 and 2020, the fair value of investments in the endowment fund was \$884,500 and \$735,500, respectively. The fair value of the unspent portion of endowments in excess of corpus at June 30, 2021 and 2020 was \$148,600 and \$48,900, respectively.

There were no endowment accounts with market value below corpus at June 30, 2021. At June 30, 2020, accumulated loss of \$229 related to endowment accounts with market value below corpus was reflected in nonexpendable restricted net position.

(m) Federal Income Taxes

OHSU, as a division of the State, is not subject to federal income taxes of the Internal Revenue Code, except for unrelated business income.

(n) State Appropriations

The Oregon State Legislature makes an appropriation to OHSU on a biennial basis. The appropriation is recognized as nonoperating revenues over the related appropriation period as applicable eligibility requirements are met.

(o) Research Activity

Restricted grants receivable represent receivables for grant activities on which OHSU has met all applicable eligibility requirements and on which the funds are available from the granting agency. As of June 30, 2021 and 2020, the grants receivable balance was \$27,086 and \$27,323, respectively, and was included in grant and contract receivables in the accompanying statements of net position. The balance in unearned revenue as of year-end represents amounts advanced for which OHSU has not met all applicable eligibility requirements. As of June 30, 2021 and 2020, the grants unearned revenue balance was \$53,453 and \$42,474, respectively.

(p) Operating Revenues

OHSU includes patient service revenue, student tuition and fees, gifts, grants and contracts, and other income from sales and services in operating revenues. These revenues are key components of the operations of OHSU.

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

(q) Net Patient Service Revenue

A summary of patient service revenues during the years ended June 30, 2021 and 2020 is as follows:

	 2021	2020
Gross patient charges	\$ 6,249,986	5,640,374
Contractual discounts	(3,648,628)	(3,252,987)
Bad debt adjustments	 (6,310)	(12,112)
Net patient service revenues	\$ 2,595,048	2,375,275

OHSU has agreements with third-party payors that provide for payments at amounts different from established rates. Payment arrangements include prospectively determined rates per discharge, outpatient case rates, reimbursed costs, discounted charges, and per diem payments. Net patient service revenue is reported at the estimated net realizable amounts due and determined to be collectible from patients, third-party payors, and others for services rendered and includes estimates for potential retroactive revenue adjustments under reimbursement agreements with third-party payors. Such estimates are adjusted in future periods as final settlements are determined.

A significant portion of OHSU's services are provided to Medicare, Medicaid, and Oregon Health Plan (OHP) patients under contractual arrangements. Inpatient acute care services rendered by OHSU to Medicare, Medicaid, and OHP program beneficiaries are generally reimbursed at prospectively determined rates per discharge. These rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors (i.e., Medicare severity diagnosis related groups or MS DRGs). Such payments include a capital cost component and may be greater or less than the actual charges for services. Most outpatient services related to Medicare beneficiaries are reimbursed prospectively under the ambulatory payment classifications methodology. Home health services related to Medicare beneficiaries are reimbursed under a prospective payment system methodology. OHSU is reimbursed for cost reimbursable items at a tentative rate with final settlement determined after audits of OHSU's annual cost reports by the Medicare fiscal intermediary and Medicaid.

OHSU partners with the State of Oregon (the State) in an innovative collaboration resulting in significant additional federal funding for Oregon's Medicaid program. Through the Intergovernmental Transfer (IGT) partnership with the State this program reduces OHSU's losses from the Medicaid program and enables support for OHSU's research and education missions. In fiscal years 2021 and 2020, the program generated \$144,250 and \$129,500, respectively, for research and education.

The laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that estimated third-party payor settlements payable, net will change by a material amount in the near term. For the years ended June 30, 2021 and 2020, OHSU received third-party settlements of \$(140) and \$2,598, respectively, as a result of final settlements of prior years' cost reports and revisions of estimates for prior years cost report settlements.

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

OHSU has also entered into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations to provide medical services to subscribing participants. The basis for payment to OHSU under these agreements includes prospectively determined rates per discharge, discounts from established charges, prospectively determined fee schedules, and certain capitated per member per month payment arrangements.

Significant concentrations of gross patient accounts receivable as of June 30, 2021 and 2020 were approximately as follows:

	2021	2020
Medicare and Medicare managed care contracts	22 %	23 %
Medicaid and OHP	20	19
Commercial and managed care insurance	55	56
Nonsponsored	3	2
	100 %	100 %

(r) Student Tuition and Fees Revenues

A summary of student tuition and fees revenues during the years ended June 30, 2021 and 2020 is as follows. In fiscal year 2020, in response to the COVID-19 pandemic, spring term academic programs were offered remotely using digital delivery methods. During this time student rotations and similar experiences were suspended, resulting in student tuition refunds of \$2,424 for affected programs.

		2021	2020
Gross student tuition	\$	97,569	92,129
Tuition discounts	(14,799)		(14,824)
Student tuition and fees revenues, net	\$	82,770	77,305

(s) Charity Care

OHSU provides care to patients who meet certain criteria under its charity care policy without charge or at amounts less than its published rates. Because OHSU does not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue.

OHSU maintains records to identify and monitor the level of charity care it provides. These records include the amount of charges forgone for services and supplies furnished under its charity care policy. Charity care provided measured as charges forgone and based on established rates was \$83,729 and \$78,097 in 2021 and 2020, respectively.

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

(t) Pledges and Estates Receivable

Pledges and estates receivable are recorded as receivables and revenues when all eligibility criteria are met in the appropriate net asset category based upon donor-imposed restrictions and are reported at fair value at the date the promise is received. Pledges are generally received within 5 to 10 years of the date of original commitment. The majority of estates are received within one year. Pledges and estates receivable, less reserves for estimated uncollectible amounts, are discounted to their present value using rates that range from 0.30% to 4.88%.

(u) Life Income Agreements

The Foundation has been named as remainder beneficiaries for various life income agreements. Life income agreements provide for contractual payments to designated beneficiaries for a specific period, after which the remaining principal and interest revert to the Foundation. Contributions received under life income agreements are included in long-term investments, restricted, with the corresponding commitment to the beneficiary included in liability for life income agreements in the accompanying statements of net position. The Foundation has investments with a fair value of \$62,500 and \$54,100 as at June 30, 2021 and 2020, respectively, related to its individually managed life income agreements.

(v) Moda Note Receivable

OHSU has contracts with, and receives patient revenues from the major health plans in Oregon. OHSU's guiding principle in developing payor provider partnerships is to ensure that Oregonians continue to have access to Oregon's public health sciences university and academic health center and its affiliates and that OHSU has access to major populations of Oregon across its missions of patient care, education, research, and outreach.

Since 2013, OHSU has partnered with Moda Health Plan, Inc. (Moda) to advance population health management. In December 2014, OHSU invested \$50,000 in Moda through a 10-year surplus note to help capitalize Moda's Oregon healthcare efforts. The principal balance of this note shall become due and payable in full on December 15, 2024, and the note bears interest on its unpaid principal balance at a rate equal to 4% per annum. Payment of interest and principal is subject to approval by the Oregon insurance commissioner, which is part of the Department of Consumer and Business Services (DCBS).

Moda had a large share of Oregon's individual insurance market during the initial years of the Affordable Care Act and has significant receivables due from the federal government under the risk corridor program that was designed to encourage plans to offer individual coverage. At that time, it was uncertain if, or when, the federal government would pay these amounts. In light of uncertain payment of federal risk corridor receivables, higher risk from losses at Moda, and the likelihood that interest payments will be deferred, OHSU recorded a valuation reserve of \$16,500 against the surplus note receivable as of June 30, 2015. In April 2020, the U.S. Supreme Court ruled in favor of Moda Health Plan and other insurers that had sued the federal government for backing out of support under the Affordable Care Act. The justices reversed a lower court's ruling that Congress had suspended the government's obligation to make such payments under the Affordable Care Act.

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

In February 2016, DCBS issued a consent order requiring Moda to sell a variety of assets and take steps to improve its financial position. In June 2017, as a result of Moda completing several transactions to generate the capital needed to meet regulatory standards, together with Moda reducing its risk by withdrawing from some markets, DCBS lifted the consent order. In February 2019, Delta Dental of California and Moda announced the completion of a \$152,400 investment by Delta Dental of California for a 49.5% ownership interest in Moda. The California Department of Managed Health Care (DMHC) and Oregon's DCBS have approved the investment. As a result of the improved financial position of Moda, the Oregon insurance commissioner allowed payment of accrued interest to OHSU of \$2,000 in fiscal year 2021.

OHSU reviewed the valuation of the note receivable as of June 30, 2021 and 2020 and has retained the current net valuation of \$33,500, which represents 0.8% and 0.9% of the University's total net position as of June 30, 2021 and June 30, 2020, respectively.

(2) Cash and Investments

OHSU holds substantially all of its cash, cash equivalents, and investment balances at financial institutions. OHSU's cash is insured by the Federal Deposit Insurance Corporation subject to standard limits. Additionally, a portion of cash and cash equivalents are collateralized deposits as required under the Oregon Revised Statutes (ORS).

OHSU's investment policies are approved by the board of directors and are accounted for as prescribed by GASB Statement No. 31, *Accounting and Financial Reporting for Certain Investments and for External Investment Pools*. Changes in the fair value of investments are included in nonoperating revenues. The composition of investments at fair value at June 30, 2021 and 2020 is as follows:

	 2021	2020
Short-term investments:		
Cash & cash equivalents	\$ 3	80
U.S. agency securities	4,016	3,737
Corporate obligations	82,676	133,008
Other fixed income	17,726	18,841
Equities	 	98,323
	 104,421	253,989
Funds held by trustee, current portion:		
Fixed income	 36,759	38,062
	 36,759	38,062

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

	2021	2020
Funds held by trustee, less current portion:		
Other fixed income \$	10,182	13,252
	10,182	13,252
Long-term investments – less current portion:		
Cash and cash equivalents	35,571	54,229
U.S. government securities	393,402	201,051
U.S. agency securities	89,353	108,325
Corporate obligations	369,112	391,381
Fixed income	139,843	126,472
Equities	616,455	283,208
Alternative investments	245,212	241,536
Joint ventures and partnerships	638,716	401,091
Real estate investments and other	65,788	60,076
	2,593,452	1,867,369
Total investments, all categories \$	2,744,814	2,172,672

The methods used to determine the fair value of financial instruments reflect market participant objectives and are based on the application of a valuation hierarchy. These methods are prescribed by GASB No. 72, *Fair Value Measurement and Application*. The hierarchy is based on the reliability of inputs as follows:

- Level 1 Valuation is based on quoted prices for identical financial instruments in active markets.
 OHSU does not adjust the quoted price for Level 1 financial instruments.
- Level 2 Valuation is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and independent pricing models or other model-based valuation techniques using observable inputs.
- Level 3 Certain types of financial instruments are classified as Level 3 within the valuation hierarchy because these financial instruments trade infrequently and, therefore, have little or no price transparency.

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

The following table presents a categorization, based on the foregoing valuation hierarchy, of OHSU's financial instruments measured at fair value as of June 30, 2021:

		Level 1	Level 2	Level 3	Fair value
Cash and money market funds	\$	_	52,807	_	52,807
U.S. government securities			393,402	—	393,402
U.S. agency securities			93,369	—	93,369
Domestic equity securities		304,032	—	134	304,166
International equity securities		64,140	—	—	64,140
Commercial paper			5,548	—	5,548
U.S. corporate securities		27,108	285,073	—	312,181
Non-U.S. corporate securities			139,607	—	139,607
Asset-backed securities			34,992	—	34,992
Venture capital and private equity			—	25,802	25,802
Mutual funds – fixed income only		141,967	—	—	141,967
Municipal bonds			3,956	—	3,956
Other fixed income		1,835	328	11,896	14,059
Alternative Investments			—	625	625
Real estate investments and other		1,400	1,437	3,015	5,852
	\$_	540,482	1,010,519	41,472	1,592,473
Investments measured using NAV					
per share or its equivalent					1,073,938
Equity method investments					78,403
Total assets				\$	2,744,814

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

The following table presents a categorization, based on the foregoing valuation hierarchy, of OHSU's financial instruments measured at fair value as of June 30, 2020.

	 Level 1	Level 2	Level 3	Fair value
Cash and money market funds	\$ _	48,853	_	48,853
U.S. government securities	—	201,130	_	201,130
U.S. agency securities	—	112,062	—	112,062
Domestic equity securities	126,902	_	134	127,036
International equity securities	43,795	_	—	43,795
Commercial paper		7,564		7,564
U.S. corporate securities	65,549	290,520		356,069
Non-U.S. corporate securities	—	168,322		168,322
Asset-backed securities	—	57,633		57,633
Venture capital and private equity	—	—	14,936	14,936
Mutual funds – fixed income only	131,965	10		131,975
Municipal bonds	—	3,931		3,931
Other fixed income	1,523	528	12,100	14,151
Real estate investments and other	 1,235	1,510	2,068	4,813
	\$ 370,969	892,063	29,238	1,292,270
Investments measured using NAV				
per share or its equivalent				825,084
Equity method investments				55,318
Total assets				\$2,172,672

There were no transfers of financial instruments between Level 1 or Level 2 classifications either in 2021 or 2020. Changes in Level 3 financial instruments are as follows:

	 2021	2020
Balance at beginning of year	\$ 29,238	10,879
Net realized gains (losses)	23	16
Net unrealized gains (losses)	537	(21)
Purchases	26,431	14,945
Sales	(553)	(256)
Transfer from (to) NAV per share, or its equivalent,		
classification from sales	 (14,204)	3,675
Balance at end of year	\$ 41,472	29,238

(A Component Unit of the State of Oregon) Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

Net realized and unrealized gains and losses on financial instruments classified as Level 3 are reported as nonoperating revenues as investment income when earned.

OHSU uses a practical expedient for the estimation of the fair value of investments in funds for which the investment does not have a readily determinable fair value. The practical expedient used by OHSU for certain financial instruments is the NAV per share. Valuations provided by fund administrators for these financial instruments consider variables such as the financial performance of underlying investments, recent sales prices and other pertinent information. The valuation is adjusted when changes to inputs and assumptions are corroborated by evidence, such as completed or pending third-party transactions in the underlying security and changes in financial results, data, or cash flows. Management or its discretionary investment partner reviews the valuations and assumptions provided by fund administrators for reasonableness and believes that the carrying amounts of these financial instruments are reasonable estimates of fair value.

The following table presents information for investments where either the NAV per share or its equivalent was used to value the investments as of June 30, 2021 and 2020:

	Redemption frequency	Redemption notice period
Domestic equities	Quarterly	3–90 days
Non-U.S. equities	Weekly to every	
	four years	3–90 days
Global equities	Quarterly	3–90 days
Venture capital/private equity	Event-driven	N/A
Marketable alternative investments	Monthly to annually	15–90 days
Real estate investments and contracts	Event-driven	N/A

Domestic Equities, Non-U.S. Equities and Global Equities funds represent investments in equities, both U.S. and international, and may include investments in developed and emerging markets.

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

(3) Investments and Related Policies

(a) Interest Rate Risk

As of June 30, 2021 and 2020, OHSU had the following investments and maturities at fair value:

			2021							
-		Maturity								
	Less than		C 40 Va ana	More than 10 years						
-	1 year	1–5 Years	6-10 Years	or none	Total					
Cash and money market funds \$	52,031	776		_	52,807					
U.S. government securities	1,862	373,911	16,232	1,397	393,402					
U.S. agency securities	4,016	76,059	5,384	7,910	93,369					
Domestic equity securities	_	_	_	428,262	428,262					
International equity securities	_	_	_	188,194	188,194					
Commercial paper	5,548	_	_	_	5,548					
U.S. corporate securities	52,064	163,397	16,977	79,743	312,181					
Non-U.S. corporate securities	37,198	98,127	3,995	287	139,607					
Asset-backed securities	12,004	6,328	2,725	13,935	34,992					
Joint ventures and partnerships	—	_	—	638,715	638,715					
Mutual funds – fixed income only	67,726	34,544	25,834	14,345	142,449					
Municipal bonds	225	1,971	1,664	96	3,956					
Other fixed income	—	238	90	_	328					
Alternative investments	_	_	_	245,212	245,212					
Real estate investments and other				65,792	65,792					
\$	232,674	755,351	72,901	1,683,888	2,744,814					

			2020						
		Maturity							
	Less than 1 year	1–5 Years	6–10 Years	More than 10 years or none	Total				
Cash and money market funds \$	48,168	685			48,853				
U.S. government securities U.S. agency securities	886 3,737	192,853 92,928	6,870 3,671	520 11,726	201,129 112,062				
Domestic equity securities				201,927	201,927				
International equity securities Commercial paper	7,564	_	_	179,604	179,604 7,564				
U.S. corporate securities	46,975	225,663	15,440	67,992	356,070				
Non-U.S. corporate securities Asset-backed securities	26,094 15,159	139,367 22,616	2,646 4,105	216 15,752	168,323 57,632				
Joint ventures and partnerships Mutual funds – fixed income only	67,997	 31,244	 19.566	401,091 13.541	401,091 132,348				
Municipal bonds	262	1,427	2,024	217	3,930				
Other fixed income Alternative investments	_	405	122	 241,536	527 241,536				
Real estate investments and other				60,076	60,076				
\$	216,842	707,188	54,444	1,194,198	2,172,672				

(A Component Unit of the State of Oregon) Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

OHSU held \$34,992 and \$57,632 of asset-backed securities collateralized primarily by auto loans, credit card receivables, and collateralized mortgage obligations as of June 30, 2021 and 2020, respectively. These securities are valued at their estimated fair values. The valuation of these securities is sensitive to principal prepayments, which may result from a decline in interest rates, and they are sensitive to an increase in average maturity, which may result from interest rate increases that lead to decreasing prepayments.

At June 30, 2021 and 2020, OHSU had certain joint ventures and partnerships, alternative investments, real estate investments, and other investments. These investments may contain elements of both credit and market risk. Such risks may include limited liquidity, absence of regulatory oversight, dependence upon key individuals, and nondisclosure of portfolio composition. Because these investments are not readily marketable, their estimated fair value is subject to uncertainty and, therefore, may differ from the value that would have been used had a ready market for such investments existed. Such differences could be material.

OHSU's investment policies vary based on the investment objectives of the portfolio. The operating and trustee-held portfolios seek to preserve principal with the intent of maximizing total return within appropriate risk parameters. Maturities of securities selected in these portfolios are driven by prevailing market conditions, while considering cash requirements of the organization.

The Foundation investment policies are established based on the investment objectives of the portfolio. The endowment portfolio, which is included in long-term investments in the accompanying statements of net position, seeks to produce a predictable and stable payout stream that increases over time, while achieving growth of corpus. The endowment fund may invest in cash and cash equivalents, fixed-income securities, U.S. and non-U.S. equity securities and other alternative investments. The objective for the current fund is to provide a reliable source of liquidity to meet short-term working capital needs. The current fund may invest in cash, cash equivalents, fixed income securities, equity mutual funds and ETFs, and quasi endowment within the endowment fund. The duration of the C/F 1-5 year portfolio shall be within a range of 75% to 125% of the Barclay's 1–5 Year Government/Credit Bond Index. The charitable gift annuity pool seeks to produce a relatively predictable and stable payout stream that will satisfy the funds distribution obligations while achieving long-term capital appreciation of the overall fund balance. The charitable gift annuity pool may invest in cash and cash equivalents, U.S. and non-U.S. equities, fixed-income, and real estate. Charitable trusts are managed to provide for the distribution of a stated income payment while attempting to achieve reasonable expected total returns. Charitable trust investment objectives and asset allocation guidelines are determined based on the individual circumstances of each trust account. Allowable investments for charitable trusts include cash and cash equivalents, U.S. and non-U.S. equities, fixed-income, real estate, and commodities.

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

(b) Credit Risk

The current fund investment policy requires minimum ratings or better from Standard & Poor's, Moody's, or Fitch as follows:

	Minimum Standard & Poor's rating	Minimum Moody's rating	Minimum Fitch rating
U.S. and foreign corporate indebtedness	BBB- or A-2	Baa3 or P-2	BBB- or F-2
Certificates of deposit	BBB- or A-2	Baa3 or P-2	BBB- or F-2
Foreign government, foreign agency, or			
supranational organization debt	A or A-1	A2 or P-1	A or F-1
Agency mortgage-backed securities	AAA	Aaa	AAA
Commercial mortgage-backed securities	AAA	Aaa	AAA
Asset-backed securities	AAA	Aaa	AAA
Municipal bonds	А	A2	А

At the time of purchase, securities must be rated by at least two of the three rating agencies. If the security is rated by all three agencies, the middle rating will apply. If only two ratings are available, then the lower rating will be used.

If the credit quality of a holding in the current fund declines so that it is below the level required as stated above, a decision will be made by the Investment Committee to hold or sell the security.

Investments in the charitable gift annuity pool shall have a minimum credit quality rating of Baa/BBB or an average credit rating of Baa/BBB for mutual funds or pooled funds and a minimum rating of A-1/P-1 for investments in commercial paper. The charitable trust investments generally have a minimum credit quality rating in investment-grade Baa/BBB bond investments and a minimum rating of A-1/P-1 for investments in commercial paper. However, an individual trust may hold up to 9% of the portfolio in below-investment-grade investments.

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

As of June 30, 2021 and 2020, OHSU had the following investments with credit rating at fair value:

	Credit rating				
	S&P	Total			
Investment type	or equivalent	2021	2020		
Cash and money market funds	AAA \$	_	6,030		
	BBB	40	_		
	BB	70	_		
	В	196	_		
	Below B	18	_		
	A-1+	40,791	41,802		
	Not rated	972	1,012		
	NA	10,720	9		
U.S. government securities	AAA	59,049	22,576		
	AA+	333,421	176,605		
	AA	932	577		
	A+	—	1,372		
U.S. agency securities	AAA	8,949	14,831		
	AA+	83,450	96,920		
	AA	193	194		
	А	—	118		
	NA	777			
Commercial Paper	A-1+	1,874	2,225		
	A-1	3,674	5,339		
U.S. corporate securities	AAA	116	46		
	AA+	—	1,666		
	AA	1,551	7,877		
	AA-	3,188	12,724		
	A+	11,734	24,881		
	A	39,077	48,860		
	A-	29,360	47,774		
	BBB+	73,233	79,248		
	BBB	50,733	49,018		
	BBB-	18,533	14,628		
	BB+	247	—		
	BB	1,379	1,614		
	В	539	603		
	Below B	155	97		
	Not rated	448	347		
	n/a	81,888	66,683		

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

	Credit rating S&P	Total	
Investment type	or equivalent	2021	2020
Non-U.S. corporate securities			
Non 0.0. corporate securities	AA+ \$		444
	AA-	5,923	15,953
	A+	7,295	22,291
	A	14,203	23,095
	A-	45,499	47,724
	BBB+	33,548	28,008
	BBB	20,444	24,072
	BBB-	7,606	6,316
	NA	5,089	420
Asset-backed securities	AAA	18,287	32,127
Asset backed securites	AA+	1,540	6,397
	AA	1,634	1,221
	A	669	764
	BBB	705	252
	BBB-	227	
	BB	167	110
	В	136	109
	Below B	1,770	1,530
	A-1+	.,	4,184
	Not rated	2,645	1,886
	NA	7,212	9,052
Mutual funds – fixed income only	AAA	67,812	87,604
	AA	16,176	4,882
	A	20,705	11,631
	BBB	22,486	13,525
	BB	5,741	4,440
	В	4,278	4,940
	Below B	2,846	3,062
	Not rated	2,405	2,264
Municipal bonds	AAA	390	192
	AA	3,020	3,362
	A	351	224
	BBB	79	97
	BB	89	56

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

Credit rating S&P		Tota	I
or equivalent		2021	2020
BBB	\$	_	85
BB		_	194
В		_	234
Below B		_	15
Not rated		328	_
NA		638,715	401,091
NA		245,212	241,536
NA		65,792	60,076
NA		428,262	201,927
NA		188,194	179,604
	\$	2,744,814	2,172,672
	S&P or equivalent BBB BB Below B Not rated NA NA NA NA	S&P or equivalent	S&P Tota or equivalent 2021 BBB — BB — BB — BB — Below B — Not rated 328 NA 638,715 NA 245,212 NA 65,792 NA 428,262 NA 188,194

(c) Concentration of Credit Risk

The current fund's investment policy limits investments in any issuer or issuer as follows:

	Maximum concentration
U.S. and foreign corporate indebtedness	No more than 3% per issuer
Certificates of deposit	No more than 5% per issuer
Foreign government, foreign agency, or	
supranational organization debt	No more than 5% per issuer
Agency mortgage-backed securities	No more than 15% per cusip
Commercial mortgage-backed securities	No more than 5% per cusip
Asset-backed securities	No more than 5% per cusip
Municipal bonds	No more than 5% per cusip

The investment policy relating to the charitable gift annuity pool limit investments in any one issue to a maximum of 5%, except for issues of the U.S. government and its agencies or diversified mutual funds, which may be held without limitation. The investment policy for charitable trusts limits investments in any one issue to a maximum of 5%, except for issues of the U.S. government and its agencies or diversified mutual funds.

As of June 30, 2021 or 2020, OHSU had no investments in excess of the thresholds discussed above.

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020

(Dollars in thousands)

(d) Foreign Currency Risk

OHSU's investment policies permit investments in international equities and other asset classes, which can include foreign currency exposure. The endowment fund allows for investments in international equities and in non-U.S. dollar-denominated bonds. The current fund allows up to 20% of the portfolio to be invested in non-U.S. sovereign or supranational issues. The charitable gift annuity pool investment policy allows up to 30% of the portfolio to be invested in international equities. The charitable trust investment policy allows up to 32% of the portfolio to be invested in international equities, based on the individual circumstances of each trust account. The following table details the fair value of foreign denominated securities by currency type:

	 Value (U.S. dollar)			
Foreign currency	 2021	2020		
British sterling pound	\$ 13,201	11,264		
Canadian dollar	1	8,671		
Euro	 21,432	14,257		
Total	\$ 34,634	34,192		

(4) Due from/to Contractual Agencies

Due from contractual agencies, reflected in patient accounts receivable under current assets in the statements of net position, represents amounts receivable from the State Medicaid Program (Medicaid), the Federal Medicare Program (Medicare), and other contractual agencies. Due to contractual agencies, reflected in other current liabilities in the statements of net position, represents amounts payable to Medicaid, Medicare and other contractual agencies. A summary of the balances as of June 30, 2021 and 2020 is as follows:

		Due from o agen		Due to cor ageno		Net, due f	rom (to)
	_	As of June 30, 2021	As of June 30, 2020	As of June 30, 2021	As of June 30, 2020	As of June 30, 2021	As of June 30, 2020
Medicaid Intergovernmental transfer Medicare Other contractual agencies	\$	18,802 5,357 —	23,122 16,176 8,714	(1,236) (3,910) (5,766)	(1,876) (2,770)	18,802 4,121 (3,910) (5,766)	23,122 14,300 (2,770) 8,714
	\$_	24,159	48,012	(10,912)	(4,646)	13,247	43,366

In 2017, OHSU worked with the state legislature and the Oregon Health Authority to build a program that leverages federal funds for the state's Medicaid program, maintain historical principles of support for OHSU's missions, and simplify the complexity of prior funding programs between OHSU and the State. The legislature approved the program in the Oregon Health Authority's 2017–2019 budget and Oregon's OHSU

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

Intergovernmental Transfer (IGT) Program was approved by the U.S. Centers for Medicare and Medicaid Services (CMS) and implemented on January 1, 2018, with the corresponding funding payments between entities beginning in March 2018. Under this IGT program, OHSU no longer pays the provider tax paid by other hospitals in Oregon. Instead, because OHSU is an Oregon public corporation, it transfers funds directly to the state to be used for Oregon's Medicaid program. The federal government matches funds used in the Medicaid program on approximately a three-to-one basis.

Oregon's Medicaid coordinated care organizations (CCO's) pay OHSU an additional amount per clinical service provided to patients as Quality and Access payments. These additional payments have been approved by CMS and are funded through a combination of OHSU's IGT and federal dollars. The purpose of these funds is to maintain access to the high quality unique academic health center services OHSU provides to Medicaid patients.

During fiscal year 2021 and 2021, respectively, OHSU made intergovernmental transfers of \$352,483 and \$321,517 to the State of Oregon. The State of Oregon used these dollars, and the corresponding federal match, for payment of Medicaid services throughout Oregon. Oregon's Medicaid CCO's paid OHSU \$469,546 and \$424,642, in fiscal year 2021 and 2020, respectively, through Quality and Access payments. The Quality and Access Payments and the Intergovernmental transfers, are included as a net reduction in the contractual discounts and represents a portion of the Medicaid payment for patient care services. A net benefit of the program, including funding from other federal and state sources, allows the University to have resources available to support OHSU's missions. During the year ended June 30, 2021 and 2020, the University was able to provide support for research and education of \$144,250 and \$129,500, respectively.

(5) Capital Assets

Capital assets for fiscal years ended June 30, 2021 and 2020 are listed by category below:

	 2021	2020
Land and land improvements	\$ 82,303	82,303
Buildings and other improvements	2,857,836	2,757,678
Equipment	1,134,725	1,072,012
Construction in progress	114,969	151,347
Accumulated depreciation	 (2,133,846)	(1,959,749)
Total capital assets, net	\$ 2,055,987	2,103,591

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

The following is a summary of capital assets for the fiscal years ended June 30, 2021 and 2020:

	_	June 30, 2020	Increases	Decreases	June 30, 2021
Capital assets not depreciated: Land and land improvements Construction in progress	\$	82,303 151,347			82,303 114,969
Total capital assets not depreciated		233,650	23,165	(59,543)	197,272
Other capital assets: Buildings and other improvements Equipment	_	2,757,678 1,072,012	100,158 68,579	(5,866)	2,857,836 1,134,725
Total other capital assets		3,829,690	168,737	(5,866)	3,992,561
Less accumulated depreciation: Buildings and other improvements Equipment	_	(1,132,904) (826,845)	(105,359) (73,173)	(1) 4,436	(1,238,264) (895,582)
Total accumulated depreciation	_	(1,959,749)	(178,532)	4,435	(2,133,846)
Other capital assets, net	_	1,869,941	(9,795)	(1,431)	1,858,715
Total capital assets, net	\$_	2,103,591	13,370	(60,974)	2,055,987

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

	_	Balance June 30, 2019	Increases	Decreases	Balance June 30, 2020
Capital assets not depreciated: Land and land improvements Construction in progress	\$	83,645 102,172		(1,342) (113,846)	82,303 151,347
Total capital assets not depreciated	_	185,817	163,021	(115,188)	233,650
Other capital assets: Buildings and other improvements Equipment	_	2,655,655 1,058,487	102,513 56,949	(490) (43,424)	2,757,678 1,072,012
Total other capital assets	_	3,714,142	159,462	(43,914)	3,829,690
Less accumulated depreciation: Buildings and other improvements Equipment	_	(1,031,448) (795,515)	(101,469) (75,124)	13 43,794	(1,132,904) (826,845)
Total accumulated depreciation	_	(1,826,963)	(176,593)	43,807	(1,959,749)
Other capital assets, net	_	1,887,179	(17,131)	(107)	1,869,941
Total capital assets, net	\$_	2,072,996	145,890	(115,295)	2,103,591

(6) Compensated Absences Payable

Vacation pay for classified employees is earned at 8 to 24 hours per month, depending on the length of service and classification, with a maximum accrual of up to 364 hours per employee and a maximum payment upon separation of up to 364 hours. Due to the COVID-19 pandemic, in recognition of the fact that employees may not be able to take time off during this time and therefore they would reach their accrual cap and stop accruing time off, the maximum accrual cap has been temporarily increased or waived. A maximum of 96 to 288 hours of vacation can be earned per year, depending on the length of service and classification. The yearly maximum accrual has also been waived due to COVID-19. Vacation/PTO pay for unclassified employees is earned at 14.67 to 17.33 hours per month, with a maximum accrual of 256 hours; due to COVID-19 the maximum accruals for unclassified employees has been set to 575 hours. The maximum payment of unused vacation/PTO hours for unclassified employees at termination varies is 80 hours at a 50% payment rate. There are a few exceptions, such as: the previous Management Service employees who transitioned to Unclassified Administrative on July 8, 1996 will be paid up to 250 hours unused accrued vacation hours, up to 100 hours per year based on their representational group.

(A Component Unit of the State of Oregon) Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

Sick leave is recorded as an expense when paid. Sick leave for employees is earned at the rate of 8 hours per month and a maximum of 96 hours per year, with no restrictions on maximum hours accrued. Employees in the following groups earn sick leave at the rate of 1 hour for 30 hours worked: resource, flex, temporary, unclassified below 0.5FTE, OHSU student, non-OHSU student, graduate assistant. In response to the COVID-19 pandemic, effective March 2020 employees were granted additional 112 sick leave hours prorated by FTE. The additional hours were intended to support employees who become sick prior to December 20, 2020: 80 hours available immediately when needed and 32 hours available after exhausting the employee's sick leave bank. The additional sick leave hours have been extended beyond December 2020. At the end of March 2021 the additional number of sick leave hours has been set to 80 hours prorated by FTE. These hours can be used for COVID-19 symptoms, for COVID-19 testing as well as for vaccination side effects. No liability exists for terminated employees.

There are two representational groups setup with time off accruals based on the academic year: Graduate Researchers United (GRU) and House Officers Union (HOU). PTO for GRU represented employees is earned at the rate of 13.33 hours per month, with a maximum of 160 hours per year. These hours can be used for time off and sick leave. No cash-out of unused PTO GRU is available. GRU represented employees can carryover 10 days from one academic year to another. House Officers are granted 160 hours of vacation and 120 hours sick leave, front-loaded at the beginning of the academic year. Sick leave hours unused by the HOU represented employees during the academic year will carry over to the following appointment year. Vacation cash-out is not allowed for HOU represented employees and sick leave hours are not paid at separation.

In recognition of Juneteenth, employees have been granted 8 hours paid leave prorated by FTE.

(7) Retirement Plans

The University, excluding blended component units, offers various pension plans to all qualified employees: the State's Public Employees Retirement System (PERS), which includes a cost-sharing, defined-benefit plan and a defined-contribution plan (individual account plan – IAP), the University Pension Plan (UPP), and the Clinical Retirement Plan (CRP).

(a) Defined-Benefit Pension Plan Descriptions

PERS is a cost-sharing, multiemployer retirement system available to units of state government, political subdivisions, community colleges, and school districts, containing multiple actuarial pools. Plan assets may be used to pay the benefits of the employees of any employer that provides pensions through the plan. As of the June 30, 2020 measurement date, there were 901 participating employers.

PERS is administered in accordance with ORS Chapter 238, Chapter 238A, and Internal Revenue Code Section 401(a). The State's legislature has delegated authority to the Public Employees Retirement Board (PERS Board) to administer the system. The PERS Board is composed of five trustees who administer retirement (service and disability), death, and retiree health insurance benefits. All members of the PERS Board are appointed by the governor and confirmed by the state senate. The governor designates the chairperson. Statute specifies PERS Board membership must be three people with experience in business management, pension management, or investing who are not members of the PERS system; one person who is either an employee of the state in a management position or a

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

person who holds an elective office in the governing body of a participating public employer other than the state; and one person representing public employees and retirees.

The State's PERS issues a publicly available financial report that includes financial statements and required supplementary information, including a 10-year historical trend information showing the accumulation of sufficient assets to pay benefits when due. Copies of the State's PERS's Annual Comprehensive Financial Report (ACFR) and Actuarial Valuations may be obtained from the PERS Web site at https://www.oregon.gov/pers/EMP/Pages/Actuarial-Financial-Information.aspx.

PERS comprises three separate defined-benefit groups: PERS Tier 1, PERS Tier 2, and Oregon Public Service Retirement Plan (OPSRP).

(i) Benefits Provided

The following describes the benefits provided through the PERS plan:

- (1) PERS Tier 1/PERS Tier 2
 - (a) The Tier 1/Tier 2 plans are closed to new members hired on or after August 29, 2003.
 - (b) Members are provided retirement, disability, and death benefits.
 - (c) Vesting occurs if either of the following conditions are met, unless the account is withdrawn:
 - 1. An active member in each of 5 calendar years
 - 2. Reached at least 55 years of age while working in a qualifying position (age 50 for police and fire members).
 - (d) The retirement allowance is payable monthly for life. It may be selected from 13 retirement benefit options. These options include survivorship benefits and lump-sum refunds.
 - (e) The basic benefit is based on years of service and final average salary. A percentage (2.00% for police and fire employees, 1.67% for general employees) is multiplied by the number of years of service and the final average salary. Benefits may also be calculated under either a formula plus annuity (for members who were contributing before August 21, 1981) or a money match computation if a greater benefit results.
 - (f) Normal retirement age for general members is age 58 for Tier 1 and age 60 for Tier 2, or any age with 30 years or more of retirement credit. Normal retirement age for police and fire members is age 55, or age 50 with 25 years or more of retirement credit. Benefits are reduced if normal retirement age is not attained.

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

(g) Annual Cost of Living Adjustments (COLA) of up to 2% annually for service time accrued before October 1, 2013; COLA for service time after that date uses a lower rate. Service time accrued in both periods is "blended."

(2) PERS OPSRP

- (a) The OPSRP plan is open to members hired on or after August 29, 2003.
- (b) Members are provided retirement, disability, and death benefits.
- (c) Vesting occurs if either of the following conditions are met, unless the account is withdrawn:
 - 1. Completion of at least 600 hours of service in each of five calendar years
 - 2. Reached normal retirement age as an active member on that date.
- (d) The retirement allowance is payable monthly for life.
- (e) The basic benefit is based on years of service and final average salary. A percentage (1.8% for police and fire employees, 1.5% for general employees) is multiplied by the number of years of service and the final average salary.
- (f) Normal retirement age for general members is age 65, or age 58 with 30 years or more of retirement credit. Normal retirement age for police and fire members is age 60, or age 53 with 25 years or more of retirement credit. Benefits are reduced if normal retirement age is not attained.
- (g) Annual COLA of up to 2% annually for service time accrued before October 1, 2013; COLA for service time after that date uses a lower rate. Service time accrued in both periods is "blended."
- (ii) Contributions

PERS funding policy provides for monthly employer contributions at actuarially determined rates. These contributions, expressed as a percentage of covered payroll, are intended to accumulate sufficient assets to pay benefits when due. This funding policy applies to the PERS defined-benefit plan and the OPEBs.

The employer contribution rate for active employees is established by the PERS Board based upon actuarial valuations, which are performed once every two years to determine the level of employer contributions. Employer contribution rates during the period were based on the December 31, 2017 actuarial valuation. The rates were based on a percentage of payroll and first became effective July 1, 2019. The employer contribution rate for PERS Tier 1 and Tier 2 was 19.96% from July 1, 2019 to June 30, 2021. The employer contribution rate for OPSRP was 13.35% (OPSRP Police and Fire, 17.98%) from July 1, 2019 to June 30, 2021.

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

The State and certain schools, community colleges, and political subdivisions have made lump-sum payments to establish side accounts and their rates have been reduced. OHSU made \$10,000 lump-sum payments to PERS during fiscal years 2021 and 2020, respectively. Amounts contributed postmeasurement date, including fiscal year 2021 and 2020 side account contributions of \$10,000, are recorded as deferred outflows in the amount of \$58,333 and \$60,841 for the years ended June 30, 2021 and 2020, respectively. In fiscal year 2020, OHSU participated in the Employer Incentive Fund (EIF), a program that provided a 25% match on qualifying employer lump-sum payments made after June 2, 2018, receiving a \$5,000 match payment. OHSU recognized the \$5,000 match payment as state appropriations in fiscal year 2021.

The defined-benefit pension plan contributions can be found in the required supplementary information.

(iii) Net Pension Liability

OHSU's proportionate share of the net pension liability for PERS as of June 30, 2021 and 2020 is \$595,311 and \$503,720, respectively, utilizing a June 30, 2020 and 2019 measurement date, respectively. The net pension liability for the June 30, 2021 and 2020 fiscal year-end was determined based on the results of the December 31, 2018 and December 31, 2017 actuarial valuation rolled forward to the respective measurement dates using standard actuarial procedures.

The basis for OHSU's proportion is actuarially determined by comparing OHSU's projected long-term contribution effort to the PERS cost-sharing, multiple-employer defined-benefit pension plan with the total projected long-term contribution effort of all participating employers. OHSU's proportionate share was 2.73% for the June 30, 2020 measurement date and 2.91% for the June 30, 2019 measurement date.

Senate Bill 1049, signed into law in June 2019, introduced a limit on the amount of annual salary included for the calculation of benefits. Beginning in calendar year 2020, annual salary in excess of \$195,000 (as indexed in future years) will be excluded when determining member benefits. As a result, future benefits for certain active members are now projected to be lower than prior to the legislation.

The benefits valued in the Net Pension Liability are required to be in accordance with the benefit terms legally in effect as of the relevant fiscal year-end for the plan. As a result, Senate Bill 1049 was reflected in the June 30, 2019 Net Pension Liability, and the salary limit provision is the only difference in the valuation basis used to determine the Net Pension Liability between the measurement dates June 30, 2018 and June 30, 2019.

For purposes of measuring the net pension liability, deferred outflows of resources and deferred inflows of resources related to pensions and pension expense, information about the fiduciary net position of PERS, and additions to/deductions from PERS' fiduciary net position have been determined on the same basis as they are reported by PERS. For this purpose, benefit payments (including refunds of employee contributions) are recognized when due and payable in accordance with the benefit terms. Investments are reported at fair value.

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

(iv) Proportionate Share of Pension Expense and Deferrals Related to Pensions

OHSU's pension expense for the years ended June 30, 2021 and 2020 was \$113,695 and \$109,907, respectively. The pension expense, which is considered period interest cost, service cost, amortization of deferred outflows and inflows, and changes in benefit terms, has increased since prior year and is included in salaries, wages, and benefits in the statements of revenues, expenses, and changes in net position.

In July 2017, the assumed rate of return on investments was reduced from 7.50% to 7.20%. The new assumed rate was also used in the actuarial valuation, which established the employer contribution rates for the 2019-21 biennium.

Deferred outflows of resources and deferred inflows of resources for pensions were related to the following sources as of the fiscal years ended June 30, 2021 and 2020:

		Deferred of reso	outflow	Deferred inflow of resources		
		2021	2020	2021	2020	
Differences between expected	•					
and actual experience	\$	26,201	27,779			
Changes of assumptions Net difference between projected and actual earnings		31,948	68,335	(1,119)	_	
on pension plan investments		70,001	—	—	(14,280)	
Changes in proportionate share			—	(43,760)	(39,012)	
Differences between contributions and OHSU's proportionate share of system contributions		3,262	3,095	(1,335)	(2,726)	
Total (prior to post-MD contributions)		131,412	99,209	(46,214)	(56,018)	
Contributions subsequent to the measurement date		58,333	60,841			
Gross deferred outflow (inflow) of resources	\$	189,745	160,050	(46,214)	(56,018)	

The contributions made subsequent to the measurement date of \$58,333 will be recognized as a reduction in the net pension liability during the year ending June 30, 2022.

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

Remaining amounts reported as deferred outflows of resources and deferred inflows of resources related to pension will be recognized in pension expense as follows:

	Fiscal year ending		Deferred outflow (inflow) of resources
2022		\$	11,954
2023			27,151
2024			27,580
2025			19,395
2026		-	(882)
	Total	\$	85,198

(v) Actuarial Methods and Assumptions

The following methods and assumptions were used in developing total pension liability reported as of June 30, 2021 and 2020.

Actuarial Methods and Assumptions	2021	2020
Valuation date	December 31, 2018	December 31, 2017
Measurement date	June 30, 2020	June 30, 2019
Experience study report	2018, published July 2019 Based on data for the experience period January 1, 2015 to December 31, 2018	2016, published July 2017 Based on data for the experience period January 1, 2013 to December 31, 2016
Actuarial assumptions:		
Actuarial cost method	Entry Age Normal	Entry Age Normal
Inflation rate	2.50 %	2.50 %
Long-term expected rate of return	7.20	7.20
Discount rate	7.20	7.20
Projected salary increases	3.50	3.50
Cost of Living Adjustments (COLA)	Blend of 2% COLA and graded COLA (1.25%/0.15%) in accordance with <i>Moro</i> case decision; blend based on service	Blend of 2% COLA and graded COLA (1.25%/0.15%) in accordance with <i>Moro</i> case decision; blend based on service

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

Actuarial Methods and Assumptions	2021	2020
Mortality	Healthy retirees and beneficiaries: Pub-2010 Healthy retiree, sex distinct, generational with Unisex, Social Security Data Scale, with job category adjustment and set-backs as described in the valuation.	Healthy retirees and beneficiaries: RP-2014 Healthy annuitant, sex-distinct generational with Unsex, Socia Security Data Scale, with colla adjustments and set-backs as described in the valuation.
	 Active members: Pub-2010 Employee, sex distinct, generational with Unisex, Social Security Data Scale, with job category adjustments and set-backs as described in the valuation. Disabled retirees: Pub-2010 Disabled retirees, sex-distinct, generational with Unsex, Social Security Data Scale, with job category adjustments and set-backs as described in the valuation. 	 Active members: RP-2014 Employees, sex-distinct, generational with Unisex, Social Security Data Scale, wi collar adjustments and setback as described in the valuation. Disabled retirees: RP-2014 Disabled retirees, sex-distinct, generational with Unsex, Social Security Data Scale.

Actuarial valuations of an ongoing plan involve estimates of the value of projected benefits and assumptions about the probability of events far into the future. Actuarially determined amounts are subject to continual revision as actual results are compared to past expectations and new estimates are made about the future. Experience studies are performed as of December 31 of even numbered years. The 2018 experience study, used in developing total pension liability reported as of June 30, 2020, was based on the data for the experience period January 1, 2015 to December 31, 2018.

(vi) Discount Rate

The discount rate used to measure the total pension liability at June 30, 2020 and June 30, 2019 was 7.20%, respectively. The projection of cash flows used to determine the discount rate assumed that contributions from plan members and those of the contributing employers are made at the contractually required rates, as actuarially determined. Based on those assumptions, the pension plan's fiduciary net position was projected to be available to make all projected future benefit payments of current plan members. Therefore, the long-term expected rate of return on pension plan investments for PERS was applied to all periods of projected benefit payments to

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

determine the total pension liability. The impact of a 1.00% decrease and increase in the discount rate on the net pension liability is as follows:

Discount Rate Sensitivity - Net Pension Liability

(Dollars in thousands)

	Current				
OHSU's proportionate share	 1% Decrease	discount rate	1% Increase		
June 30, 2021	883,987	595,311	353,242		
June 30, 2020	\$ 806,664	503,720	250,199		

(vii) Investments

The Oregon State Treasury is the investment officer for the State. Investment standards are established in ORS 293.726 and require funds to be managed as a prudent investor would do. The Oregon Investment Council (OIC) establishes policies for the investment and reinvestment of moneys in the Oregon Public Employees Retirement Fund (OPERF).

ORS 293.701 defines the investment funds over which OIC has responsibility. Included is the OPERF, which comprises the defined-benefit pension plan, the individual account program, and the other postemployment benefit plans. OIC establishes policies for the investment and reinvestment of moneys in the investment funds as well as the acquisition, retention, management, and disposition of investments in the investment funds. OIC is also responsible for providing an examination of the effectiveness of the investment program.

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

(1) Assumed Asset Allocation

The following table illustrates both the assumed and actual asset allocation. Deferred outflows of resources and deferred inflows of resources for pensions were related to the following sources as of the measurement date June 30, 2020:

Asset class/strategy	OIC policy low range	OIC policy high range	OIC target allocation	Asset class/strategy	Actual allocation ³
Debt securities	15.0 %	25.0 %	20.0 %	Debt securities	20.0 %
Public equity	27.5	37.5	32.5	Public equity	31.8
Real estate	9.5	15.5	12.5	Real estate	11.4
Private equity	14.0	21.0	17.5	Private equity	22.9
Alternatives portfolio	7.5	17.5	15.0	Alternatives portfolio	10.5
Opportunity portfolio ¹	_	3.0	—	Opportunity portfolio ¹	2.1
Risk Parity ²	_	2.5	2.5	Risk Parity ²	1.3
Total			100.0 %	Total	100.0 %

OIC Target and Actual Investment Allocation as of June 30, 2020*

¹ Opportunity portfolio is an investment strategy, and it may be invested up to 3% of total plan net position.

² Risk Parity is a new investment strategy added to the asset allocation mix in 2019.

³ Based on the actual investment value at 6/30/2020.

The following table illustrates both the assumed and actual asset allocation. Deferred outflows of resources and deferred inflows of resources for pensions were related to the following sources as of the measurement date June 30, 2019:

Asset class/strategy	OIC policy low range	OIC policy high range	OIC target allocation	Asset class/strategy	Actual allocation
Debt securities	15.0	25.0	20.0 %	Debt securities	20.1 %
Public equity	32.5	42.5	37.5	Public equity	36.4
Real estate	9.5	15.5	12.5	Real estate	11.1
Private equity	14.0	21.0	17.5	Private equity	21.4
Alternative equity	_	12.5	12.5	Alternative equity	8.9
Opportunity portfolio ¹	_	3.0		Opportunity portfolio ¹	2.1
Total			100.0 %	Total	100.0 %

OIC Target and Actual Investment Allocation as of June 30, 2019*

¹ Opportunity portfolio is an investment strategy, and it may be invested up to 3% of total plan net assets.

* The OIC target allocations are based on OIC asset classes as determined by each manager's primary investment type, not the financial statement classification of individual holdings. The target allocation amounts do not include deferred compensation plan investments. The actual investment allocation is based on the financial statement

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

investment classifications, including deferred compensation plan investments. Risk parity is included with the alternatives portfolio.

(2) Long-Term Expected Rate of Return

To develop an analytical basis for the selection of the long-term expected rate of return assumption the PERS Board reviews long-term assumptions developed by the consulting actuary's capital market assumptions team and the OIC investment advisers. The table below shows the actuary's assumptions for each of the asset classes in which the plan was invested at that time based on the OIC long-term target asset allocation. The OIC's description of each asset class was used to map the target allocation to the asset classes shown below. Each asset class assumption is based on a consistent set of underlying assumptions and includes adjustment for the inflation assumption. These assumptions are not based on historical returns, but instead are based on a forward-looking capital market economic model.

....

		2021		2020
	2021	Compound	2020	Compound
	Target	annual return	Target	annual return
Asset class	allocation*	(Geometric)	allocation*	(Geometric)
Core fixed income	9.60 %	4.07 %	8.00 %	3.49 %
Short-term bonds	9.60	3.68	8.00	3.38
Bank/leveraged loans	3.60	5.19	3.00	5.09
High-yield bonds	1.20	5.74	1.00	6.45
Large/mid cap U.S. equities	16.17	6.30	15.75	6.30
Small cap U.S. equities	1.34	6.68	1.30	6.69
Micro cap U.S. equities	1.34	6.79	1.30	6.80
Developed foreign equities	13.48	6.97	13.13	6.71
Emerging market equities	4.22	7.69	4.12	7.45
Non-U.S. small cap equities	1.93	7.25	1.88	7.01
Private equity	17.50	8.33	17.50	7.82
Real estate (property)	10.00	5.55	10.00	5.51
Real estate (REITs)	2.50	6.69	2.50	6.37
Hedge fund of funds – diversified	1.50	4.06	2.50	4.09
Hedge fund – event-driven	0.38	5.59	0.63	5.86
Timber	1.13	5.61	1.88	5.62
Farmland	1.13	6.12	1.88	6.15
Infrastructure	2.25	6.67	3.75	6.60
Commodities	1.13	3.79	1.88	3.84
Assumed inflation – mean		2.50		2.50
	100.00 %		100.00 %	

* Based on the OIC Statement of Investment Objectives and Policy Framework for the Oregon Public Employees Retirement Fund, revised as of April 24, 2019 ~~~~

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

(b) Other Retirement Plans

In addition to the PERS defined-benefit retirement plan, OHSU has two defined-contribution plans – the UPP and the CRP.

Effective July 1, 1996, OHSU established the UPP. The UPP is a defined-contribution plan, which is available as an alternate to PERS for employees who are not eligible for the CRP. Employees become fully vested in employer contributions over a three- to four-year period (depending on collective bargaining agreements) or upon reaching age 50. Contribution levels are determined by the collective bargaining agreements for union represented employees and the board of directors of OHSU for noncollective bargaining employees. In fiscal years 2021 and 2020, all employer contributions to the plan were 6% of salary.

For Oregon Nurse Association (ONA) represented employees and noncollective bargaining employees, which includes faculty, research, and unclassified administrative participating in the UPP; OHSU offers a 6% employee contribution, which is employer paid and is fully vested at the time of the contribution.

For employees who are members of the OPP who work in a qualifying position, OHSU offers participation in the CRP. The CRP is an employer-paid, defined-contribution plan, and contributions to this plan are fully vested at the time of the contribution. A variable contribution rate is used for employees enrolled prior to January 1, 2009. After January 1, 2009, a 12% contribution rate is used.

	<u> </u>	2021	2020
UPP:			
Employer contribution	\$	50,758	46,850
Employee contribution ⁽¹⁾		22,809	23,519
	\$	73,567	70,369
		2021	2020
CRP:			
Employer contribution	\$	33,705	31,251
	\$	33,705	31,251

⁽¹⁾ Of the employees' share, the employer paid \$22,809 and \$23,519 related to noncollective bargaining employees and ONA-represented employees in fiscal years 2021 and 2020, respectively.

OHSU offers all eligible employees, full and part time, an option to participate in one of two tax-deferred savings plans through the University Voluntary Savings Program. The 403(b) Plan is often referred to as a tax-deferred investment plan while the 457(b) Plan is referred to as a deferred compensation plan.

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

Both plans offer a variety of investment options. The contribution and investment earnings under these plans are tax deferred, which may be accumulated by the employee for distribution at a future date. ONA-represented, research and unclassified administrative employees hired July 1, 2017 or later, and enrolled in the UPP, are eligible for a 403(b) match paid by the employer, otherwise, all other contributions to these plans are made by the employee and are fully vested at the time of the contribution.

The Foundation has defined-contribution plans available for substantially all employees. The plans are funded through the purchase of a group annuity contract with an insurance company at a discretionary amount equal to 12% of eligible compensation. Contributions are fully vested after five years. The Foundation contributed \$1,300 and \$1,000 for the purchase of retirement annuities during the fiscal years ended June 30, 2021 and 2020, respectively.

(8) Postemployment Benefits Other than Pensions (OPEB)

OHSU administers a single-employer, defined-benefit healthcare plan for qualified employees and postemployment healthcare for retiring employees eligible to receive medical coverage. Additionally, for eligible PERS members, PERS administers the Retirement Health Insurance Account (RHIA) cost-sharing, multiple-employer defined-benefit OPEB plan.

(a) Single-Employer, Defined-Benefit Plans

(i) Plan Description

OHSU provides retiree health program coverage to current and future retirees of OHSU who qualify for retirement. Members who terminate prior to retirement eligibility or are not participating in the plan at retirement are not eligible to participate in the program. The employee must be actively enrolled in an OHSU medical plan at the time of separation from OHSU.

No assets are accumulated in a trust that meets the criteria in paragraph 4 of GASB Statement No. 75.

(ii) Employees Covered by Benefit Terms

The plan provides access for retiring employees to OHSU's employee medical plans at the same premium rates assessed to active employees. As of the measurement date of October 1, 2020, the following employees were covered by the benefit terms.

	October 1, 2020	October 1, 2019
Active employees	14,460	14,460
Retired members and others, receiving benefits	115	115
Total participants	14,575	14,575

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020

(Dollars in thousands)

(iii) Benefit Payments

Benefit payments made for the fiscal year-end June 30, 2021 and June 30, 2020 were \$674 and \$634, respectively.

(iv) Total OPEB Liability

The total OPEB liability as of the reporting date June 30, 2021 and 2020 is \$23,224 and \$20,955, respectively. The total OPEB liability was determined by an actuarial valuation as of October 1, 2019, calculated based on the discount rate and actuarial assumptions below, and was then projected forward to the measurement date. The liability is included in other noncurrent liabilities in the accompanying statements of net position.

(v) Actuarial Assumptions and Other Inputs

The following methods and assumptions were used in developing the total OPEB liability.

Fiscal year ending	June 30, 2021	June 30, 2020		
Valuation date	October 1, 2019	October 1, 2019		
Measurement date	October 1, 2020	October 1, 2019		
Reporting date	June 30, 2021	June 30, 2020		
Experience study report	2018 Oregon PERS	2018 Oregon PERS		
	Experience Study	Experience Study		
	Based on January 1, 2015	Based on January 1, 2015		
	to December 31, 2018	to December 31, 2018		
Inflation	2.50 %	2.50 %		
Discount rate*	2.21 %	2.66 %		

* The discount rate was based on the Bond Buyer General Obligation 20-Bond Municipal Index.

(vi) Expense and Deferred (Inflows)/Outflows of Resources Related to OPEB

The OPEB expense, which is considered concurrent period interest cost, service cost, amortization of deferred outflows and inflows, and effect of plan changes, was \$3,369 and \$860 for the fiscal year ended June 30, 2021 and June 30, 2020, respectively.

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

As of June 30, 2021 and 2020, the deferred inflows and outflows of resources were as follows:

		Deferred outflow of resources		Deferred of reso	
	_	2021	2020	2021	2020
Differences between expected and actual experience	\$	905	1.098		
Changes of assumptions	φ -	6,786	7,060	(824)	(1,037)
Total (prior to post-MD contributions)		7,691	8,158	(824)	(1,037)
Contributions subsequent to the measurement date	_	675	633		
Gross deferred outflow (inflow) of resources	\$_	8,366	8,791	(824)	(1,037)

The contributions made subsequent to the measurement date of \$675 will be recognized as a reduction in the total OPEB liability during the year ending June 30, 2022.

(b) Cost-Sharing, Multiple-Employer Defined-Benefit Plans

(i) Plan Description

ORS 238.420 established the RHIA. RHIA is a cost-sharing, multiple-employer OPEB plan for 904 participating employers. The plan was closed to new entrants hired on or after August 29, 2003.

The State's PERS issues a publicly available financial report that includes financial statements and required supplementary information, including a 10-year historical trend information showing the accumulation of sufficient assets to pay benefits when due. Copies of the Oregon Public Employees Retirement System's Comprehensive Annual Financial Report and Actuarial Valuations may be obtained from the PERS Web site at:

www.oregon.gov/pers/Pages/Financials/Actuarial-Financial-Information.aspx.

(ii) Benefits Provided

The plan authorizes a payment of up to sixty dollars from RHIA toward the monthly cost of health insurance for eligible PERS members.

(iii) Contributions

Contributions are advance-funded on an actuarially determined basis. The contractually required contributions for retiree healthcare liabilities for the period July 1, 2019 through June 30, 2021 are

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

0.06% for Tier One and Tier Two member-covered salaries to amortize the unfunded actuarial accrued liability. These rates were based on the December 31, 2017 actuarial valuation.

Contributions to the OPEB plan from OHSU were \$78 and \$153 for the years ended June 30, 2021 and June 30, 2020, respectively. Employees are not required to contribute to the OPEB plan.

(iv) OPEB Asset (Liability), OPEB Expense (Income), and Deferred Outflows of Resources and Deferred Inflows of Resources Related to OPEB

At fiscal year ended June 30, 2021 and 2020, OHSU reported an asset of \$4,328 and \$6,200 for its proportionate share of the net OPEB asset (liability), respectively. The net OPEB asset (liability) was measured as of June 30, 2019 and 2018 and the total OPEB asset (liability) used to calculate the net OPEB asset (liability) was determined by an actuarial valuation as of December 31, 2018 and December 31, 2017, respectively. OHSU's proportion of the net OPEB asset (liability) was based on a projection of OHSU's long-term share of contributions to the OPEB plan relative to the projected contributions of all participating members, actuarially determined. At the June 30, 2020 and 2019 measurement date, OHSU's proportionate share was 2.12% and 3.21%, respectively.

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

The OPEB expense (income), which is considered concurrent period interest cost, service cost, amortization of deferred outflows and inflows, and effect of plan changes, was \$(128) and \$(823), for the year ended June 30, 2021 and 2020, respectively. As of June 30, 2021 and 2020, the deferred inflows and outflows of resources were as follows:

	Deferred outflow of resources		Deferred inflow of resources		
	 2021	2020	2021	2020	
Differences between expected					
and actual experience	\$ —	—	(442)	(818)	
Changes of assumptions	—	—	(230)	(6)	
Net difference between					
projected and actual earnings	101				
on investments	481		—		
Changes in proportionate share	1,110	17	—	(383)	
Differences between					
contributions and OHSU's					
proportionate share of					
system contributions	 		(23)	(50)	
Total (prior to					
post-MD					
contributions)	1,591	17	(695)	(1,257)	
Contributions subsequent to					
the measurement date	78	153	_	_	
Gross deferred					
outflow (inflow)			()	(
of resources	\$ 1,669	170	(695)	(1,257)	

The contributions made subsequent to the measurement date of \$78 will be recognized as a reduction in the total OPEB liability during the year ending June 30, 2022.

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

(v) Actuarial Assumptions and Other Inputs

The total OPEB asset (liability) in the December 31, 2018 and 2017 actuarial valuations were determined using the following actuarial assumptions, applied to all periods included in the measurement.

Fiscal year ending	June 30, 2021	June 30, 2020
Valuation date	December 31, 2018	December 31, 2017
Measurement date	June 30, 2020	June 30, 2019
Reporting date	June 30, 2021	June 30, 2020
Experience study report	2018, published	2016, published
	July 24, 2019	July 26,2017
	Based on data for the	Based on data for the
	experience period	experience period
	January 1,2015 to	January 1,2013 to
	December 31,2018	December 31,2016
Actuarial assumptions:		
Actuarial cost method	Entry age normal	Entry age normal
Inflation rate	2.50%	2.50 %
Long-term expected rate of return	7.20%	7.20 %
Discount rate	7.20%	7.20 %

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

(9) Long-Term Debt, Bonds, and Capital Leases

Long-term debt, including related unamortized original issue discounts and premiums and capital leases at June 30, 2021 and 2020, is as follows:

		2021	2020
Revenue Bonds			
Series 1995A	\$	12,550	23,027
Series 2012A		73,905	79,230
Series 2015C		100,000	100,000
Series 2016B		199,835	199,835
Series 2017A		65,460	65,460
Series 2019A, B1, B2, and C		269,260	271,125
Direct Placement and Direct Purchase Revenue Bonds			
Series 2016A		50,000	50,000
Series 2017B		50,000	50,000
Series 2019D		50,000	50,000
Other Debt			
State of Oregon DSPA and TIC Agreements		25,369	26,084
City of Portland Local Improvement District Agreements		11,396	13,251
Unamortized Bond Premiums and Discounts		59,981	67,396
Capital Leases	_	2,202	1,987
	\$	969,958	997,395
Less: Current Portion of Long-Term Debt and Capital Leases	_	(24,082)	(23,419)
Noncurrent Long-Term Debt and Capital Leases	\$_	945,876	973,976

(a) Revenue Bonds

1995A Insured Revenue Bonds

The OHSU 1995A Insured Revenue Bonds (1995A Bonds) are tax-exempt capital appreciation bonds with interest accreted until maturity. The total amount outstanding for the 1995A Bonds is \$12,550 as of June 30, 2021; including principal amount of \$2,958 and an accreted interest balance of \$9,592. The 1995A Bonds have one remaining outstanding maturity due July 1, 2021 OHSU is required to maintain funds held by a trustee for debt service reserve requirements for these bonds in amounts sufficient to pay specified principal and interest payments. The 1995A Bonds are limited obligations of OHSU and are secured by OHSU's gross revenue. Pursuant to the Oregon Uniform Revenue Bond Act, the 1995A Bonds are not general obligation bonds and are payable solely from the revenue pledged.

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

2012A Revenue Bonds

OHSU Series 2012A Revenue Bonds (2012A Bonds) are tax-exempt fixed rate bonds with an outstanding principal amount of \$73,905 as of June 30, 2021. The 2012A Bonds have remaining maturities due July 1, 2021 through July 1, 2028, and require semiannual interest payments with coupon rates ranging from 3.0% to 5.0%. The 2012A Bonds are limited obligations of OHSU and are secured by OHSU's gross revenue. Pursuant to the Oregon Uniform Revenue Bond Act, the 2012A Bonds are not general obligation bonds and are payable solely from the revenue pledged.

2012E Revenue Bonds (Refunded)

OHSU Series 2012E Revenue Bonds (2012E Bonds) were refunded on December 19, 2019. The 2012E Bonds had an outstanding principal amount of \$126,365 that was refunded partially on a current refunding basis for \$21,900 through a tender offer and partially on an advance refunding basis for \$104,465 through the issuance of taxable debt. Bond proceeds from the issuance of the OHSU Series 2019A, Series 2019C, and Series 2019D Revenue Bonds were used in the refunding.

The 2012E Bonds are considered to be defeased in substance and the liability related to these bonds has been removed from long-term debt. The amount of in substance defeased debt outstanding as of June 30, 2021 is \$104,465. At the time of the advance refunding, funds were deposited into an irrevocable escrow account to provide for all future payments of principal and interest for the Series 2012E up to the redemption date of July 1, 2022 on which the University intends to redeem the bonds. The funds held in escrow for the refunding of the Series 2012E as of June 30, 2021 is \$108,998.

While the refunding resulted in an economic gain for OHSU, the event generated a deferred accounting loss, which has been reflected as a deferred outflow in the financial statements. The deferred accounting loss is being amortized using the effective-interest method over the original life of the 2012E Bonds. The balance of the deferred accounting loss from the refunding of the 2012E Bonds as of June 30, 2021 and 2020 are \$8,427 and \$9,361, respectively.

2015C Revenue Bonds

OHSU Series 2015C Revenue Bonds (2015C Bonds) are taxable fixed rate bonds with an outstanding principal amount of \$100,000 as of June 30, 2021. The 2015C Bonds have a maturity date of July 1, 2045, and require semiannual interest payments at a coupon rate of 5.0%. Proceeds from the Series 2015C were used for general public corporation or other public purposes, including, but not limited to, financing capital expenses, noncapital expenses, and costs related to the issuance of the bonds. The 2015C Bonds are limited obligations of OHSU and are secured by OHSU's gross revenues. Pursuant to the Oregon Uniform Revenue Bond Act, the 2015C Bonds are not general obligation bonds and are payable solely from revenue pledged.

2016B Revenue Bonds

OHSU Series 2016B Revenue Bonds (2016B Bonds) are tax-exempt fixed rate bonds with an outstanding principal amount of \$199,835 as of June 30, 2021. The 2016B Bonds have maturities due beginning July 1, 2028 through July 1, 2046 requiring semiannual interest payments with coupon rates ranging from 2.5% to 5.0%. The 2016B Bonds were issued to advance refund the Series 2009A Bonds

(A Component Unit of the State of Oregon) Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

and for capital improvements related to the construction of an ambulatory care tower and as a prerequisite to the receipt of state matching grant funds for the construction of a new Knight Cancer Research Building. The 2016B Bonds are limited obligations of OHSU and are secured by OHSU's gross revenues. Pursuant to the Oregon Uniform Revenue Bond Act, the 2016B Bonds are not general obligation bonds and are payable solely from revenue pledged.

2017A Revenue Bonds

OHSU Series 2017A Revenue Bonds (2017A Bonds) are tax-exempt fixed rate bonds with an outstanding principal amount of \$65,460 as of June 30, 2021. The 2017A Bonds have maturities due beginning July 1, 2033 through July 1, 2046 requiring semiannual interest payments with coupon rates ranging from 3.5% to 5.0%. The Series 2017A Bonds were issued for capital improvements related to the construction of an ambulatory care tower and as a prerequisite to the receipt of State matching grant funds for the construction of a new Knight Cancer Research Building. The 2017A Bonds are limited obligations of OHSU and are secured by OHSU's gross revenues. Pursuant to the Oregon Uniform Revenue Bond Act, the 2017A Bonds are not general obligation bonds and are payable solely from revenue pledged.

2019ABC Revenue Bonds

OHSU Series 2019A Revenue Bonds (2019A Bonds) are tax-exempt fixed rate bonds with an outstanding principal amount of \$129,145 as of June 30, 2021. The 2019A Bonds have remaining maturities due July 1, 2021 through July 1, 2049, requiring semiannual interest payments with coupon rates ranging from 3.0% to 5.0%.

OHSU Series 2019B1 Revenue Bonds (2019B1 Bonds) are tax-exempt put bonds with an outstanding principal amount of \$25,950 as of June 30, 2021. The 2019B1 Bonds have maturities due beginning July 1, 2040 through July 1, 2042, a first optional redemption date of November 1, 2022, and a mandatory purchase date of February 1, 2023. The 2019B1 Bonds require semiannual debt service payments at a coupon rate of 5.0%.

OHSU Series 2019B2 Revenue Bonds (2019B2 Bonds) are tax-exempt put bonds with an outstanding principal amount of \$49,120 as of June 30, 2021. The 2019B2 Bonds have maturities due beginning July 1, 2040 through July 1, 2042, a first optional redemption date of November 1, 2024, and a mandatory purchase date of February 1, 2025. The 2019B2 Bonds require semiannual debt service payments at a coupon rate of 5.0%.

OHSU Series 2019C Revenue Bonds (2019C Bonds) are taxable fixed rate bonds with an outstanding principal amount of \$65,045 as of June 30, 2021. The 2019C Bonds have maturities due beginning July 1, 2023 through July 1, 2032, and require semiannual interest payments with coupon rates ranging from 2.2% to 3.0%.

The 2019A, 2019B1, 2019B2, and 2019C Bonds were issued to refund the OHSU Series 2012E Revenue Bonds on a current and advance refunding basis, to refund the OHSU Series 2012C and Series 2012B-3 Revenue Bonds on a current refunding basis, to refund the OHSU Series 2015A and 2015B Revenue Bonds on a current refunding basis, to pay for capital improvements for the University,

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

and to pay for costs of issuance for the bonds. The 2019A, 2019B1, 2019B2, and 2019C Bonds are limited obligations of OHSU and are secured by OHSU's gross revenues. Pursuant to the Oregon Uniform Revenue Bond Act, the 2019A, 2019B1, 2019B2, and 2019C Bonds are not general obligation bonds and are payable solely from revenue pledged.

(b) Direct Placement and Direct Purchase Bonds

2016A Revenue Bonds

OHSU Series 2016A Revenue Bonds (2016A Bonds) are tax-exempt fixed rate direct placement bonds with an outstanding principal amount of \$50,000 as of June 30, 2021. The 2016A Bonds were issued for capital improvements related to the construction of an ambulatory care tower and as a prerequisite to the receipt of state matching grant funds for the construction of a new Knight Cancer Research Building. The 2016A Bonds are subject to event of default provisions that may cause the full outstanding amount to become immediately due and payable at the discretion of the bondholder representative. Event of default provisions are extensive with certain provisions subjective in nature based on materiality. Some notably event of default provisions included, but not limited to, are if the University fails to pay principal or interest on any bond when due, if the University makes any material misrepresentation in connection to the agreement and if the University fails to meet the debt covenants requiring financial disclosures. The 2016A Bonds are limited obligations of OHSU and are secured by OHSU's gross revenues. Pursuant to the Oregon Uniform Revenue Bond Act, the 2016A Bonds are not general obligation bonds and are payable solely from revenue pledged.

2017B Revenue Bonds

OHSU Series 2017B Revenue Bonds (2017B Bonds) are tax-exempt fixed rate direct placement bonds with an outstanding principal amount of \$50,000 as of June 30, 2021. The 2017B Bonds were issued for capital improvements related to the construction of an ambulatory care tower and as a prerequisite to the receipt of state matching grant funds for the construction of a new Knight Cancer Research Building. The 2017B Bonds are subject to event of default provisions that may cause the full outstanding amount to become immediately due and payable at the discretion of the bondholder representative. Event of default provisions are extensive with certain provisions subjective in nature based on materiality. Some notably event of default provisions included, but not limited to, are if the University fails to pay principal or interest on any bond when due, if the University makes any material misrepresentation in connection to the agreement, and if the University fails to meet the debt covenants requiring financial disclosures. The 2017B Bonds are limited obligations of OHSU and are secured by OHSU's gross revenues. Pursuant to the Oregon Uniform Revenue Bond Act, the 2017B Bonds are not general obligation bonds and are payable solely from revenue pledged.

2019D Revenue Refunding Bonds

OHSU Series 2019D Revenue Bonds (2019D Bonds) are taxable fixed rate direct purchase rate bonds with an outstanding principal amount of \$50,000 as of June 30, 2021. The 2019D Bonds were issued to refund a portion of the OHSU Series 2012E Revenue Bonds on an advance refunding basis. The 2019D Bonds are subject to event of default provisions that may cause the full outstanding amount to become immediately due and payable at the discretion of the bondholder representative. Event of

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

default provisions are extensive with certain provisions subjective in nature based on materiality. Some notably event of default provisions included, but not limited to, are if the University fails to pay principal or interest on any bond when due, if the University makes any material misrepresentation in connection to the agreement, and if the University fails to meet the debt covenants requiring financial disclosures. The 2019D Bonds are limited obligations of OHSU and are secured by OHSU's gross revenues. Pursuant to the Oregon Uniform Revenue Bond Act, the 2019D Bonds are not general obligation bonds and are payable solely from revenue pledged.

(c) Other Debt

State of Oregon DSPA and TIC Agreements

OHSU has agreements with the Oregon State Board of Higher Education (on behalf of the State of Oregon) pursuant to which OHSU makes semiannual payments to the State in amounts sufficient to pay when due principal, interest and other charges with respect to debt incurred by the State for the benefit of OHSU. These agreements between OHSU and the State are commonly referred to as the Debt Service Payment Agreement (DSPA) and the Tenancy in Common Agreement (TIC).

In 1995, OHSU became an independent public corporation pursuant to an act of the Oregon Legislative Assembly (the Act). Pursuant to the Act, OHSU assumed liability for outstanding indebtedness of the State previously incurred for the benefit of OHSU. To evidence this obligation, OHSU and the Oregon State Board of Higher Education (on behalf of the State of Oregon) entered into the DSPA.

In 2011, OHSU entered into a joint construction project with the Oregon State Board of Higher Education to build the Robertson Life Sciences Building (previously referred to as the Collaborative Life Sciences Building) on OHSU's Schnitzer Campus located in Portland's South Waterfront to be jointly owned, developed, and operated collaboratively with Portland State University and Oregon State University. As partial consideration for OHSU's receipt of 50% undivided percentage interest in the tenancy in common of the Robertson Life Sciences Building, OHSU entered into the TIC in which OHSU agreed to pay to the State for a portion of the debt issued by the State to fund the construction of the project.

Pursuant to the DSPA and TIC, OHSU has an obligation to the State, and the State is the bond issuer. From time to time, the State has refinanced its bonds, some of which has affected the underlying bonds that were assigned to the DSPA and TIC. In fiscal year 2021, the State refunded several bonds that affected OHSU's debt service due under the DSPA and TIC.

On July 16, 2020, the State of Oregon refunded OHSU assigned debt principal of \$11,988 from State bonds including the 2010 Series A, 2011 Series E, 2011 Series G, and a portion of the 2012 Series A. To refund this debt, the State issued the 2020 Series O Bonds of which OHSU is assigned \$12,895 in principal to be repaid with maturities out to fiscal year 2042. The State's refunding increased the amount of debt principal due for OHSU, but resulted in interest savings over the life of the bonds. OHSU debt service payments, including principal and interest, was \$22,056 under the old refunded bonds and is \$17,747 under the new bonds issued, a decrease of \$4,309. The economic gain or net present value savings for OHSU, as calculated by the State, was \$3,850.

(A Component Unit of the State of Oregon) Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

Additionally, on May 12, 2021, the State of Oregon refunded debt that minimally impacted OHSU. The State refunded OHSU assigned debt of \$1.8 thousand from the State bonds including the 2013 Series A, and 2013 Series B. To refund this debt, the State issued the 2021 Series H and 2021 Series I Bonds of which OHSU is assigned \$15.0 thousand in principal to be repaid with maturities out to fiscal year 2024. The State's refunding increased the amount of debt principal due for OHSU, but resulted in interest savings over the life of the bonds. OHSU debt service payments, including principal and interest, was \$19.2 thousand under the old refunded bonds and is \$15.2 thousand under the new bonds issued, a decrease of \$4.0 thousand. The economic gain or net present value savings for OHSU, as calculated by the State, was one hundred sixty nine dollars. This refunding was part of a larger transaction that benefited other State universities, but only minimally impacted OHSU.

The total amount outstanding for debt assigned to OHSU under the DSPA and TIC as of June 30, 2021 and 2020 are \$25,369 and \$26,084. These balances are included in long-term debt in the statements of net position. Payments under the terms of the DSPA and TIC by OHSU represents full satisfaction of any legal obligation related to such outstanding indebtedness.

City of Portland Local Improvement District Agreements

OHSU initially entered into various local improvement district agreements (LIDs) with the City of Portland, Oregon during fiscal years 2007 and 2008 for real improvements to Portland's South Waterfront District. During fiscal year 2012, OHSU entered into additional LIDs with the City of Portland for real improvements to the same Portland South Waterfront District. All outstanding LIDs debt is scheduled to be repaid in semiannual installments, with maturities through fiscal year 2029 and interest rates ranging between 4.19% and 4.71%. The total outstanding amount of principal as of June 30, 2021 and 2020 are \$11,396 and \$13,251, respectively, and have been included in long-term debt in the statements of net position.

(d) Lines of Credit

Pursuant to the First Amendment to Credit Agreement dated April 13, 2021 between OHSU and U.S. Bank National Association, OHSU entered into a revolving line of credit with U.S. Bank National Association in an aggregate principal not to exceed \$100,000. The credit agreement has a maturity date within one year ending on April 12, 2022. Interest is payable on a monthly basis and interest rates are variable based on the one-month LIBOR rate and an applicable spread. The line of credit is subject to event of default provisions that would cause the full outstanding amount to become immediately due and payable. Event of default provisions are extensive with certain provisions subjective in nature based on materiality. Some notably event of default provisions included, but not limited to, are if the University fails to pay principal or interest on the loan when due, if the University makes any material misrepresentation in connection to the agreement, and if the University fails to meet the debt covenants requiring financial disclosures.

Previously, OHSU obtained two revolving lines of credit on April 14, 2020 in the amounts of \$100,000 and \$50,000, respectively, with both credit agreements having a maturity date within one year ending on April 13, 2021. These lines of credit were established to provide short-term operational flexibility in connection with OHSU's ongoing efforts to respond to the COVID-19 pandemic. Upon the execution of

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020

(Dollars in thousands)

the First Amendment to Credit Agreement on April 13, 2021, OHSU now only has a single line of credit available with U.S. Bank National Association in the amount of \$100,000. As of June 30, 2021, OHSU has not drawn its line of credit.

(e) Unamortized Bond Premiums and Discounts

OHSU has issued bonds at a premium and bonds at a discount. The premium and discount are amortized over the life of the bond and the unamortized balances are included in long-term debt in the statements of net position. The unamortized net premium balances as of June 30, 2021 and June 30, 2020 are \$59,981 and \$67,396.

(f) Interest Rate Swap Agreement

As of June 30, 2021 and 2020, OHSU held one interest rate swap agreement with Wells Fargo Bank, NA. The balances of OHSU's swap as of June 30, 2021 and 2020 are as follows:

		Notional		Fair va	lue	
	_	2021	2020	2021	2020	
Wells Fargo swap	\$	70,200	70,200	(17,315)	(26,699)	
	\$	70,200	70,200	(17,315)	(26,699)	

The notional amount of the outstanding swap with Wells Fargo Bank, NA declines over time and terminates on July 1, 2042. OHSU's interest rate swap agreement with Wells Fargo Bank, NA was established when OHSU entered into an International Swaps and Derivatives Association swap novation in fiscal year 2016.

Under the swap agreement with Wells Fargo Bank, NA, OHSU makes fixed rate interest payments of 2.506% and receives a variable rate payment computed as 70.00% of the London Interbank Offered Rate. The fair value represents the estimated amount that OHSU would pay or receive if the swap agreement was terminated at year-end, taking into account current interest rates and the creditworthiness of the underlying counterparty. Total net cash payments made to the swap counterparty were \$1,694 and \$1,030 during the years ended June 30, 2021 and 2020, respectively.

On December 19, 2019, OHSU refunded the Series 2012B-3 and Series 2015A Bonds, which were the assigned hedges under the interest rate swap. As of June 30, 2021, the outstanding interest rate swap has no assigned hedges and is not associated with any variable rate debt.

The companion debt instrument for the interest rate swap and deferred amortization of debt instruments were adjusted based on the market value of the swap on the date of the termination of the related hedge assignments. The value of the companion debt instrument is \$13,763 and \$14,815 as of June 30, 2021 and 2020, respectively. The deferred amortization of debt instruments is \$6,091 and \$7,342 as of June 30, 2021 and 2020, respectively. OHSU continues to amortize both the companion debt instrument and the deferred amortization of debt instruments. In addition, without the hedged debt

(A Component Unit of the State of Oregon) Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

associated with the swap, the change in market value of the interest rate swap, as determined after the date of debt refinancing, is now recorded to an unrealized gain or loss. In fiscal year 2021, OHSU recorded an unrealized gain of \$9,384 for the swap. In the previous fiscal year 2020, OHSU recorded an unrealized loss of \$11,884 for the swap.

OHSU is exposed to swap credit risk, which is the risk that the counterparty will not fulfill its obligation. As of June 30, 2021 and 2020, the counterparties' long-term credit ratings were A+ from Standard & Poor's, Aa2 from Moody's, and AA- from Fitch. Additionally, the swap exposes OHSU to basis risk, which is the risk that arises when the relationship between the rates on the variable rate bonds and the swap formulas noted above vary from historical norms. If this occurs, swap payments received by OHSU may not fully offset its bond interest payments.

OHSU may be additionally responsible for posting collateral based on its credit ratings and if the total swap liability exceeds a predetermined value on its reporting date. Based on current credit ratings for OHSU and the current market value of the swap, OHSU is not required to post any collateral at this time.

OHSU or the counterparty may terminate the swap if the other party fails to perform under the terms of the contracts. The swap has the option of early termination with a cash settlement.

(g) Capital Leases

OHSU has entered into agreements for the lease of certain equipment and vehicles. Amortization of the capitalized value of these assets is included in depreciation and amortization expense on the statements of revenues, expenses, and changes in net position. Future minimum lease payments under these agreements are as follows:

Year ending June 30:	
2022	1,284
2023	348
2024	302
2025	269
2026	135
2027 - 2031	
	2,338
Less amount representing interest	(136)
	2,202
Less current portion	(1,234)
\$	968

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

(h) Summary of Long-Term Debt, Bonds, and Capital Leases

Long-term debt and capital lease balances as of June 30, 2021 and 2020 are \$969,958 and \$997,395, respectively. As of June 30, 2021, the total long-term debt balance of \$969,958 includes the current portion of \$24,082 and the noncurrent portion of \$945,876. These balances comprises revenue bonds, direct placement and purchase rate bonds, other debt related to the DSPA, TIC and LID agreements, unamortized balances for bond premiums and discounts, and capital leases.

Principal and interest payments under the long-term debt obligations and capital leases are as follows:

	Principal	Interest	Total
Year(s) ending June 30:			
2022	14,490	46,143	60,633
2023	23,389	35,710	59,099
2024	23,815	34,637	58,452
2025	24,623	33,681	58,304
2026	25,438	32,630	58,068
2032–2036	143,501	145,760	289,261
2037–2041	142,995	117,645	260,640
2042–2046	150,315	85,823	236,138
2047–2051	242,840	47,963	290,803
2051–2055	108,995	2,645	111,640
	\$900,401	582,637	1,483,038

(i) Changes in Long-Term Liabilities

Changes in OHSU's total long-term liabilities during the fiscal years ended June 30, 2021 and 2020 is summarized below:

		June 30,			June	30, 2021
		2020			Current	Noncurrent
	_	Balance	Increases	Decreases	Portion	Portion
Liability for self-funded						
insurance programs	\$	73,796	36,093	(22,382)	40,868	46,639
Liability for life income						
agreements		20,741	5,254	(2,503)	—	23,492
Long-term debt		995,408	1,620	(29,272)	22,848	944,908
Long-term capital leases		1,987	1,303	(1,088)	1,234	968
Other noncurrent liabilities		55,098	65,916	(32,881)	—	88,133
Pension liability	_	503,720	302,855	(211,264)		595,311
	\$_	1,650,750	413,041	(299,390)	64,950	1,699,451

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

		June 30,	Jun			e 30, 2020		
	_	2019 Balance	Increases	Decreases	Current Portion	Noncurrent Portion		
Liability for self-funded insurance programs Liability for life income	\$	72,903	27,006	(26,113)	33,935	39,861		
agreements		23,235	947	(3,441)	_	20,741		
Long-term debt		973,506	356,904	(335,002)	22,476	972,932		
Long-term capital leases		5,825	104	(3,942)	943	1,044		
Other noncurrent liabilities		33,483	21,615	—	_	55,098		
Pension liability	_	456,006	277,791	(230,077)		503,720		
	\$	1,564,958	684,367	(598,575)	57,354	1,593,396		

(10) Life Income Fund – Annuities

Assets contributed as life income agreements are recorded at their fair value. The present value of estimated future payments to beneficiaries of annuity agreements is recorded as a liability. The present values of these estimated payments were determined on the basis of published actuarial factors for the ages of the respective annuity beneficiaries. Differences between the assets contributed and the expected payments to be made to beneficiaries have been recorded as donations in the year established.

Life income contributions, including gifts, grants, and contracts in the accompanying statements of revenues, expenses, and changes in net position, are as follows for the fiscal years ended June 30, 2021 and 2020:

		2021	
	Agreements	Asset	Liability
Charitable remainder unitrusts	3 \$	781	2
Charitable lead unitrusts	7	1,805	1,045
Life estate agreements	1	535	55
Total	\$	3,121	1,102

		2020	
	Agreements	 Asset	Liability
Charitable remainder unitrusts	3	\$ 2,297	1,250
Charitable lead unitrusts			—
Charitable gift annuities	/	 310	148
Total	10	\$ 2,607	1,398

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

The assets and corresponding liabilities related to life income agreements are included in long-term investments, restricted, and the liability for life income agreements in the accompanying statements of net position.

Total life income instruments held at June 30, 2021 and 2020 are as follows:

		2021	
	Agreements	Asset	Liability
Charitable remainder unitrusts	47 \$	22,405	6,958
Charitable lead unitrusts	3	26,143	9,116
Charitable remainder trust annuities	1	79	59
Charitable gift annuities	168	12,021	6,586
Life estate agreements	4	2,031	773
Total	\$	62,679	23,492

		2020	
	Agreements	 Asset	Liability
Charitable remainder unitrusts	55	\$ 21,649	6,335
Charitable lead unitrusts	3	21,188	7,857
Charitable remainder trust annuities	1	93	67
Charitable gift annuities	178	10,170	5,906
Life estate agreements	3	 977	576
Total	240	\$ 54,077	20,741

Thirteen charitable gift annuities, included above, have been reinsured with insurance carriers in order to reduce liability exposure. Under the reinsurance contracts, the future beneficiary payments are paid by the insurance carrier. To the extent the insurance carriers are unable to perform under the contract, OHSU would be responsible for payment.

(11) Funds Held in Trust by Others

The Foundation is the named beneficiaries of 39 and 40 trusts held by outside trustees as of June 30, 2021 and 2020, respectively. The reported fair market value of trust assets held by others was \$59,500 and \$47,100 of the years ended June 30, 2021 and 2020, respectively. The Foundation record contributions as trust distributions occur. Trust distributions of \$1,800 and \$1,900 were recorded as contributions during the fiscal years ended June 30, 2021 and 2020, respectively.

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

(12) Pledges and Estates Receivables

The Foundation had the following pledges and estates receivable as of June 30, 2021 and 2020:

		2021	2020
Pledges maturing within 1 year Pledges maturing within 2–10 years	\$	121,862 252,048	86,308 323,229
		373,910	409,537
Less allowance for uncollectible pledges		(920)	(2,373)
		372,990	407,164
Less discount for net present value		(9,542)	(14,711)
Total net pledges receivable		363,448	392,453
Estates receivable		6,512	15
Less allowance for uncollectible estates Less discount for net present value (rates of 0.22% to 0.98%	.) <u> </u>	(1) (239)	(1)
Total net estates receivable		6,272	14
Total pledges and estates receivable	\$	369,720	392,467

(13) Commitments and Contingencies

(a) Liability for Self-Funded Insurance Programs

Coverage for professional liability, patient general liability, and automobile liability is provided through OHSU's solely owned captive insurance company, OHSU Insurance Company. Current coverage limits are \$4,650 per claim with an annual aggregate of \$17,500 for professional liability and \$3,000 per claim for general liabilities.

Coverage for the directors' and officers' liability and employment practices liability deductible is also provided through OHSU Insurance Company. Current coverage limits for claims made on or after July 1, 2014 are \$1,000 for each and every claim.

Coverage for the cyber liability deductible is also provided through OHSU Insurance Company. The coverage limit for cyber liability is \$250 for each and every claim.

Excess coverage and reinsurance is provided by a variety of insurers for claims that may exceed these limits. Coverage is written on a claims-made basis.

(A Component Unit of the State of Oregon)

Notes to Financial Statements June 30, 2021 and 2020

Sunc 30, 2021 and 202

(Dollars in thousands)

OHSU has contracted with independent actuaries to estimate the ultimate costs of settlement related to the coverage provided by OHSU Insurance Company. The liabilities are discounted at 1.5% in 2021 and 1.5% in 2020 and, in management's opinion, provide an adequate reserve for loss contingencies.

In December 2007, the Oregon Supreme Court found unconstitutional certain provisions of the Oregon Tort Claims Act (OTCA) that limited OHSU's liability for the acts of its employees and agents in large damages cases.

Effective July 1, 2009, the OTCA was amended by Senate Bill 311 for events occurring on or after December 28, 2007. The new OTCA limits are as follows:

Date of event	New OTCA limit (per claim)	Occurrence aggregate
07/01/2010–06/30/2011	\$ 1,600	3,200
07/01/2011–06/30/2012	1,700	3,400
07/01/2012–06/30/2013	1,800	3,600
07/01/2013–06/30/2014	1,900	3,800
07/01/2014–06/30/2015	2,000	4,000
07/01/2015–06/30/2016	2,048	4,096
07/01/2016–06/30/2017	2,074	4,147
07/01/2017–06/30/2018	2,118	4,236
07/01/2018–06/30/2019	2,182	4,363
07/01/2019–06/30/2020	2,247	4,494
07/01/2020–06/30/2021	2,308	4,615

The impact of this decision has been included in the liability for self-funded insurance programs in the accompanying financial statements.

In September 2013, a judgment was awarded against OHSU in a professional liability case that was in excess of the OTCA, which limits OHSU's and other Oregon public body's liability for the acts of its employees and agents. OHSU disbursed the sum of \$3,000, the amount of the tort cap in place at the date of the event. In May 2016, the Oregon Supreme Court affirmed the OTCA in this case.

Effective January 1, 2017, OHSU Insurance Company affiliated with a newly formed Oregon limited liability company called OHSU Project Co., LLC (a controlled affiliate of OHSU), which comprises OHSU and other nonaffiliated healthcare providers and systems, referred to as members. The operating agreement of OHSU Project Co., LLC asserts that OHSU's membership interest or voting power with respect to OHSU Project Co., LLC may not constitute less than ten percent (10%) of the outstanding membership interests. OHSU's membership interest was 36.5% and 31.4% as of June 30, 2021 and 2020, respectively.

The OHSU Project Co., LLC's sole purpose is to purchase casualty stop-loss insurance from OHSU Insurance Company for the benefit of its members. Each provider is entitled to coverage equal to its

(A Component Unit of the State of Oregon) Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

percentage membership interest in the limited liability company. The contracted payor effectuated the health insurance products entering into a provider-networking contract with OHSU Project Co., LLC.

Insco provides to OHSU Project Co., LLC medical aggregate excess of loss coverage for its share of the medical loss ratio (MLR) risk and cedes a portion of the risk to Swiss Re. Should MLR deteriorate sufficiently so as to trigger the risk ceded to Swiss Re, then Swiss Re will be liable for 90% of OHSU Project Co., LLC's risk share, subject to a maximum liability of \$1,500 with the 10% retention staying with OHSU Insurance Company.

On January 1, 2006, workers compensation coverage for all employees was placed with the SAIF Corporation in accordance with statutory requirements. The State Accident Insurance Fund also provides Employers Liability coverage in the amount of \$500, without retention. The State Accident Insurance Fund policy was written as a paid loss retrospective plan until July 1, 2017 at which time it converted its coverage to a guaranteed cost plan. This paid premium is an estimate and varies with audited payroll. In addition, the State Accident Insurance Fund bills monthly for the prior year's claims paid losses. (2006 to June 2017), adding a 16.5% loss conversion factor to the paid loss costs. Six months after the policy term, and every 12 months thereafter, a retrospective evaluation is completed (for years 2006 to June 2017) to determine any additional amounts to be paid, including outstanding reserves, for claims relating to the policy year.

(b) Unemployment Compensation

Unemployment compensation claims are administered by the Oregon Employment Division pursuant to Oregon Revised Statutes. The estimated amount of future benefits payments to claimants and the resulting liability to OHSU have been reflected as accrued salaries, wages, and benefits in the accompanying statements of net position.

(c) Employee Health Programs

OHSU is self-insured for its risk of loss related to costs to insure its employees for medical, dental, and vision coverage. OHSU has utilized a third-party actuary to assist in the estimation of its liability for the employee health programs related to claims payable and those claims incurred but not yet paid or reported of approximately \$23,756 and \$19,240 as of June 30, 2021 and 2020, respectively. These amounts are included in current portion of self-funded insurance program liabilities in the accompanying statements of net position.

(d) Labor Organizations

As of fiscal year-end June 30, 2021, approximately 53.9% of OHSU's employees are represented by labor organizations: 15.0% of OHSU's employees are nurses represented by the ONA, 38.8% of OHSU's employees are represented by the AFSCME, and less than 1% of OHSU's employees are represented by the OHSU Police Association. The current contract with ONA expires on June 30, 2023. The current contract with AFSCME will be in effect until June 30, 2022. The current contract with the OHSU Police Association expires on June 30, 2024.

(A Component Unit of the State of Oregon) Notes to Financial Statements June 30, 2021 and 2020

(Dollars in thousands)

(e) Construction Contracts

OHSU had outstanding commitments on unexpended construction contracts totaling approximately \$35,129 and \$34,136 at June 30, 2021 and 2020, respectively. These commitments will be primarily funded from gifts, grants, funds held by trustee, and other investment accounts.

(f) Legal Proceedings

The healthcare industry and academic medical centers are subject to numerous laws and regulations of federal, state, and local governments. These laws and regulations include, but are not limited to, laws and regulations related to licensure, accreditation, government health program participation, reimbursement for patient services, Medicare and Medicaid fraud and abuse, and laws and regulations governing the conduct of federally funded research, research involving human and animal subjects, and other facets of research. Government monitoring and enforcement activity continues with respect to possible violations of fraud and abuse laws and regulations, including academic medical centers. Violations of these laws and regulations could result in expulsion from government healthcare programs, together with the imposition of significant fines and penalties and repayments for patient services previously billed. Management believes OHSU is in compliance with applicable fraud and abuse laws and regulations.

OHSU's compliance with the referenced laws and regulations may be subject to current or future government review and interpretation, as well as regulatory actions unknown or unasserted at this time.

OHSU is involved in litigation and is periodically the subject of regulatory inquiries in the normal course of its business. In past years, OHSU was subject to several federal healthcare audits as a part of national initiatives targeting large numbers of hospitals and academic medical centers and was the subject of government-issued subpoenas and postpayment reviews concerning specific OHSU billing practices. OHSU responded to these audits, subpoenas, and reviews, and these matters were resolved or are expected to be resolved without material adverse effect on OHSU's financial position, changes in financial position, or liquidity.

(g) Operating Leases

Leases that do not meet the criteria for capitalization are classified as operating leases, with the related rentals charged to operations as incurred.

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

Rental expenses under operating leases were approximately \$19,107 and \$21,582 in 2021 and 2020, respectively. The following is a schedule of future minimum rental commitments under operating leases as of June 30, 2021 and 2020 that have initial or remaining lease terms in excess of one year:

Year ending June 30:	
2022	15,446
2023	13,386
2024	10,527
2025	9,860
2026	9,523
Thereafter	 18,702
	\$ 77,444

(h) Tuality Health Affiliation

On February 1, 2016, OHSU affiliated with Tuality Healthcare (Tuality) through the execution of a management agreement (the Tuality Agreement) between the organizations. Under the Tuality Agreement, OHSU agrees to oversee the unified and integrated clinical enterprises of OHSU and Tuality as a single, integrated economic unit. OHSU and Tuality remain as separate entities, own their own assets, and continue to be the licensed operators of their own facilities. Per the agreement, OHSU has guaranteed Tuality's operating income and will provide operating cash flow support. The initial term of the Tuality Agreement is 20 years and it may be renewed or extended by written agreement of the parties. The Tuality Agreement is subject to termination in the event of material breaches of the agreement or for certain other reasons specified in the Tuality Agreement.

After February 1, 2016, OHSU guarantees operating income support in the following manner: to the extent Tuality incurs an operating loss for any fiscal year, OHSU will provide operating support in the form of a cash payment to Tuality in an amount equal to the operating loss, which will result in Tuality's operating income being equal to zero. OHSU may recoup prior payments for operating support from Tuality's positive operating cash flow generated in future fiscal years as specified in the Tuality Agreement.

If in any fiscal year, Tuality's operating cash flow, defined in the Tuality Agreement as operating income plus depreciation less regular principal payments on long-term debt and less capital spending, is negative, OHSU will provide Tuality a capital advance in the form of a cash payment to bring Tuality's operating cash flow to a balance of zero. The capital advance will be recorded on Tuality's financial statements as a payable to OHSU, and on OHSU's financial statements as a receivable from Tuality, subject to any required reserves for estimates of collectibility. Such capital advances will not bear interest and will be repayable by Tuality to OHSU from positive operating cash flow generated in future fiscal years under general guidelines specified in the Tuality Agreement.

(A Component Unit of the State of Oregon) Notes to Financial Statements June 30, 2021 and 2020 (Dollars in thousands)

For fiscal years 2021 and 2020, operating income support amounted to \$746 and \$25,321, respectively. The operating cash flow capital advance, recorded as a note receivable, in other noncurrent assets on the statements of net position, was \$0 and \$4,036 for the years ended June 30, 2021 and 2020, respectively. In light of uncertain operating income in the near term and the likelihood that cash flow available for repayment will be deferred into future years, OHSU recorded a valuation reserve of \$19,591 against the note receivable under other noncurrent assets as of June 30, 2021. The total note receivable as of June 30, 2021 was \$19,591.

(i) Adventist Health

On January 1, 2018, OHSU and Adventist Health entered into a Health System agreement, an operating agreement and an academic affiliation agreement. Under this affiliation, OHSU and Adventist Health will operate as a unified clinical system with a shared bottom line. The affiliation applies to OHSU's Portland-area clinical services and activities and Adventist Health Portland, which includes the 302-bed Adventist Health Portland Medical Center and its 34 affiliated clinics and home care and hospice services in the Portland-Vancouver metro area. The other 19 Adventist Health hospitals in the western United States are excluded from the agreements. Each organization will retain its existing hospital licenses, capital assets, and employees and will not join each other's master trust indenture obligated group or otherwise guarantee each other's outstanding debt.

Each entity will continue to maintain its individual mission and culture but will together strive to transform access and the delivery of healthcare to Oregonians through a unified clinical enterprise and shared brand experience. A board of managers comprising representatives from each organization has been created to oversee the system.

The initial term of the Adventist agreement is 20 years and it may be renewed or extended by written agreement of the parties, and the agreement is subject to termination in the event of material breaches or for certain other reasons specified in the agreement.

OHSU and Adventist Health's allocation amount is determined by multiplying the consolidated Metro Health System net operating results by such party's proportional allocation percentage, including the amount of such party's total capital charges (for the same period for which such allocation amount is determined). The result shall equal the party's net share of the Metro Health System earnings before interest, depreciation, and amortization (EBIDA).

OHSU and Adventist's net share for each period shall be compared to each party's actual metro clinical enterprise adjusted EBIDA for the same period. OHSU and Adventist Health agree that if a party's net share for a period is less than such party's metro clinical enterprise adjusted EBIDA for such period, such party shall pay to the other party the amount of the difference (net share payment). OHSU and Adventist agree that if a party's net share for a period is more than such party's metro clinical enterprise adjusted EBIDA for such period, such party shall pay to the other party the amount of the difference (net share payment). OHSU and Adventist agree that if a party's net share for a period is more than such party's metro clinical enterprise adjusted EBIDA for the same period, such party shall receive from the other party a payment in the amount of the difference (net share receivable).

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

For fiscal years 2021 and 2020, support payments to/(from) Adventist amounted to (\$4,180) and \$10,000 per year. For FY20, the net share payment cap was met. In order to optimize healthcare provider coverage and accessibility within the Portland metropolitan area, OHSU also paid \$1,408 and \$992 for physician recruitments in fiscal year 2021 and 2020, respectively.

(14) Blended Component Units

Condensed combining statements for OHSU and its blended component units are shown below:

University INSCO Foundation Field assets Total combined Assets: Current assets \$ 1,284,286 7,056 170,524 (60,507) 1,401,359 Noncurrent assets: Capital assets, net of accumulated depreciation 2,055,819 - 168 - 2,055,987 Other noncurrent assets 1,170,196 87,474 1,636,954 - 2,094,624 Total noncurrent assets 3,226,015 87,474 1,637,122 - 4,950,611 Total assets 4,510,301 94,530 1,807,646 (60,507) 6,351,970 Deferred outflows 234,013 - - 234,013 - - 234,013 Total assets and deferred outflows \$ 620,834 599 73,972 (60,507) 634,898 Noncurrent liabilities \$ 620,834 599 73,972 (60,507) 2,334,349 Deferred inflows 49,024 - 104,542 - 153,566 Net position: Net investment in capital assets 1,232,634 - 103,663					2021		
Current assets \$ 1,284,286 7,056 170,524 (60,507) 1,401,359 Noncurrent assets: Capital assets, net of accumulated depreciation 2,055,819 - 168 - 2,055,987 Other noncurrent assets 1,170,196 87,474 1,636,954 - 2,894,624 Total noncurrent assets 3,226,015 87,474 1,637,122 - 4,950,611 Total assets 4,510,301 94,530 1,807,646 (60,507) 6,351,970 Deferred outflows 234,013 - - - 234,013 Total assets and deferred outflows 4,744,314 94,530 1,807,646 (60,507) 6,585,983 Liabilities: Ourrent liabilities \$ 620,834 599 73,972 (60,507) 634,898 Noncurrent liabilities \$ 620,834 599 73,972 (60,507) 634,898 Noncurrent liabilities \$ 62,813 - 1,699,451 1,699,451 Total liabilities \$ 9,024 - 104,542		_	University	INSCO			
Noncurrent assets: Capital assets, net of accumulated depreciation 2,055,819 - 168 - 2,055,987 Other noncurrent assets 1,170,196 87,474 1,636,954 - 2,894,624 Total noncurrent assets 3,226,015 87,474 1,637,122 - 4,950,611 Total assets 4,510,301 94,530 1,807,646 (60,507) 6,351,970 Deferred outflow s 234,013 - - - 234,013 Total assets and deferred outflow s 4,744,314 94,530 1,807,646 (60,507) 6,585,983 Liabilities: Current liabilities 620,834 599 73,972 (60,507) 634,898 Noncurrent liabilities 2,247,656 46,415 100,785 (60,507) 2,334,349 Deferred inflow s 49,024 - 104,542 - 153,566 Net investment in capital assets 1,232,634 - 168 - 1,232,802 Restricted, expendable 98,356 - 304,696 - 304,696 <	Assets:						
Capital assets, net of accumulated depreciation Other noncurrent assets 2,055,819 - 168 - 2,055,967 Other noncurrent assets 1,170,196 87,474 1,636,954 - 2,894,624 Total noncurrent assets 3,226,015 87,474 1,637,122 - 4,950,611 Total assets 4,510,301 94,530 1,807,646 (60,507) 6,351,970 Deferred outflow s 234,013 - - - 234,013 Total assets and deferred outflow s 4,744,314 94,530 1,807,646 (60,507) 6,585,983 Liabilities: Ourrent liabilities 2,247,656 46,415 100,785 (60,507) 2,34,349 Deferred inflow s 49,024 - 104,542 - 153,566 Net investment in capital assets 1,232,634 - 168 - 1,232,802 Restricted, expendable 98,358 - 703,653 - 801,921 Net investment in capital assets 1,232,634 - - - 304,696 -	Current assets	\$	1,284,286	7,056	170,524	(60,507)	1,401,359
Other noncurrent assets 1,170,196 87,474 1,636,954 2,894,624 Total noncurrent assets 3,226,015 87,474 1,637,122 4,950,611 Total assets 4,510,301 94,530 1,807,646 (60,507) 6,351,970 Deferred outflow s 234,013 234,013 Total assets and deferred outflow s 4,744,314 94,530 1,807,646 (60,507) 6,585,983 Liabilities: Current liabilities 620,834 599 73,972 (60,507) 634,898 Noncurrent liabilities 2,247,656 46,415 100,785 (60,507) 2,334,349 Deferred inflow s 49,024 104,542 153,566 Net position: Net investment in capital assets 1,232,634 104,542 103,266 Net position: Net investment in capital assets 1,232,634 - 304,696 - 304,696 - 304,696 - 304,696 - 304,696 <							
Total noncurrent assets 3,226,015 87,474 1,637,122 — 4,950,611 Total assets 4,510,301 94,530 1,807,646 (60,507) 6,351,970 Deferred outflow s 234,013 — — — 234,013 Total assets and deferred outflow s \$ 4,744,314 94,530 1,807,646 (60,507) 6,585,983 Liabilities: Current liabilities \$ 6,20,834 599 73,972 (60,507) 634,898 Current liabilities \$ 6,20,834 599 73,972 (60,507) 634,898 Total liabilities \$ 2,247,656 46,415 100,785 (60,507) 2,334,349 Deferred inflow s 49,024 — 104,542 — 153,566 Net position:	accumulated depreciation		2,055,819	_	168	_	2,055,987
Total assets 4,510,301 94,530 1,807,646 (60,507) 6,351,970 Deferred outflow s 234,013 - - - 234,013 Total assets and deferred outflow s \$ 4,744,314 94,530 1,807,646 (60,507) 6,585,983 Liabilities: Current liabilities \$ 620,834 599 73,972 (60,507) 634,898 Noncurrent liabilities \$ 620,834 599 73,972 (60,507) 634,898 Total labilities 1,626,822 45,816 26,813 - 1,699,451 Total liabilities 2,247,656 46,415 100,785 (60,507) 2,334,349 Deferred inflow s 49,024 - 104,542 - 153,566 Net investment in capital assets 1,232,634 - 168 - 1,232,802 Restricted, expendable 98,358 - 703,563 - 801,921 Restricted, nonexpendable 98,358 - 304,696 - 304,696 - 3	Other noncurrent assets		1,170,196	87,474	1,636,954		2,894,624
Deferred outflows 234,013 - - - 234,013 Total assets and deferred outflows \$ 4,744,314 94,530 1,807,646 (60,507) 6,585,983 Liabilities: Current liabilities \$ 620,834 599 73,972 (60,507) 634,898 Noncurrent liabilities 1,626,822 45,816 26,813 - 1,699,451 Total liabilities 2,247,656 46,415 100,785 (60,507) 2,334,349 Deferred inflows 49,024 - 104,542 - 153,566 Net position: Net investment in capital assets 1,232,634 - 168 - 1,232,802 Restricted, expendable 98,358 - 703,563 - 801,921 Restricted, nonexpendable 98,358 - 304,696 - 304,696 Uhrestricted 1,116,642 48,115 593,892 - 1,758,649 Total net position 2,447,634 48,115 1,602,319 - 4,098,068 Total liabili	Total noncurrent assets	_	3,226,015	87,474	1,637,122		4,950,611
Total assets and deferred outflows 4,744,314 94,530 1,807,646 (60,507) 6,585,983 Liabilities: Current liabilities \$ 620,834 599 73,972 (60,507) 634,898 Noncurrent liabilities \$ 620,834 599 73,972 (60,507) 634,898 Noncurrent liabilities \$ 1,626,822 45,816 26,813 1,699,451 Total liabilities \$ 2,247,656 46,415 100,785 (60,507) 2,334,349 Deferred inflow s \$ 49,024 104,542 153,566 Net position: Net investment in capital assets 1,232,634 168 1,232,802 Restricted, nonexpendable \$98,358 703,563 801,921 Qurrestricted 1,116,642 48,115 593,892 1,758,649 Unrestricted 2,447,634 48,115 1,602,319 4,098,068 Total liabilities, deferred inflow s, and net 2,447,634 48,115	Total assets		4,510,301	94,530	1,807,646	(60,507)	6,351,970
deferred outflows \$ 4,744,314 94,530 1,807,646 (60,507) 6,585,983 Liabilities: Current liabilities Current liabilities \$ 620,834 599 73,972 (60,507) 634,898 Noncurrent liabilities \$ 620,834 599 73,972 (60,507) 634,898 Noncurrent liabilities \$ 1,626,822 45,816 26,813 - 1,699,451 Total liabilities \$ 2,247,656 46,415 100,785 (60,507) 2,334,349 Deferred inflow s \$ 49,024 - 104,542 - 153,566 Net position: Net investment in capital assets 1,232,634 - 168 - 1,232,802 Restricted, expendable 98,358 - 703,563 - 801,921 Uhrestricted, nonexpendable - - 304,696 - 304,696 Uhrestricted 1,116,642 48,115 593,892 - 1,758,649 Total net position 2,447,634 48,115	Deferred outflows	_	234,013				234,013
Liabilities: Current liabilities \$ 620,834 599 73,972 (60,507) 634,898 Noncurrent liabilities 1,626,822 45,816 26,813 1,699,451 Total liabilities 2,247,656 46,415 100,785 (60,507) 2,334,349 Deferred inflow s 49,024 104,542 153,566 Net position: 168 1,232,802 Restricted, expendable 98,358 703,563 801,921 Restricted 304,696 304,696 Unrestricted 1,116,642 48,115 593,892 1,758,649 Total net position 2,447,634 48,115 1,602,319 4,098,068	Total assets and						
Current liabilities \$ 620,834 599 73,972 (60,507) 634,898 Noncurrent liabilities 1,626,822 45,816 26,813 1,699,451 Total liabilities 2,247,656 46,415 100,785 (60,507) 2,334,349 Deferred inflow s 49,024 104,542 153,566 Net position: 1,232,634 168 1,232,802 Restricted, expendable 98,358 703,563 801,921 Restricted, nonexpendable 304,696 304,696 Unrestricted 1,116,642 48,115 593,892 1,758,649 Total net position 2,447,634 48,115 1,602,319 4,098,068 Total liabilities, deferred inflow s, and net - - 4,098,068 -	deferred outflow s	\$	4,744,314	94,530	1,807,646	(60,507)	6,585,983
Noncurrent liabilities 1,626,822 45,816 26,813 - 1,699,451 Total liabilities 2,247,656 46,415 100,785 (60,507) 2,334,349 Deferred inflow s 49,024 - 104,542 - 153,566 Net position: Net investment in capital assets 1,232,634 - 168 - 1,232,802 Restricted, expendable 98,358 - 703,563 - 801,921 Restricted, nonexpendable - - 304,696 - 304,696 Unrestricted 1,116,642 48,115 1,602,319 - 4,098,068 Total net position 2,447,634 48,115 1,602,319 - 4,098,068	Liabilities:						
Total liabilities 2,247,656 46,415 100,785 (60,507) 2,334,349 Deferred inflow s 49,024 - 104,542 - 153,566 Net position: Net investment in capital assets 1,232,634 - 168 - 1,232,802 Restricted, expendable 98,358 - 703,563 - 801,921 Restricted, nonexpendable - - 304,696 - 304,696 Unrestricted 1,116,642 48,115 593,892 - 1,758,649 Total net position 2,447,634 48,115 1,602,319 - 4,098,068	Current liabilities	\$	620,834	599	73,972	(60,507)	634,898
Deferred inflows 49,024 - 104,542 - 153,566 Net position: Net investment in capital assets 1,232,634 - 168 - 1,232,802 Restricted, expendable 98,358 - 703,563 - 801,921 Restricted, nonexpendable - - 304,696 - 304,696 Unrestricted 1,116,642 48,115 593,892 - 1,758,649 Total net position 2,447,634 48,115 1,602,319 - 4,098,068 Total liabilities, deferred inflow s, and net - - 4,098,068 -	Noncurrent liabilities	_	1,626,822	45,816	26,813		1,699,451
Net position: 1,232,634 - 168 - 1,232,802 Restricted, expendable 98,358 - 703,563 - 801,921 Restricted, nonexpendable - - 304,696 - 304,696 Unrestricted 1,116,642 48,115 593,892 - 1,758,649 Total net position 2,447,634 48,115 1,602,319 - 4,098,068 Total liabilities, deferred inflow s, and net - 304,696 - - 1,758,649 - - 1,758,649 -<	Total liabilities	_	2,247,656	46,415	100,785	(60,507)	2,334,349
Net investment in capital assets 1,232,634 168 1,232,802 Restricted, expendable 98,358 703,563 801,921 Restricted, nonexpendable 304,696 304,696 Unrestricted 1,116,642 48,115 593,892 1,758,649 Total net position 2,447,634 48,115 1,602,319 4,098,068 Total liabilities, deferred inflow s, and net <td< td=""><td>Deferred inflow s</td><td></td><td>49,024</td><td>_</td><td>104,542</td><td>_</td><td>153,566</td></td<>	Deferred inflow s		49,024	_	104,542	_	153,566
Restricted, expendable 98,358 - 703,563 - 801,921 Restricted, nonexpendable - - 304,696 - 304,696 Unrestricted 1,116,642 48,115 593,892 - 1,758,649 Total net position 2,447,634 48,115 1,602,319 - 4,098,068 Total liabilities, deferred inflow s, and net - - - - -	Net position:						
Restricted, nonexpendable — — 304,696 — 304,696 Unrestricted 1,116,642 48,115 593,892 — 1,758,649 Total net position 2,447,634 48,115 1,602,319 — 4,098,068 Total liabilities, deferred inflow s, and net	Net investment in capital assets		1,232,634	_	168	_	1,232,802
Unrestricted 1,116,642 48,115 593,892 — 1,758,649 Total net position 2,447,634 48,115 1,602,319 — 4,098,068 Total liabilities, deferred inflow s, and net	Restricted, expendable		98,358	_	703,563	_	801,921
Total net position 2,447,634 48,115 1,602,319 — 4,098,068 Total liabilities, deferred inflow s, and net	Restricted, nonexpendable		—	—	304,696	_	304,696
Total liabilities, deferred inflow s, and net	Unrestricted		1,116,642	48,115	593,892		1,758,649
inflows, and net	Total net position	_	2,447,634	48,115	1,602,319		4,098,068
position \$ 4,744,314 94,530 1,807,646 (60,507) 6,585,983							
	position	\$_	4,744,314	94,530	1,807,646	(60,507)	6,585,983

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

						20	20				
	-	University	1	NSCO	 UMG	OHS Found		DC Found		Eliminations/ reclassification	Total combined
Assets:											
Current assets	\$	1,337,730		9,685	12,014	106	6,396	5	,354	(61,164)	1,410,015
Noncurrent assets: Capital assets, net of		0 400 004			500						0.400 504
accumulated depreciation Other noncurrent assets		2,102,981 757,729		73,288	506	1 31'	104 3,065	87	.383	_	2,103,591 2,231,465
Other Honcurrent assets	-	151,129		73,200	 	1,51	3,005	0/	,505		2,231,403
Total noncurrent assets	_	2,860,710		73,288	 506	1,313	3,169	87	,383		4,335,056
Total assets		4,198,440		82,973	12,520	1,419	9,565	92	2,737	(61,164)	5,745,071
Deferred outflow s	_	206,985		_	 _		_		_		206,985
Total assets and											
deferred outflow s	\$_	4,405,425		82,973	 12,520	1,419	9,565	92	2,737	(61,164)	5,952,056
Liabilities:											
Current liabilities	\$	602,148		964	4,193		5,207		708	(61,164)	612,056
Noncurrent liabilities	-	1,532,974		36,900	 49	2'	1,874	1	,599		1,593,396
Total liabilities	_	2,135,122		37,864	 4,242	8	7,081	2	2,307	(61,164)	2,205,452
Deferred inflows		59,858		_	_	79	9,481	1	,923	_	141,262
Net position:											
Net investment in capital assets		1,254,101		_	_		104		_	_	1,254,205
Restricted, expendable		91,070		_	_		0,307		,737	_	683,114
Restricted, nonexpendable		_					4,179		,747	_	295,926
Unrestricted	-	865,274		45,109	 8,278	418	8,413	35	5,023		1,372,097
Total net position	_	2,210,445		45,109	 8,278	1,253	3,003	88	8,507		3,605,342
Total liabilities, deferred											
inflow s, and net position	\$_	4,405,425		82,973	 12,520	1,419	9,565	92	2,737	(61,164)	5,952,056

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

Condensed combining information related to revenues, expenses, and changes in net position for the years ended June 30, 2021 and 2020 is as follows:

			2021		
-	University	INSCO	OHSU Foundation	Eliminations/ reclassifications	Total combined
-					
Operating revenues: Patient service revenue \$	2,595,048				2,595,048
Student tuition and fees, net	2,395,048	—	—		2,595,048 82,770
Gifts, grants, and contracts	715,430	_	72,576	(84,941)	703.065
Other revenue	225,407	21,279	1,322	(22,617)	225,391
	· · · · ·	,	·		
Total operating revenues	3,618,655	21,279	73,898	(107,558)	3,606,274
Operating expenses:					
Salaries, wages, and benefits	2,150,917	—	15,097	_	2,166,014
Defined-benefit pension	113,695	—	_	_	113,695
Services, supplies, and other	1,183,211	19,109	105,196	(112,739)	1,194,777
Depreciation and amortization	178,888	_	84	_	178,972
Interest	32,990				32,990
Total operating expenses	3,659,701	19,109	120,377	(112,739)	3,686,448
Operating income (loss)	(41,046)	2,170	(46,479)	5,181	(80,174)
Nonoperating revenues (expenses):					
Investment income and change					
in fair value of investments	147,231	835	291,733	_	439,799
State appropriations	44,243		201,700	_	44,243
CARES Act grant	72,593				72,593
Other	(72)		4,205		4,133
	(12)		4,200		4,100
Total nonoperating					
revenues (expenses),	000.005	005			500 700
net	263,995	835	295,938		560,768
Net income (loss) before					
other changes in net					
position	222,949	3,005	249,459	5,181	480,594
Other changes in net position:					
Contributions for capital and other	5,964	_	_	(5,181)	783
Nonexpendable donations			11,349		11,349
Total other changes					
in net position	5,964		11,349	(5,181)	12,132
Total increase (decrease)					
in net position	228,913	3,005	260,808	_	492,726
Net position – beginning of year	2,218,721	45,110	1,341,511		3,605,342

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

							2020			
	-						OHSUF	DCH	Eiminations/	Total
	-	University	11	ISCO		UMG	Foundations	Foundations	reclassifications	combined
Operating revenues:										
Patient service revenue	\$	2,375,275		_		_	_	_	_	2,375,275
Student tuition and fees, net	Ψ	77,305		_		_	_	_	_	77,305
Gifts, grants, and contracts		698,157		_		_	71,318	13,936	(118,765)	664,646
Other revenue		197,448		22,576		18,622	1,976	115	(44,842)	195,895
		,		,••	·		.,		(,	,
Total operating revenues		3,348,185		22,576		18,622	73,294	14,051	(163,607)	3,313,121
	-									
Operating expenses:										
Salaries, wages, and benefits		2,013,525		_		13,574	14,578	_	—	2,041,677
Defined-benefit pension		109,907								109,907
Services, supplies, and other		1,145,469		14,443		5,612	122,420	14,004	(167,334)	1,134,614
Depreciation and amortization		176,524		_		93	83	—	—	176,700
Interest	-	36,656		_		_				36,656
Total operating expenses	_	3,482,081		14,443		19,279	137,081	14,004	(167,334)	3,499,554
Operating income (loss)	_	(133,896)		8,133		(657)	(63,787)	47	3,727	(186,433)
Nonoperating revenues (expenses): Investment income and change in fair value of investments State appropriations CARES Act grants Other	-	56,148 39,581 37,859 (12,088)		5,784 — — —		1 	19,823 — — 623	1,122 — — (1,070)		82,878 39,581 37,859 (12,535)
Total nonoperating										
revenues (expenses),										
net		121,500		5.784		1	20.446	52	_	147,783
	-	.2.,000		0,101	·					,
Net income (loss) before other changes in net position		(12,396)		13.917		(656)	(43,341)	99	3,727	(38,650)
position	-	(12,000)		10,917		(000)	(+3,3+1)		5,727	(30,030)
Other changes in net position: Contributions for capital and other		7,088		_		_	_	_	(3,727)	3,361
Nonexpendable donations	_	—		—		—	19,794	1,638		21,432
Total other changes									(
in net position	-	7,088		_		_	19,794	1,638	(3,727)	24,793
Total increase (decrease) in net position		(5,308)		13,917		(656)	(23,547)	1,737	_	(13,857)
Net position – beginning of year	-	2,215,752		31,192		8,934	1,276,551	86,770		3,619,199
Net position – end of year	\$	2,210,444		45,109		8,278	1,253,004	88,507		3,605,342

(A Component Unit of the State of Oregon)

Notes to Financial Statements

June 30, 2021 and 2020

(Dollars in thousands)

Condensed combining information related to cash flows for the years ended June 30, 2021 and 2020 is as follows:

				2021		
	_	University	INSCO	OHSU Foundation	Eliminations/ reclassifications	Total combined
Net cash provided by (used in) operating activities	\$	218,031	12,240	(36,157)	_	194,114
Net cash provided by noncapital financing activities Net cash provided by (used in)		94,365	—	19,464	—	113,829
capital and related financing activities Net cash provided by (used in)		(191,191)	_	(48)	_	(191,239)
investing activities	_	(126,707)	(14,005)	36,840		(103,872)
Net change in cash and cash equivalents		(5,502)	(1,765)	20,099	_	12,832
Cash and cash equivalents, beginning of year	_	394,366	5,115	23,261		422,742
Cash and cash equivalents, end of year	\$_	388,864	3,350	43,360		435,574

	_				2020			
	_	University	INSCO	UMG	OHSUF Foundations	DCH Foundations	Eliminations/ reclassifications	Total combined
Net cash provided by (used in) operating activities	\$	269,656	11,278	307	(79,467)	1,598	_	203,372
Net cash provided by noncapital financing activities Net cash provided by (used in)		81,039	_	_	1,893	91	_	83,023
capital and related financing activities Net cash provided by (used in)		(222,863)	_	(123)	(20)	_	_	(223,006)
investing activities	-	206,778	(10,248)		76,168	(360)		272,338
Net change in cash and cash equivalents		334,610	1,030	184	(1,426)	1,329	_	335,727
Cash and cash equivalents, beginning of year	_	49,809	4,085	9,763	20,611	2,747		87,015
Cash and cash equivalents, end of year	\$_	384,419	5,115	9,947	19,185	4,076		422,742

(A Component Unit of the State of Oregon) Notes to Financial Statements June 30, 2020 and 2019

(Dollars in thousands)

(15) Coronavirus Impacts

On March 11, 2020, the World Health Organization declared the Novel Coronavirus Disease Outbreak a global pandemic and shortly following a national emergency declaration concerning the COVID-19 outbreak was enacted. In response to COVID-19, and guidance from state and local public health authorities, OHSU began modified operations in mid-March 2020 and continues to operate under some level of modified operations through the fiscal year ending June 30, 2021.

The impacts of the current COVID-19 pandemic continue to present risks and uncertainties in all missions across OHSU. Depending on the magnitude of such effects, OHSU may be affected by changes in patient payor mix, reduced volume in patient activities and additional costs to operate in a COVID-19 environment.

In fiscal year 2021, the CARES Act grant funding and loan programs, such as Medicare Advance Payment Program and FICA deferrals, continue to provide relief to addressing the losses incurred as a result of the pandemic, however, OHSU cannot reasonably estimate the length or severity of this pandemic, or to the extent it may materially impact OHSU's financial position, results of operations and cash flows in the future.

OHSU continues to build strategies and policies and take actions to proactively manage evolving developments, and to aggressively pursue additional relief measures and funding provided through federal and state programs.

(A Component Unit of the State of Oregon) Required Supplementary Information (Unaudited)

June 30, 2021 and 2020

Required Supplementary Information – Unaudited OHSU's Proportionate Share of the Net Pension (Asset) Liability and Related Ratios

(Dollar amounts in thousands)										
Defined-benefit pension plan ¹		2021	2020	2019	2018	2017	2016			
OHSU's proportion of the net pension (asset) liability (rounded)		2.73 %	2.91 %	3.01 %	3.51 %	3.51 %	3.98 %			
OHSU's proportionate share of the										
net pension (asset) liability	\$	595,311	503,720	456,006	424,000	526,200	228,337			
Covered payroll		340,369	330,868	323,343	337,473	326,959	345,363			
OHSU's proportionate share of the net pension (asset) liability as a percentage of covered										
payroll		174.90 %	152.24 %	141.03 %	125.64 %	160.94 %	66.12 %			
Plan fiduciary net position as a percentage of the total pension										
liability		75.80 %	80.20 %	82.10 %	83.10 %	80.50 %	91.90 %			

¹ Ten-year trend information will be presented prospectively.

Required Supplementary Information – Unaudited Schedule of Defined-Benefit Pension Plan Contributions

(Dollars in thousands)										
Year ended June 30 ¹		2021	2020	2019	2018	2017	2016			
Contractually required contributions Contributions in relation to the	\$	48,333	50,841	37,919	37,087	30,809	31,353			
contractually required contributions		58,333	60,841	47,919	47,087	30,809	31,353			
Contribution excess	\$	(10,000)	(10,000)	(10,000)	(10,000)					
OHSU's covered payroll	\$	330,673	340,369	330,868	323,343	337,473	326,959			
Contributions as a percentage of covered payroll		17.64 %	17.88 %	14.48 %	14.56 %	9.13 %	9.59 %			

¹ Ten-year trend information will be presented prospectively.

See accompanying independent auditors' report.

Combining Schedules of Net Position

As of June 30, 2021 with comparative totals for June 30, 2020

(Dollars in thousands)

Current assets: Cash and cash equivalents \$ 335,373 56,841 392,214 43,360 435,574 422,742 Short-term Investments 83,773 20,645 104,418 3 104,421 253,989 Current portion of funds held by trustee 25,218 11,541 36,759 36,759 38,062 Patients accounts receivable, net of bad debt allowances - - 459,884 459,884 390,926 Student receivables - - 27,025 27,025 - 225,208 61,970 Current portion of pledges and estates receivable - - 121,502 121,502 85,605 Other receivables, net 43,875 65,665 109,540 5,048 60,353) 54,235 46,087 Inventories, at cost 13,915 26,243 40,158 611 - 40,769 32,767 Total current assets 1,015,595 275,593 1,291,188 170,524 <td< th=""><th>Assets</th><th>Hospital</th><th>Other University</th><th>Total University</th><th>Foundation</th><th>Eliminations/ Reclassifications</th><th>2021</th><th>2020</th></td<>	Assets	Hospital	Other University	Total University	Foundation	Eliminations/ Reclassifications	2021	2020
Cash and cash equivalents \$ 335,373 56,841 392,214 43,360 435,574 422,742 Short-term Investments 83,773 20,645 104,418 3 104,421 253,989 Current portion of funds held by trustee 25,218 11,541 36,759 36,759 38,062 Patients accounts receivable, net of bad debt allowances 0\$ \$2,518 and \$1,528 - in 2021 and 2020 459,013 871 459,884 459,884 390,926 Student receivables 27,025 27,025 27,025 28,644 Grant and contract receivables 62,900 62,900 62,900 62,900 62,900 62,900 61,970 62,900 61,970 61,970 62,900 61,970 62,900 121,502 86,605 60,353) 54,235 46,087 43,875 65,665 109,540 5,048 (60,353) 54,235 46,087 Inventories, at cost 13,915 26,243 40,15	Current assets:							
Short-term Investments 83,773 20,645 104,418 3 — 104,421 253,989 Current portion of funds held by trustee 25,218 11,541 36,759 — — 36,759 38,062 Patients accounts receivable, net of bad debt allowances - 25,218 11,541 36,759 — — 36,759 38,062 Patients accounts receivable, net of bad debt allowances - 27,025 - — 459,884 390,926 Student receivables - 27,025 27,025 - — 27,025 28,644 Grant and contract receivable - 62,900 62,900 - - 62,900 61,970 Current portion of pledges and estates receivable - - - 121,502 85,605 Other receivables, net 43,875 65,665 109,540 5,048 (60,353) 54,235 46,087 Inventories, at cost 13,915 26,243 40,158 611 — 49,769 32,767 Total cu		335.373	56.841	392.214	43,360	_	435.574	422,742
Current portion of funds held by trustee 25,218 11,541 36,759 36,759 38,062 Patients accounts receivable, net of bad debt allowances of \$2,518 and \$1,528 – in 2021 and 2020 459,013 871 459,884 459,884 390,926 Student receivables 27,025 27,025 27,025 28,644 Grant and contract receivable 62,900 62,900 62,900 61,970 Current portion of pledges and estates receivable 121,502 121,502 86,655 Other receivables, net 43,875 65,665 109,540 5,048 (60,353) 54,235 46,087 Inventories, at cost 54,428 3,862 58,290 58,290 49,223 Prepaid expenses 13,915 26,243 40,158 611 40,769 32,767 Total current assets: 1,015,595 275,593 1,291,188 170,524 (60,353) 1,401,359<		,	/ -	,	-,	_	, -	,
Patients accounts receivable, net of bad debt allowances of \$2,518 and \$1,528 - in 2021 and 2020 459,013 871 459,884 459,884 390,926 Student receivables - 27,025 27,025 27,025 28,644 Grant and contract receivable 62,900 62,900 62,900 61,970 Current portion of pledges and estates receivable 121,502 121,502 85,043 Other receivables, net 43,875 65,665 109,540 5,048 (60,353) 54,235 46,087 Inventories, at cost 54,428 3,862 58,290 58,290 40,769 32,767 Total current assets 1,015,595 275,593 1,291,188 170,524 (60,353) 1,410,015 Noncurrent assets: Capital assets, net of accumulated depreciation 1,056,665 999,154 2,055,819 168 2,055,987 2,103,591 Funds held by trustee – less current portion 8,461 1,721 10,182 10,182			,		_	_		
Student receivables - 27,025 27,025 - - 27,025 28,644 Grant and contract receivable - 62,900 62,900 - - 62,900 61,970 Current portion of pledges and estates receivable - - - 121,502 - 121,502 85,605 Other receivables, net 43,875 65,665 109,540 5,048 (60,353) 54,235 46,087 Inventories, at cost 54,428 3,862 58,290 - - 58,290 49,223 Prepaid expenses 13,915 26,243 40,158 611 - 40,769 32,767 Total current assets 1,015,595 275,593 1,291,188 170,524 (60,353) 1,410,015 Noncurrent assets: Capital assets, net of accumulated depreciation 1,056,665 999,154 2,055,819 168 - 2,055,987 2,103,591 Funds held by trustee – less current portion 8,461 1,721 10,182 - - 10,182 13,252		,	,	,			,	,
Grant and contract receivable — 62,900 62,900 — — 62,900 61,970 Current portion of pledges and estates receivable — — — — 121,502 — 121,502 85,605 Other receivables, net 43,875 65,665 109,540 5,048 (60,353) 54,235 46,087 Inventories, at cost 54,428 3,862 58,290 — — 58,290 49,223 Prepaid expenses 13,915 26,243 40,158 611 — 40,769 32,767 Total current assets 1,015,595 275,593 1,291,188 170,524 (60,353) 1,410,359 1,410,015 Noncurrent assets: Capital assets, net of accumulated depreciation 1,056,665 999,154 2,055,819 168 — 2,055,987 2,103,591 Funds held by trustee – less current portion 8,461 1,721 10,182 — — 10,182 13,252	of \$2,518 and \$1,528 – in 2021 and 2020	459,013	871	459,884	_	_	459,884	390,926
Current portion of pledges and estates receivable — — — — — 121,502 — 121,502 85,605 Other receivables, net 43,875 65,665 109,540 5,048 (60,353) 54,235 46,087 Inventories, at cost 54,428 3,862 58,290 — — 58,290 49,223 Prepaid expenses 13,915 26,243 40,158 611 — 40,769 32,767 Total current assets 1,015,595 275,593 1,291,188 170,524 (60,353) 1,401,359 1,410,015 Noncurrent assets: Capital assets, net of accumulated depreciation 1,056,665 999,154 2,055,819 168 — 2,055,987 2,103,591 Funds held by trustee – less current portion 8,461 1,721 10,182 — — 10,182 13,252	Student receivables	_	27,025	27,025	_	_	27,025	28,644
Other receivables, net 43,875 65,665 109,540 5,048 (60,353) 54,235 46,087 Inventories, at cost 54,428 3,862 58,290 58,290 49,223 Prepaid expenses 13,915 26,243 40,158 611 40,769 32,767 Total current assets 1,015,595 275,593 1,291,188 170,524 (60,353) 1,401,359 1,410,015 Noncurrent assets: Capital assets, net of accumulated depreciation 1,056,665 999,154 2,055,819 168 2,055,987 2,103,591 Funds held by trustee – less current portion 8,461 1,721 10,182 10,182 13,252	Grant and contract receivable	_	62,900	62,900	_	_	62,900	61,970
Inventories, at cost 54,428 3,862 58,290 - - 59,290 49,223 Prepaid expenses 13,915 26,243 40,158 611 - 40,769 32,767 Total current assets 1,015,595 275,593 1,291,188 170,524 (60,353) 1,401,359 1,410,015 Noncurrent assets: 2 2 999,154 2,055,819 168 - 2,055,987 2,103,591 Funds held by trustee – less current portion 8,461 1,721 10,182 - - 10,182 13,252	Current portion of pledges and estates receivable	_	_	_	121,502	_	121,502	85,605
Prepaid expenses 13,915 26,243 40,158 611 — 40,769 32,767 Total current assets 1,015,595 275,593 1,291,188 170,524 (60,353) 1,401,359 1,410,015 Noncurrent assets: Capital assets, net of accumulated depreciation 1,056,665 999,154 2,055,819 168 — 2,055,987 2,103,591 Funds held by trustee – less current portion 8,461 1,721 10,182 — — 10,182 13,252	Other receivables, net	43,875	65,665	109,540	5,048	(60,353)	54,235	46,087
Total current assets 1,015,595 275,593 1,291,188 170,524 (60,353) 1,401,359 1,410,015 Noncurrent assets: Capital assets, net of accumulated depreciation 1,056,665 999,154 2,055,819 168 — 2,055,987 2,103,591 Funds held by trustee – less current portion 8,461 1,721 10,182 — — 10,182 13,252	Inventories, at cost	54,428	3,862	58,290	_	_	58,290	49,223
Noncurrent assets: 1,056,665 999,154 2,055,819 168 2,055,987 2,103,591 Funds held by trustee – less current portion 8,461 1,721 10,182 — 10,182 13,252	Prepaid expenses	13,915	26,243	40,158	611		40,769	32,767
Capital assets, net of accumulated depreciation 1,056,665 999,154 2,055,819 168 — 2,055,987 2,103,591 Funds held by trustee – less current portion 8,461 1,721 10,182 — 10,182<	Total current assets	1,015,595	275,593	1,291,188	170,524	(60,353)	1,401,359	1,410,015
Capital assets, net of accumulated depreciation 1,056,665 999,154 2,055,819 168 — 2,055,987 2,103,591 Funds held by trustee – less current portion 8,461 1,721 10,182 — 10,182<	Noncurrent assats:							
Funds held by trustee – less current portion 8,461 1,721 10,182 — — 10,182 13,252		1 056 665	000 15/	2 055 810	168	_	2 055 087	2 103 501
			,	, ,	100	_	, ,	, ,
		0,401	,	,	_	_	,	,
	Other long-term receivables, net of reserves	_	33,300	55,500	_	_	55,500	55,500
Long-term investments:								
Long-term investments, restricted — 68,638 68,638 778,041 — 846,679 652,633		—	,	,	- , -	—	,	,
Long-term investments, unrestricted 889,736 249,802 1,139,538 607,235 — 1,746,773 1,214,736	Long-term investments, unrestricted	889,736	249,802	1,139,538	607,235		1,746,773	1,214,736
Total long-term investments 889,736 318,440 1,208,176 1,385,276 — 2,593,452 1,867,369	Total long-term investments	889,736	318,440	1,208,176	1,385,276	—	2,593,452	1,867,369
Prepaid financing costs, net 1,079 405 1,484 — — 1,484 1,705	Prepaid financing costs, net	1.079	405	1.484	_	_	1.484	1.705
Pledges and estates receivable – less current portion — — — — 248,218 — 248,218 306,862			_	, -	248.218	_	,	,
Restricted postemployment benefit asset — 4,328 4,328 — — 4,328 6,200		_	4,328	4,328		_		6,200
Other noncurrent assets — — — — 3,460 — 3,460 2,577		_	_	· _	3,460	_	3,460	2,577
Interest in the Foundations 1,602,319 (1,602,319) (1,602,319)	Interest in the Foundations		1,602,319	1,602,319		(1,602,319)		
Total noncurrent assets1,955,9412,959,8674,915,8081,637,122(1,602,319)4,950,6114,335,056	Total noncurrent assets	1,955,941	2,959,867	4,915,808	1,637,122	(1,602,319)	4,950,611	4,335,056
Total assets	Total assets	2,971,536	3,235,460	6,206,996	1,807,646	(1,662,672)	6,351,970	5,745,071
Deferred outflows:	Deferred outflows:							
Deferred amortization of derivative instruments 3.399 2.692 6.091 — — 6.091 7.342		3 399	2 692	6 091	_		6 091	7 342
Loss on refunding of debt 24,357 3,437 27,794 — — 27,794 30,197		,			_	_		,
Pension obligation — 189,745 189,745 — — 189,745 160,050		,		,	_	_		,
Goodwill 348 — 348 — 348 — 348 435		348		,	_	_	,	,
Other postemployment benefits (OPEB) obligation — 10,035 10,035 — — 10,035 8,961			10,035					
Total deferred outflows 28,104205,909234,013 234,013 206,985	Total deferred outflows	28,104	205,909	234,013			234,013	206,985
Total assets and deferred outflows \$ 2,999,640 3,441,369 6,441,009 1,807,646 (1,662,672) 6,585,983 5,952,056	Total assets and deferred outflows	2,999,640	3,441,369	6,441,009	1,807,646	(1,662,672)	6,585,983	5,952,056

(Continued)

Schedule 1

Combining Schedules of Net Position

As of June 30, 2021 with comparative totals for June 30, 2020

(Dollars in thousands)

Liabilities	Hospital	Other University	Total University	Foundation	Eliminations/ Reclassifications	2021	2020
Current liabilities:							
Current portion of long-term debt	\$ 15,648	7,200	22,848	_	_	22,848	22,476
Current portion of long-term capital leases	1,132	102	1,234	_	_	1,234	943
Current portion of self-funded insurance programs liability		40,868	40,868	_	_	40,868	33,935
Accounts payable and accrued expenses	94,680	62,978	157,658	14,085	_	171,743	154,540
Accrued salaries, wages, and benefits	29,577	89,671	119,248	_	_	119,248	106,188
Compensated absences payable	47,706	28,726	76,432	_	_	76,432	68,996
Unearned revenue	5,543	76,288	81,831	—	—	81,831	74,543
Unearned/Medicare Advance Payment	111,948	6,472	118,420	_	_	118,420	145,975
Other Current Liabilities	2,412	328	2,740	59,887	(60,353)	2,274	4,460
Total current liabilities	308,646	312,633	621,279	73,972	(60,353)	634,898	612,056
Noncurrent liabilities:							
Long-term debt – less current portion	623,658	321,250	944,908	_	_	944,908	972,932
Long-term capital leases – less current portion	876	92	968	_	_	968	1,044
Liability for self-funded insurance programs – less current portion	_	46,639	46,639	_	_	46,639	39,861
Liability for life income agreements	—	_	_	23,492	_	23,492	20,741
Pension Liability	—	595,311	595,311	—	—	595,311	503,720
Other noncurrent liabilities	20,932	63,880	84,812	3,321		88,133	55,098
Total noncurrent liabilities	645,466	1,027,172	1,672,638	26,813		1,699,451	1,593,396
Total liabilities	954,112	1,339,805	2,293,917	100,785	(60,353)	2,334,349	2,205,452
Deferred inflows:							
Deferred amortization of derivative instruments	_	_	_	_	_	_	_
Gain on refunding of debt	681	610	1,291	_	_	1,291	1,546
Life income agreements	—	_	—	39,087	_	39,087	33,269
Pending Funds	_	_	—	65,455	—	65,455	48,135
Pension obligation	_	46,214	46,214	_	_	46,214	56,018
Other Postemployment Benefits (OPEB) obligation		1,519	1,519			1,519	2,294
Total Deferred Inflows	681	48,343	49,024	104,542		153,566	141,262
Net position:							
Investments in capital assets	463.997	768,805	1,232,802	_	_	1,232,802	1,254,205
Restricted, expendable		801,921	801,921	703,563	(703,563)	801,921	683,114
Restricted, nonexpendable	_	304,696	304,696	304,696	(304,696)	304,696	295,926
Unrestricted	1,580,850	177,799	1,758,649	594,060	(594,060)	1,758,649	1,372,097
Total net position	2,044,847	2,053,221	4,098,068	1,602,319	(1,602,319)	4,098,068	3,605,342
Total liabilities, deferred inflows, and net position	\$2,999,640	3,441,369	6,441,009	1,807,646	(1,662,672)	6,585,983	5,952,056

See accompanying independent auditors' report.

Consolidated Statements of Revenues, Expenses, and Changes in Net Position

Years ended June 30, 2021 and 2020

(Dollars in thousands)

	_	Hospital	Other University	Total University	Foundation	Eliminations/ Reclassifications	2021	2020
Operating revenues:								
Patient service revenue, net of bad debt adjustments								
of \$6,310 and \$12,112 – in 2021 and 2020, respectively	\$	2,130,207	464,841	2,595,048	_	_	2,595,048	2,375,275
Student tuition and fees, net			82,770	82,770	_		82,770	77,305
State appropriations Gifts, grants, and contracts		1,382 35,184	42,861 680,246	44,243 715,430	72,576	(44,243) (84,941)	 703,065	664,646
Other		183,488	42,888	226,376	1,322	(2,307)	225,391	195,895
Research and education support	_	(144,250)	144,250					
Total operating revenues	_	2,206,011	1,457,856	3,663,867	73,898	(131,491)	3,606,274	3,313,121
Operating expenses:								
Salaries, wages, and benefits		992,747	1,158,170	2,150,917	15,097	_	2,166,014	2,041,677
Defined-benefit pension		_	113,695	113,695		—	113,695	109,907
Services, supplies, and other		929,687	252,323	1,182,010	105,196	(92,429)	1,194,777	1,134,614
Depreciation and amortization Interest		96,106 20,157	82,782 12,833	178,888 32,990	84	_	178,972 32,990	176,700 36,656
	_	2,038,697	1,619,803	3,658,500	120,377		,	
Total operating expenses	_	, ,			,	(92,429)	3,686,448	3,499,554
Operating income (loss)	_	167,314	(161,947)	5,367	(46,479)	(39,062)	(80,174)	(186,433)
Nonoperating revenues, incl. state appropriations:								
Investment income and gain (loss) in fair value of investments		101,291	46,775	148,066	291,733	-	439,799	82,878
State appropriations			_		—	44,243	44,243	39,581
CARES Act grants Other		71,501 (465)	1,092 393	72,593	4 205	—	72,593 4,133	37,859
				(72)	4,205			(12,535)
Total nonoperating revenues (expenses), net	_	172,327	48,260	220,587	295,938	44,243	560,768	147,783
Net income (loss) before contributions for capital and other	_	339,641	(113,687)	225,954	249,459	5,181	480,594	(38,650)
Other changes in net position:								
Contributions for capital and other		10,555	(4,590)	5,965	_	(5,182)	783	3,361
Change in interest in the Foundation		—	260,807	260,807	—	(260,807)	—	—
Nonexpendable donations					11,349		11,349	21,432
Total other changes in net position	_	10,555	256,217	266,772	11,349	(265,989)	12,132	24,793
Total increase (decrease) in net position		350,196	142,530	492,726	260,808	(260,808)	492,726	(13,857)
Net position – beginning of year	_	1,694,651	1,910,691	3,605,342	1,341,511	(1,341,511)	3,605,342	3,619,199
Net position – end of year	\$_	2,044,847	2,053,221	4,098,068	1,602,319	(1,602,319)	4,098,068	3,605,342

See accompanying independent auditors' report.

109



KPMG LLP Suite 3800 1300 South West Fifth Avenue Portland, OR 97201

Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

The Board of Directors Oregon Health & Science University:

Report on Compliance for Each Major Federal Program

We have audited Oregon Health & Science University's (OHSU) compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of OHSU's major federal programs for the year ended June 30, 2021. OHSU's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of OHSU's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about OHSU's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for the major federal programs. However, our audit does not provide a legal determination of OHSU's compliance.

Opinion on Each Major Federal Program

In our opinion, OHSU complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on its major federal programs for the year ended June 30, 2021.

Report on Internal Control over Compliance

Management of OHSU is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered OHSU's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal



program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of OHSU's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the financial statements of the business-type activities and discretely presented component units of OHSU as of and for the year ended June 30, 2021, and the related notes to the financial statements, which collectively comprise OHSU's basic financial statements. We issued our report thereon dated October 29, 2021, which contained unmodified opinions on the financial statements. Our audit was conducted for the purpose of forming opinions on the financial statements that collectively comprise the basic financial statements. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the basic financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the basic financial statements. The information has been subjected to the auditing procedures applied in the audit of the basic financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the basic financial statements and certain additional procedures, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the basic financial statements as a whole.



Portland, Oregon May 23, 2022

Schedule of Expenditures of Federal Awards

Year ended June 30, 2021

Federal grantor/pass-through grantor	Program or cluster title	Additional Award Identification	Assistance listing number	Passed through to subrecipients	Total federal expenditures
Research and Development Cluster – Direct Programs:	*		-		
U.S. Department of Defense (DOD):					
Department of the Army (USA): U.S. Army Medical Research and Materiel Command	Military Medical Research and Development		12.420	\$ 143.560	551.425
U.S. Army Medical Research Acquisition Activity	Military Medical Research and Development		12.420	1.543.781	8,687,755
Subtotal Department of the Army (USA)	······································			1,687,341	9,239,180
U.S. Army Corps of Engineers:					
Department of the Army	Defense Programs	W912HQ-16-C-0044	12.UNK	—	(5,701)
Department of the Army	Defense Programs	W912HQ-17-C-0045	12.UNK	-	14,184
Department of the Army	Defense Programs	W912HQ20C0047	12.UNK	22,746	239,415
Department of the Army	Defense Programs	W912HQ19C0069	12.UNK	61,680	118,751
Subtotal U.S. Army Corps of Engineers Subtotal U.S. Department of Defense (DOD)				84,426 1,771,767	<u>366,649</u> 9,605,829
U.S. Department of Justice (DOJ):				1,771,707	5,005,025
U.S. Department of Justice (DOJ)	National Institute of Justice Research, Evaluation, and Development Project Grants		16.560		144,040
Subtotal U.S. Department of Justice (DOJ)					144,040
National Science Foundation (NSF):					
National Science Foundation (NSF): National Science Foundation (NSF)			47.041	_	3.722
National Science Foundation (NSF) National Science Foundation (NSF)	Mathematical and Physical Sciences		47.041 47.049	_	3,722
National Science Foundation (NSF)	Computer and Information Science and Engineering		47.070	_	8.943
National Science Foundation (NSF)	Biological Sciences		47.074	43,935	349,320
National Science Foundation (NSF)	Social, Behavioral, and Economic Sciences		47.075	· —	89,151
National Science Foundation (NSF)	Education and Human Resources		47.076		309,714
Subtotal National Science Foundation (NSF) U.S. Department of Veterans Affairs (VA)				43,935	943,042
U.S. Department of Veterans Affairs (VA)					
U.S. Department of Veterans Affairs (VA)	VA Programs	36C24E21C0006	64.UNK	_	11,599
U.S. Department of Veterans Affairs (VA)	VA Programs	36C24E20P0151 PO#534D07163	64.UNK		2,625
Subtotal U.S. Department of Veterans Affairs (VA)					14,224
U.S. Department of Education (ED): U.S. Department of Education (ED)	Research in Special Education		84.324	_	85,145
Subtotal U.S. Department of Education (ED)					85,145
U.S. Department of Health and Human Services (HHS):					
Agency for Healthcare Research and Quality (AHRQ):					
DHHS Agency for Healthcare Research and Quality	Research on Healthcare Costs, Quality and Outcomes		93.226	1,168,841	5,236,041
DHHS Agency for Healthcare Research and Quality	DHHS Programs	75Q80119F32021	93.UNK	—	24,740
DHHS Agency for Healthcare Research and Quality	DHHS Programs	75Q80120D00006	93.UNK		111,769
Subtotal Agency for Healthcare Research and Quality (AHRQ)				1,168,841	5,372,550
Substance Abuse and Mental Health Services Administration DHHS Substance Abuse and Mental Health Services Administration	Substance Abuse & Mental Health Services Projects of Regional and National Significance		93.243	_	138,136
Subtotal Substance Abuse and Mental Health Services Administration					138,136
Centers for Disease Control and Prevention:					
DHHS CDCP National Center for Injury Prevention & Control	Injury Prevention and Control Research and State and Community Based Programs		93.136	481,573	599,638
DHHS CDCP National Institute for Occupational Safety & Health	Occupational Safety and Health Program		93.262	96,615	1,106,537
DHHS CDCP National Center for Chronic Disease Prevention & Health Promotion Centers for Disease Control and Prevention	Assistance Programs for Chronic Disease Prevention and Control CDCP Programs	75D30121C11154	93.945 93.UNK	223,618	483,080 22,861
Subtotal Centers for Disease Control and Prevention		75050121011154	55.0NR	801,806	2,212,116
Centers for Medicare and Medicaid Services (CMS):					
DHHS Centers for Medicare and Medicaid Services (CMS)	Accountable Health Communities		93.650	97,508	1,302,439
Subtotal Centers for Medicare and Medicaid Services (CMS)				97,508	1,302,439
DHHS Indian Health Service (IHS): DHHS Indian Health Service (IHS)	Health Professions Recruitment Program for Indians		93.970	\$ 27,392	160,452
Subtotal DHHS Indian Health Service (IHS)	Ů, v v v v v v v v v v v v v v v v v v v			27,392	160,452
DHHS Office of Population Affairs (OPA):				<u> </u>	
DHHS Office of Population Affairs (OPA)	Public Health Service Evaluation Funds		93.343	69,066	195,214
					,
	112			((Continued

(Continued)

Schedule of Expenditures of Federal Awards

Federal grantor/pass-through grantor Program or cluster title	Additional Award Identification	Assistance listing number	Passed through to subrecipients	Total federal expenditures
DHHS Office of Population Affairs (OPA) Family Planning Service Delivery Improvement Research Grants		93.974	56,832	171,089
Subtotal DHHS Office of Population Affairs (OPA)			125,898	366,303
Food and Drug Administration (FDA):				
DHHS Food and Drug Administration (FDA) Food and Drug Administration Research		93.103	3,500	154,065
Subtotal Food and Drug Administration (FDA)			3,500	154,065
Health Resources and Services Administration (HRSA):				
DHHS HRSA Bureau of Health Professions Training in General, Pediatric, and Public Health Dentistry		93.059	_	118,091
Health Resources and Services Administration (HRSA) Centers of Excellence		93.157	42,626	105,539
DHHS HRSA Bureau of Health Professions Centers of Excellence		93.157	42,502	701,112
DHHS HRSA Bureau of Health Professions Graduate Psychology Education		93.191	_	322,682
DHHS HRSA Bureau of Health Professions – Division of Nursing Advanced Nursing Education Workforce Grant Program		93.247	_	754
DHHS HRSA Bureau of Health Professions – Division of Nursing Nurse Education, Practice Quality and Retention Grants		93.359	_	528,558
Health Resources and Services Administration (HRSA) Mental and Behavioral Health Education and Training Grants		93,732	_	367,440
DHHS HRSA Office of Rural Health Policy Grants to States for Operation of State Offices of Rural Health		93.913	_	233,446
Subtotal Health Resources and Services Administration (HRSA)			85,128	2,377,622
National Institutes of Health (NIH):				
BHIS NIH National Cancer Institute The Family Smoking Prevention and Tobacco Control Act (TCA)		93.077	5.515	5.515
DHHS NIN National Peart, Lung, and Blood Institute The Family Smoking Prevention and Tobacco Control Act (TCA)		93.077	95.449	439.776
DHAS NIN National Institute of Environmental Health Environmental Health		93.113	196,796	1,030,904
DHS NIT National instatute of Denvironmental and Craniofacial Oral Diseases and Disorders Research		93.121	286,793	4.812.564
DH1S NIT National Institute of Dental and Chamoradian Olar Diseases and Disorder's Research DH1S NIT National Human Genome Research Institute Human Genome Research		93.121	314.142	744.410
		93.172	110.766	547.476
DHHS NIH National Eye Institute on Deafness & Other Communication Disorders Research Related to Deafness and Communication Disorders Research Related to Deafness and Communication Disorders Research Related to Deafness A		93.173	1.403.887	8.738.044
		93.173		
DHIS NIH National Center for Complementary & Integrative Health Research and Training in Complementary and Integrative Health		93.213	197,722 26,713	1,708,117 1,539,136
DHHS NIH National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research				
DHHS NIH National Institute of Mental Health Mental Health Mental Health Research Grants		93.242	433,138	6,709,257
DHHS NIH National Institute on Alcohol Abuse and Alcoholism Alcohol Research Programs		93.273	76,249	7,198,569
DHHS NIH National Institute on Drug Abuse Drug Abuse Drug Abuse and Addiction Research Programs		93.279	15,741	84,187
DHIS NIH National Institute on Drug Abuse Drug Abuse Drug Abuse and Addiction Research Programs		93.279	2,645,656	13,947,144
DHLS NIH National Institute of Biomedical Imaging & Bioengineering Discovery and Applied Research for Technological Innovations to Improve Hun	iman Health	93.286	149,520	656,663
DHHS NIH National Institute on Minority Health & Health Disparities Minority Health and Health Disparities Research		93.307	354,854	1,630,783
DHHS NIH National Cancer Institute Trans-NIH Research Support		93.310	123,283	349,413
DHHS NIH National Human Genome Research Institute Trans-NIH Research Support		93.310	35,475	129,820
DHHS NIH National Institute of General Medical Science Trans-NIH Research Support		93.310	1,918,131	10,766,956
DHHS NIH Office of the Director Trans-NIH Research Support		93.310	236,336	2,863,172
DHHS NIH National Center for Advancing Translational Sciences National Center for Advancing Translational Sciences		93.350	7,057,879	15,285,011
DHHS NIH Office of the Director Research Infrastructure Programs		93.351	88,332	16,580,797
DHHS NIH Office of the Director Construction Support		93.352	-	130,483
DHHS NIH National Cancer Institute 21st Century Cures Act – Beau Biden Cancer Moonshot		93.353	1,968,623	7,657,505
DHHS NIH National Institute of Nursing Research Nursing Research		93.361	63,574	510,285
DHHS NIH National Institute of Child Health & Human Development Child Health and Human Development Extramural Research		93.365	-	(193)
DHHS NIH National Cancer Institute Cancer Cause and Prevention Research		93.393	730,431	3,492,790
DHHS NIH National Cancer Institute Cancer Detection and Diagnosis Research		93.394	169,457	2,293,341
DHHS NIH National Cancer Institute Cancer Treatment Research		93.395	14,865,205	19,834,007
DHHS NIH National Cancer Institute Cancer Biology Research		93.396	669,402	5,603,302
DHHS NIH National Cancer Institute Cancer Support Grants		93.397	437,014	5,674,240
DHHS NIH National Cancer Institute Cancer Research Manpower		93.398	_	2,341,943
DHHS NIH National Heart, Lung, and Blood Institute Cardiovascular Diseases Research		93.837	683.227	10.503.659
		30.001		
DHHS NIH National Heart, Lung, and Blood Institute Lung Diseases Research		93.838	611,306	3,979,903
DHHS NIH National Heart, Lung, and Blood Institute Lung Diseases Research DHHS NIH National Heart, Lung, and Blood Institute Blood Diseases and Resources Research				3,979,903 3,531,058

Schedule of Expenditures of Federal Awards

Federal grantor/pass-through grantor	Program or cluster title	Additional Award Identification	Assistance listing number	Passed through to subrecipients	Total federal expenditures
DHHS NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases	Arthritis, Musculoskeletal and Skin Diseases Research		93.846	\$ 567.928	2.625.643
DHHS NIH National Institute of Diabetes and Digestive and Kidney Diseases	Diabetes, Digestive, and Kidney Diseases Extramural Research		93.847	738.643	9.328.705
DHHS NIH Fogarty International Center	Extramural Research Programs in the Neurosciences and Neurological Disorders		93.853	190.221	450.328
DHHS NIH National Institute of Neuro Disorders & Stroke	Extramural Research Programs in the Neurosciences and Neurological Disorders		93.853	1,851,351	17.204.571
DHHS NIH National Institute of Allerov & Infectious Disease	Allergy and Infectious Diseases Research		93.855	5,407,762	26.641.063
DHHS NIH National Institute of General Medical Science	Biomedical Research and Research Training		93.859	262,039	6,934,741
DHHS NIH National Institute of Child Health & Human Development	Child Health and Human Development Extramural Research		93.865	2,137,313	11,648,149
DHHS NIH National Institute of Allergy & Infectious Disease	Child Health and Human Development Extramural Research		93.865	_	94,627
DHHS NIH National Institute on Aging	Aging Research		93.866	2,104,716	15,463,714
DHHS NIH National Eye Institute	Vision Research		93.867	789,129	12,943,915
DHHS NIH National Library of Medicine	Vision Research		93.867	_	28,917
DHHS NIH National Library of Medicine	Medical Library Assistance		93.879	_	1,555,835
DHHS NIH National Institute of Neuro Disorders & Stroke	Modification of Trauma Care Component of State EMS Plan		93.953	—	222,683
DHHS NIH National Institute of Allergy & Infectious Disease	DHHS Programs	HHSN272201400055C	93.UNK	140,685	185,450
DHHS NIH National Institute of Allergy & Infectious Disease	DHHS Programs	75N93019C00043	93.UNK	940,196	1,749,627
DHHS NIH National Institute of Child Health & Human Development	DHHS Programs	75N94020F00001	93.UNK	_	2,820
DHHS NIH National Institute of Child Health & Human Development	DHHS Programs	HHSN27500008	93.UNK	—	126,357
DHHS NIH National Institute of Child Health & Human Development	DHHS Programs	HHSN2752013	93.UNK	_	56,091
DHHS NIH National Institute of Child Health & Human Development	DHHS Programs	HHSN275201300008I	93.UNK	_	(415)
DHHS NIH National Institute of Child Health & Human Development	DHHS Programs	HHSN275201300008I T.O. #4	93.UNK	_	24,522
DHHS NIH National Institute of Child Health & Human Development	DHHS Programs	HHSN275201300008I T.O.#	93.UNK	_	83,093
DHHS NIH National Institute of Child Health & Human Development	DHHS Programs	HHSN275201300008I T.O.#2	93.UNK	703	66,558
DHHS NIH National Institute of Child Health & Human Development	DHHS Programs	HHSN27520130008I T.O.#7	93.UNK	-	114,535
DHHS NIH National Institute of Child Health & Human Development	DHHS Programs	TO#75N94021F00001	93.UNK		664
Subtotal National Institutes of Health (NIH)				52,778,620	269,032,682
Subtotal U.S. Department of Health and Human Services				55,088,693	281,116,365
U.S. Department of Homeland Security (DHS): Federal Emergency Management Agency (FEMA)	Assistance to Firefighters Grant		97.044	28,136	363,550
Subtotal U.S. Department of Homeland Security (DHS)				28,136	363,550
Total Research and Development Cluster – Direct Programs				\$ 56,932,531	292,272,195

Schedule of Expenditures of Federal Awards

Federal grantor/pass-through grantor/program or cluster title	Assistance listing number	Pass-through entity name	Pass-through entity identifying number	Passed through to subrecipients	Total federal expenditures
Research and Development Cluster – Indirect Programs:					
U.S. Department of Agriculture (USDA):					
Agriculture and Food Research Initiative (AFRI)	10.310	Oregon State University	C0525A-A	\$	25,659
Subtotal U.S. Department of Agriculture (USDA)					25,659
U.S. Department of Commerce:					
Integrated Ocean Observing System (IOOS)	11.012	University of Washington	UWSC9205		(1,997)
Subtotal U.S. Department of Commerce					(1,997)
U.S. Department of Defense (DOD):					
Scientific Research – Combating Weapons of Mass Destruction	12.351	Washington University	WU-15-244-MOD-15, PO 2929109A		110,299
Subtotal Assistance listing 12.351					110,299
Military Medical Research and Development	12.420	National Trauma Institute	NTI-CLOTT17-08		184,172
Military Medical Research and Development	12.420	Critical Innovations LLC	SRA-20-084	126,100	126,100
Military Medical Research and Development	12.420	Critical Innovations LLC	SRA-20-084	_	(27,963)
Military Medical Research and Development	12.420 12.420	Henry M. Jackson Foundation for the Advancement of J. David Gladstone Institutes	5245 PO#984502 HJF#65543	-	21,731 180.623
Military Medical Research and Development			SC-00030	_	
Military Medical Research and Development	12.420	National Trauma Institute	NTRAP-18-05	_	20,951
Military Medical Research and Development	12.420	Research Foundation for Mental Hygiene Inc.	148683		15,245
Military Medical Research and Development	12.420	Resusite of Oallie Day Francisco	SRA-18-090	-	(4,931)
Military Medical Research and Development	12.420	University of California, San Francisco	10568sc	—	172,732
Military Medical Research and Development	12.420	University of California, San Francisco	12035sc	_	123,016
Military Medical Research and Development	12.420	University of Nebraska	35-1905-2048-001	_	116,191
Military Medical Research and Development	12.420	University of Pittsburgh	CNVA00054906 (414552-1)		30,344
Military Medical Research and Development	12.420	Wake Forest University School of Medicine	WFUHS 441051 ER-01	88,468	187,716
Military Medical Research and Development	12.420	Wayne State University	WSU20030		99,472
Subtotal Assistance listing 12.420				214,568	1,245,399
Uniform Services University Medical Research	12.750	Henry M. Jackson Foundation for the Advancement	4353 PO#942950 HJF#65201	—	1,177
Air Force Defense Research Sciences Program	12.800	University of Maryland, Baltimore	1802055	-	11,059
Air Force Defense Research Sciences Program	12.800	Henry M. Jackson Foundation for the Advancement	#4494 PO#947864 HJF#65535		1,439
Subtotal Assistance listing 12.800					12,498
Research and Technology Development	12.910	Harvard University	152220.5102578.0007	-	158,538
Defense Programs	12.UNK	Villanova University	530035XuOHSU	_	44,108
Defense Programs	12.UNK	Department of the Navy	N3943020P2247	_	23,730
Defense Programs	12.UNK	Critical Innovations LLC	SRA-20-075	_	14,091
Defense Programs	12.UNK	University of Colorado at Denver	FY20.891.006	_	73,449
Defense Programs	12.UNK	University of Pittsburgh	0055964-1	_	179,700
Defense Programs	12.UNK	University of Pittsburgh	0058514-4	_	(19,085)
Defense Programs	12.UNK	University of Pittsburgh	0061688-5		28,963
Subtotal Assistance listing 12.UNK					344,956
Subtotal U.S. Department of Defense (DOD)				214,568	1,872,867
U.S. Department of Justice (DOJ):					
National Institute of Justice Research, Evaluation, and Development Project Grants	16.560	Vera Institute of Justice	2016-IJ-CX-0016	_	(968)
Comprehensive Opioid, Stimulant, and Substance Abuse Program	16.838	Clackamas County – Dept of Community Corrections	20-024		50,048
Subtotal U.S. Department of Justice (DOJ)					49,080
National Aeronautics and Space Administration (NASA):					
Science	43.001	University of California, Riverside	S-000731	_	(64)
Exploration	43.003	University of Texas, Southwestern Medical Ctr at Dallas	GMO210207 PO0000002060	_	178
Exploration	43.003	Medical College of Wisconsin	PO# 6115080	_	75,211
Exploration	43.003	Colorado State University	G-00066-04		23,572
	-5.005	Colorado Cialo University	3 3300-04		
Subtotal Assistance listing 43.003					98,961
Subtotal National Aeronautics and Space Administration (NASA)				_	98,897

Schedule of Expenditures of Federal Awards Year ended June 30, 2021

Federal grantor/pass-through grantor/program or cluster title	Assistance listing number	Pass-through entity name	Pass-through entity identifying number	Passed through to subrecipients	Total federal expenditures
	number	Pass-unough entity name		Subrecipients	experiance
National Science Foundation (NSF): Engineering Grants	47.041	Health Technology Innovations, LLC	SRA-20-122	s —	47,561
Computer and Information Science and Engineering	47.070	Computing Research Association	CIF2020-OHSU-29	_	106,942
Computer and Information Science and Engineering	47.070	Virginia Polytechnic Institute & State University	479590-19E67		22,742
Subtotal Assistance listing 47.070					129,684
Biological Sciences	47.074	Pennsylvania State University	5671-OHSU-NSF-1497	_	896
Biological Sciences	47.074	Reed College	40255-5326		28,546
Subtotal Assistance listing 47.074					29,442
Subtotal National Science Foundation (NSF)					206,687
.S. Environmental Protection Agency (EPA): Research, Development, Monitoring, Public Education,					
Training, Demonstrations, and Studies	66.716	Oregon State University	E0197A-A		12,713
Subtotal U.S. Environmental Protection Agency (EPA)					12,713
.S. Department of Energy (DOE):					
Office of Science Financial Assistance Program Energy Programs	81.049 81.UNK	University of Massachusetts Amherst Battelle Memorial Institute	21-016258-A-00 PO# A001148738 478631	_	890 8,814
Subtotal U.S. Department of Energy (DOE)	01.0141				9,704
S. Department of Health and Human Services (HHS):					0,101
Birth Defects and Developmental Disabilities – Prevention and Surveillance	93.073	University of South Carolina	19-3773 PO# 2000043062	15,054	56,879
Subtotal Assistance listing 93.070				15,054	56,879
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	University of California, San Francisco	12021sc	-	9,863
Food and Drug Administration_Research	93.103	American College of Medical Toxicology	20200REG	-	18,071
Maternal and Child Health Federal Consolidated Programs	93.110	University of California, Los Angeles	1920 G WA068	_	17,145
Maternal and Child Health Federal Consolidated Programs	93.110	Children's Hospital & Research Center Oakland	807958.OHSU.18.2		362
Maternal and Child Health Federal Consolidated Programs	93.110	American College of Obstetricians & Gynecologists	09-699-7515	37,000	159,961
Subtotal Assistance listing 93.110				37,000	177,468
Environmental Health Environmental Health	93.113 93.113	Oregon State University Nzumbe Inc.	P0508E-A SRA-20-162	_	136,932 40,488
Environmental Health	93.113	Nzumbe Inc.	SRA-19-035-A	_	21,103
Environmental Health	93.113	University of New Mexico	3RBB7	_	88,623
Environmental Health	93.113	University of New Mexico	3RGN4	-	23,272
Environmental Health	93.113	Vanderbilt University	UNIV60485		178,311
Subtotal Assistance listing 93.113					488,729
Oral Diseases and Disorders Research	93.121	Louisiana State University	SOD-21-136-002	-	28,386
Oral Diseases and Disorders Research Oral Diseases and Disorders Research	93.121 93.121	Oregon State University Seattle Children's Research Institute	P0460A-A 11902SUB	-	89,602
Oral Diseases and Disorders Research Oral Diseases and Disorders Research	93.121 93.121	Seattle Children's Research Institute University of Alabama at Birmingham	11902SOB 000525031-SC001-Wu	_	92,076 41,764
Oral Diseases and Disorders Research	93.121	University of Alabama at Birmingham	000524960-001	_	550.751
Oral Diseases and Disorders Research	93.121	University of Florida	UFDSP00011300	_	5,890
Oral Diseases and Disorders Research	93.121	University of Michigan	SUBK00010103 PO#3005442974	_	78,267
Subtotal Assistance listing 93.121		, ,			886,736
Emergency Medical Services for Children	93.127	Medical College of Wisconsin	None		1,586
Subtotal Assistance listing 93.127		~			1,586
Injury Prevention and Control Research					
and State and Community Based Programs	93.136	Brigham and Women's Hospital Inc.	122303	_	29,616
Injury Prevention and Control Research and State and Community Based Programs	93.136	Oregon Health Authority	162279	_	294,898
, ,	00.100				324,514
Subtotal Assistance listing 93.136					324,514

Schedule of Expenditures of Federal Awards Year ended June 30, 2021

Federal grantor/pass-through grantor/program or cluster title	Assistance listing number	Pass-through entity name	Pass-through entity identifying number	Passed through to subrecipients	Total federal expenditures
Rural Health Research Centers	93.155	JBS International, Inc.	02900-HRSA RCORPEVAL-OHSU	\$ 107,889	657,490
Human Genome Research	93.172	Johns Hopkins University	2003978369	-	66,995
Human Genome Research	93.172	Johns Hopkins University	2003282958	_	340,272
Human Genome Research	93.172	Ontario Institute for Cancer Research	P2017-0001	_	356,622
Human Genome Research	93.172	Ontario Institute for Cancer Research	P2020-0049	_	50,476
Human Genome Research	93.172	Southcentral Foundation	2019-217	_	143,506
Human Genome Research	93.172	Pennsylvania State University	S001687-DHHS		15,981
Subtotal Assistance listing 93.172					973,852
Research Related to Deafness and Communication Disorders	93.173	Biospeech Inc.	Biospeech#DC017403-01A1	-	13,553
Research Related to Deafness and Communication Disorders	93.173	Cincinnati Children's Hospital Medical Center	312761	_	80,050
Research Related to Deafness and Communication Disorders	93.173	Creighton University School of Medicine	270753-7323	_	146,783
Research Related to Deafness and Communication Disorders	93.173	Duke University	A033632	_	3,969
Research Related to Deafness and Communication Disorders	93.173	Massachusetts Ear and Eye Infirmary	530510	_	49,888
Research Related to Deafness and Communication Disorders	93.173	Northwestern University	SP0034193-PROJ0011721	_	44,290
Research Related to Deafness and Communication Disorders	93.173	Research Foundation of SUNY	R975303	_	76,248
Research Related to Deafness and Communication Disorders	93.173	Securboration Inc.	SCB-OHS-001/SRA-18-107	_	4,176
Research Related to Deafness and Communication Disorders	93.173	University of Texas at Austin	UTA19-001007	_	2.091
Research Related to Deafness and Communication Disorders	93.173	University of Utah	10041913-015	_	287
Research Related to Deafness and Communication Disorders	93.173	Veterans Health Foundation	NIH 2020-1004	_	7.424
Subtotal Assistance listing 93.173					428,759
Research and Training in Complementary and Integrative Health	93.213	Duke University	A033748		127,797
Research and Training in Complementary and Integrative Health	93.213	National University of Natural Medicine	5R90AT008924	_	132
Research and Training in Complementary and Integrative Health	93.213	Northern California Institute for Research & Education	SEAL2078-02		168,258
Research and Training in Complementary and Integrative Health	93.213	Oregon State University	P0410C-A	_	39,596
Research and Training in Complementary and Integrative Health	93.213	Pacific University	PU OHSU S01-2019-009841		24,084
Subtotal Assistance listing 93.213				-	359.867
Research on Healthcare Costs, Quality and Outcomes	93.226	Case Western Reserve University	RES516008		11.364
Research on Healthcare Costs, Quality and Outcomes	93.226		C00062010-1		20,396
	93.226	Curators of the University of Missouri		—	
Research on Healthcare Costs, Quality and Outcomes		OCHIN Inc.	EVERYWOMEN	—	131,200
Research on Healthcare Costs, Quality and Outcomes	93.226	Oregon State University	P0477B-C	—	47,610
Research on Healthcare Costs, Quality and Outcomes	93.226	University of California, San Francisco	11485sc		28,163
Subtotal Assistance listing 93.226					238,733
National Center on Sleep Disorders Research	93.233	Ohio State University	60078529	-	317
Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention	93.236	Oregon Health Authority	158331	_	60,631
Mental Health Research Grants	93.242	Emory University	A241984	_	2,000
Mental Health Research Grants	93.242	Emory University	A258046	_	16,341
Mental Health Research Grants	93.242	Emory University	A390384	—	45,665
Mental Health Research Grants	93.242	Emory University	A412954	—	22,354
Mental Health Research Grants	93.242	Harvard Pilgrim Health Care	R34MH122291/739A	_	17,584
Mental Health Research Grants	93.242	Cambridge Health Alliance	3304-2-OR	_	152,667
Mental Health Research Grants	93.242	New York University Langone Health	20-00-00-1005730	_	1,764
Mental Health Research Grants	93.242	Nous Imaging, Ing	R44MH122066_Sub2	_	(5,962)
Mental Health Research Grants	93.242	Portland State University	100155	_	25,840
Mental Health Research Grants	93.242	Purdue University	11001073-002	_	27,313
Mental Health Research Grants	93.242	University of California, San Diego	122575937 MP Inv/PO S900002393	_	18,730
Mental Health Research Grants	93.242	University of Washington	UWSC11329	_	23.236
Mental Health Research Grants	93.242	U Mass-Lowell	S51110000046594	_	11,466
Mental Health Research Grants	93.242	University of Oregon	217230A	_	(363)
Mental Health Research Grants	93.242	University of Washington	UWSC10899 BPO#36424	_	101,300
Subtotal Assistance listing 93.242					459,935
Substance Abuse and Mental Health Services					
Projects of Regional and National Significance	93.243	University of Maryland, Baltimore	1600258D Request: 2944 Task 9		13,923
Subtotal Assistance listing 93.243					13,923
-					

Schedule of Expenditures of Federal Awards Year ended June 30, 2021

Federal grantor/pass-through grantor/program or cluster title	Assistance listing number	Pass-through entity name	Pass-through entity identifying number	Passed through to subrecipients	Total federal expenditures
Occupational Safety and Health Program	93.262	OHA Health Services, Public Health Division	150136	\$ —	308,694
Occupational Safety and Health Program	93.262	University of Washington	UWSC12279 BPO51769		8,411
Subtotal Assistance listing 93.262					317,105
Alcohol Research Programs	93.273	University of California, San Diego	93526028	_	19,657
Alcohol Research Programs	93.273	University of Rhode Island	0008911/12142020		65,008
Subtotal Assistance listing 93.273					84,665
Drug Abuse and Addiction Research Programs	93.279	American College of Medical Toxicology	20200REG	_	2,381
Drug Abuse and Addiction Research Programs	93.279	Boulder Care	R44DA050354-01-OHSU	-	71,656
Drug Abuse and Addiction Research Programs	93.279	Hennepin Healthcare Research Institute	15159-2-OHSU	-	103,679
Drug Abuse and Addiction Research Programs	93.279 93.279	Legacy Emanuel Hospital & Health Center	None 18-A0-00-1001703		33,366
Drug Abuse and Addiction Research Programs Drug Abuse and Addiction Research Programs	93.279	New York University New York University School of Medicine	20-A0-S2-003671 Project 117236 / PO M210400267	229,542	449,140 43,708
Drug Abuse and Addiction Research Programs	93.279	University of California, San Diego	115103176 MP Invoice#S9002287	_	12.813
Drug Abuse and Addiction Research Programs	93.279	University of California, San Elego	11395sc	_	(283)
Drug Abuse and Addiction Research Programs	93.279	University of California, San Francisco	11474sc	_	1.001
Drug Abuse and Addiction Research Programs	93.279	University of California, San Francisco	11476sc	_	(1.009)
Drug Abuse and Addiction Research Programs	93.279	University of California, San Francisco	8954sc. 9139sc	_	(.,,
Drug Abuse and Addiction Research Programs	93.279	University of Michigan	SUBK00011072/PO 3005819424	_	86,955
Drug Abuse and Addiction Research Programs	93.279	University of Oregon	217300A	_	286,564
Drug Abuse and Addiction Research Programs	93.279	Virogenomics BioDevelopment Inc.	SRA-19-112		40,709
Subtotal Assistance listing 93.279				229,542	1,130,681
Discovery and Applied Research for					10.050
Technological Innovations to Improve Human Health	93.286	University of Massachusetts Worcester	OPS/WPM33765-OHSU	_	42,358
Minority Health and Health Disparities Research	93.307	Kaiser Foundation Research Institute	00S030163-NW	-	14,701
Minority Health and Health Disparities Research	93.307 93.307	Northwest Portland Area Indian Health Board Stanford University	C19-43/PO 29975 62501995-137317	_	64,130
Minority Health and Health Disparities Research Subtotal Assistance listing 93.307	93.307	Stanford University	62501995-137317		18,979 97,810
•	00.040	Oblighter in the entited of Dhills determine	0000070500 0004		12.319
Trans-NIH Research Support Trans-NIH Research Support	93.310 93.310	Children's Hospital of Philadelphia Duke University	3200670520-03S1 A03-2351	_	97,731
Trans-NIH Research Support	93.310	Portland State University	100123	_	71.618
Trans-NIH Research Support	93.310	Portland State University	100123	_	443.478
Trans-NIH Research Support	93.310	Rutgers, The State University of New Jersey	1684 / PO 1394972	_	6.482
Trans-NIH Research Support	93.310	University of Rochester	417409G/UR FAO GR510837		1,851
Subtotal Assistance listing 93.310					633,479
National Center for Advancing Translational Sciences	93.350	Duke University	2037876	_	1.320
National Center for Advancing Translational Sciences	93.350	Johns Hopkins University	None PO#2003261860	_	(1,292)
National Center for Advancing Translational Sciences	93.350	New York University School of Medicine	16-A0-00-007000-01	_	73,382
National Center for Advancing Translational Sciences	93.350	NYU Grossman School of Medicine	None	-	11,249
National Center for Advancing Translational Sciences	93.350	Oregon State University	P0503C-C	—	72,543
National Center for Advancing Translational Sciences National Center for Advancing Translational Sciences	93.350 93.350	University of Colorado at Denver University of Pittsburgh	FY21.1058.001 0055353 (130910-12)	_	33,585 33,774
Subtotal Assistance listing 93.350	30.000	University of Fitabulgh	0000000 (100010-12)		224,561
Research Infrastructure Programs	93.351	Actuated Medical Inc.	SRA-20-029 5054-S02		(7,729)
Research Infrastructure Programs	93.351	University of Washington	UWSC10727 BPO34472	_	(3,566)
Research Infrastructure Programs	93.351	University of Washington	UWSC10945 BPO36911	_	89,297
Subtotal Assistance listing 93.351		, ,		_	78,002
21st Century Cures Act – Beau Biden Cancer Moonshot	93.353	Brigham Young University	19-0537 R0102089	_	5,697
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	University of Alabama at Birmingham	000526841-SC004		16,901
Subtotal Assistance listing 93.353					22,598
Biodefense Medical Countermeasure Development	93.360	Philips Research North America	75A50120C000097-1	91,772	1,785,278

Schedule of Expenditures of Federal Awards Year ended June 30, 2021

Federal grantor/pass-through grantor/program or cluster title	Assistance listing number	Pass-through entity name	Pass-through entity identifying number	Passed through to subrecipients	Total federal expenditures
Nursing Research	93.361	Stanford University	62151744-125082	s —	29.229
Nursing Research	93.361	University of North Carolina at Chapel Hill	5118337	• _	48,202
Subtotal Assistance listing 93.361				_	77,431
Cancer Cause and Prevention Research	93.393	Children's Hospital of Philadelphia	AI TE11C2 PO#8902720318		584
Cancer Cause and Prevention Research	93.393	Columbia University	1(GG015020-01)		72.600
Cancer Cause and Prevention Research	93.393	Fred Hutch Cancer Rsch Ctr	0001061803		20.356
Cancer Cause and Prevention Research	93.393	Johns Hopkins University	2004899666		21,350
Cancer Cause and Prevention Research	93.393	Icahn School of Medicine Mount Sinai	0255-0851-4609	_	98,150
Cancer Cause and Prevention Research	93.393	Kaiser Foundation Research Institute	OOS030159-OHSU	_	126
Cancer Cause and Prevention Research	93.393	University of Texas, M.D. Anderson Cancer Center	3001451125	_	1.584
Cancer Cause and Prevention Research	93.393	Vanderbilt University	UNIV60509		357,853
Subtotal Assistance listing 93.393					572,603
Cancer Detection and Diagnosis Research	93.394	Dartmouth College	R309	_	9,026
Cancer Detection and Diagnosis Research	93.394	Fred Hutch Cancer Research Center	0001007734	-	(9,914)
Cancer Detection and Diagnosis Research	93.394	Fred Hutch Cancer Research Center	0001012511	-	173,601
Cancer Detection and Diagnosis Research	93.394	Pacific NorthWest National Laboratory	371217	_	318,968
Cancer Detection and Diagnosis Research	93.394	Oregon State University	P0511A-A	_	186,577
Cancer Detection and Diagnosis Research	93.394	Quantitative Imaging Systems LLC	SRA-19-061 201809	_	42,438
Cancer Detection and Diagnosis Research	93.394	Research Institute at Nationwide Childrens Hospital	700110-0320-03	21,679	53,158
Cancer Detection and Diagnosis Research	93.394	University of Massachusetts Worcester	OSP2016158	_	631
Cancer Detection and Diagnosis Research Cancer Detection and Diagnosis Research	93.394 93.394	University of Texas, M.D. Anderson Cancer Center University of Washington	3001225332 UWSC11821	_	72,568 70,529
Subtotal Assistance listing 93.394	93.394	University of Washington	0003011621	21.679	917,582
	00.005				
Cancer Treatment Research	93.395	Children's Hospital of Philadelphia	FP00026529_SUB709_01 PO#20222694	-	170,989
Cancer Treatment Research Cancer Treatment Research	93.395 93.395	Case Western Reserve University	RES515655	_	15,676 10.630
Cancer Treatment Research	93.395	City of Hope Natl Medical Center Fred Hutch Cancer Rsch Ctr	62765.2009123.669301 0001043991	—	8.631
Cancer Treatment Research	93.395	Inherent Targeting LLC.	SRA-21-119	—	5.678
Cancer Treatment Research	93.395	University of Michigan	SUBK00011987	_	37.198
Cancer Treatment Research	93.395	Cytoimage Dx	SRA-19-111		29.035
Cancer Treatment Research	93.395	Leidos Biomedical Research Inc	P17054		2,830
Cancer Treatment Research	93.395	Mayo Clinic Arizona Grants	ORF-245947/PO #67153802	_	43.632
Cancer Treatment Research	93.395	Memorial Sloan-Kettering Cancer Center	224268	_	40,002
Cancer Treatment Research	93.395	Oregon State University	P0480B-A	_	278.108
Cancer Treatment Research	93.395	PDX Pharmaceuticals LLC	SRA-18-149-A	_	71.202
ancer Treatment Research	93.395	Seattle Children's Research Institute	12117SUB	_	38,630
ancer Treatment Research	93.395	University of California, San Diego	103111218 MP Invoice#S9001993	_	76,176
Cancer Treatment Research	93.395	University of Kansas	ZAH00020	2,045	37,843
Subtotal Assistance listing 93.395				2,045	826,307
Cancer Biology Research	93.396	Brigham and Women's Hospital Inc.	119536	_	23,453
Cancer Biology Research	93.396	Dana-Farber Cancer Institute	1239004	_	(19)
Cancer Biology Research	93.396	Dana-Farber Cancer Institute	1239005	_	115,377
Cancer Biology Research	93.396	Sage Bionetworks	CSBCOHSU	_	51,861
Cancer Biology Research	93.396	University of California, San Francisco	9443sc		245,485
Subtotal Assistance listing 93.396					436,157
Cancer Centers Support Grants	93.397	University of Texas, M.D. Anderson Cancer Center	3001277530	_	9,449
Cancer Centers Support Grants	93.397	University of Texas, M.D. Anderson Cancer Center	3001272157	-	4,029
Cancer Centers Support Grants	93.397	University of Texas, M.D. Anderson Cancer Center	3001629056	-	154,728
Cancer Centers Support Grants	93.397	University of Texas, M.D. Anderson Cancer Center	3001688149		165,561
Subtotal Assistance listing 93.397					333,767
Cancer Research Manpower	93.398	University of California, San Francisco	9021sc	-	(46,165)
Cancer Cause and Prevention Research	93.399	Fred Hutch Cancer Rsch Ctr	0001068908	-	25,000

Schedule of Expenditures of Federal Awards Year ended June 30, 2021

Federal grantor/pass-through grantor/program or cluster title	Assistance listing number	Pass-through entity name	Pass-through entity identifying number	Passed through to subrecipients	Total federal expenditures
ACL National Institute on Disability,					
Independent Living, and Rehabilitation Research	93.433	Pennsylvania State University	5325-OHSU-DHHS-0200	\$ —	(3)
ACL National Institute on Disability,					
Independent Living, and Rehabilitation Research	93.433	Ohio State University	60075292 PO#RF01620971		6,884
Subtotal Assistance listing 93.433					6,881
Cardiovascular Diseases Research	93.837	Boston Children's Hospital	PO GENDFD0001609699	_	12,941
Cardiovascular Diseases Research	93.837	Cedars-Sinai Medical Center	1218159	_	18,065
Cardiovascular Diseases Research	93.837	Cedars-Sinai Medical Center	1583894	_	26,012
Cardiovascular Diseases Research	93.837	Children's Hospital of Philadelphia	3200660619	_	155,484
Cardiovascular Diseases Research	93.837	Duke University	EPM 6718	_	(14,871)
Cardiovascular Diseases Research	93.837	East Tennessee State University	18-130-1-S1.1	—	167,989
Cardiovascular Diseases Research	93.837	Northeast Ohio Medical University	G0132-B	—	108,860
Cardiovascular Diseases Research	93.837	Northwestern University	60043010 OHSU	_	5,818
Cardiovascular Diseases Research	93.837	Stanford University	60997111-11497	_	4,779
Cardiovascular Diseases Research	93.837	University of Alabama at Birmingham	000503570-031	_	11,578
Cardiovascular Diseases Research	93.837	University of California, Davis	201602990-01	_	46,288
Cardiovascular Diseases Research Cardiovascular Diseases Research	93.837	University of California, Los Angeles	1900 G XA547	5.000	1,001
Cardiovascular Diseases Research Cardiovascular Diseases Research	93.837 93.837	University of Michigan University of Minnesota	SUBK00012351 N004944405	5,000	51,825 3,796
Cardiovascular Diseases Research Cardiovascular Diseases Research	93.837	University of Pennsylvania	574952	_	34,485
Cardiovascular Diseases Research	93.837	University of Pennsylvania	574952 / PO 4359545	_	(15,806)
Cardiovascular Diseases Research	93.837	University of Rochester	417240G		(3,220)
Cardiovascular Diseases Research	93.837	Virogenomics BioDevelopment Inc	SRA-20-050		24.579
Cardiovascular Diseases Research	93.837	Yale University	None	_	7,374
Subtotal Assistance listing 93.837	00.001		1010	5.000	646,977
Lung Diseases Research	93.838	IHC Health Services	None	_	20,492
Lung Diseases Research	93.838	Joan & Sanford I Weill Medical College	183434-4E	_	10,453
Lung Diseases Research Lung Diseases Research	93.838 93.838	Oregon State University Massachusetts General Hosp	P0476C-A 236620	_	181,000 24,246
Lung Diseases Research Lung Diseases Research	93.838	NorthShore University HealthSystem	EH17-325-S8	—	42,793
Lung Diseases Research	93.838	Partners Healthcare	None	36.972	243.237
Lung Diseases Research	93.838	University of Vermont & State Agriculture College	31438SUB00000175	50,972	20,133
Lung Diseases Research	93.838	University of South Alabama	A18-0094-S001		19,048
Lung Diseases Research	93.838	University of Washington	UWSC12110 / BPO# 50505	_	1,436
Lung Diseases Research	93.838	University of Washington	UWSC8435 BPO41539		(8,681)
Subtotal Assistance listing 93.838				36,972	554,157
Blood Diseases and Resources Research	93.839	Aptitude Medical Systems Inc	SRA-20-076	_	2.846
Blood Diseases and Resources Research	93.839	Boston Children's Hospital	OHSU34	_	3.824
Blood Diseases and Resources Research	93.839	Emory University	T848029	_	8,370
Blood Diseases and Resources Research	93.839	National Marrow Donor Program	1702	_	26
Blood Diseases and Resources Research	93.839	National Marrow Donor Program	1703-1801	_	18,358
Blood Diseases and Resources Research	93.839	National Marrow Donor Program	BMT CTN Protocol# 1102	_	1,087
Blood Diseases and Resources Research	93.839	University of Arizona	544626	_	645
Blood Diseases and Resources Research	93.839	University of North Carolina at Chapel Hill	5120671	_	4,947
Blood Diseases and Resources Research	93.839	University of Pittsburgh	CNVA00054669 (131801-23)	_	825
Blood Diseases and Resources Research	93.839	Washington University School of Medicine	WU-18-276	—	1,188
Blood Diseases and Resources Research	93.839	Vanderbilt University	UNIV60760		55,677
Subtotal Assistance listing 93.839					97,793
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Baylor College of Medicine	7000001116	-	3,510
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Baylor College of Medicine	PO 7000001036	_	90,593
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital Inc	None	—	21,501
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Hebrew Rehabilitation Center	90094	_	78,416
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Johns Hopkins University	2004917090	_	19,579
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Florida	SUB00002039	_	33,855
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Florida	SUB00002541		186,918
Subtotal Assistance listing 93.846					434,372

Schedule of Expenditures of Federal Awards Year ended June 30, 2021

Federal grantor/pass-through grantor/program or cluster title	Assistance listing number	Pass-through entity name	Pass-through entity identifying number	Passed through to subrecipients	Total federal expenditures
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Augusta University, Center for Biotechnology and G	35235-2	\$ -	69,205
Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cal Poly Corporation	35235-2 2021-1-58765	\$	8.030
Diabetes, Digestive, and Kidney Diseases Extramutal Research	93.847	Children's Hospital Los Angeles	RGF011634-B		47,018
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Mercy Hospital	18-0011	_	49.537
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Duke University	A030942	=	55.947
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Emory University	A234182	_	6,013
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	S-GRD1718-SC14	_	433,131
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	S-GRD1920-SC14	_	51,017
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Kaiser Foundation Research Institute	OOS030228 OHSU	_	39,247
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	New York Medical College	12488	_	250,164
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Pacific Diabetes Technologies Inc	SRA-20-055	—	27,819
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Research Institute at Nationwide Children's Hospital	700198-0521-00	_	38,144
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	Stanford University Tricol Biomedical Inc.	61689816-1030046 SRA-18-127	-	(8,709) 93.731
Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of California. San Francisco	12028SC	—	93,731
Diabetes, Digestive, and Kidney Diseases Extramulal Research	93.847	Miriam Hospital	710-7147209	—	12.849
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Oklahoma Health Sciences Ctr.	RS20200170-02		604,340
Diabetes, Digestive, and Kidney Diseases Extramutal Research	93.847	University of Pennsylvania	568442		134,991
Diabetes, Digestive, and Kidney Diseases Extramutal Research	93.847	Yale University	GR107921(CON-80002826)	_	23,117
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Southern California	115956308	=	8,972
Subtotal Assistance listing 93.847					1,960,691
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Albert Einstein College of Medicine	311833		50,064
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Interventional AnalgesiX Inc.	IAXSUB-001	_	69,254
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Joan & Sanford I Weill Medical College	183840	_	50,147
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic Jacksonville	ORE-224063	_	63,073
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Dartmouth-Hitchcock Clinic	GC10418-01-DGR15362	_	82,115
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northwestern University	60054977 OHSU	_	22,351
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Southern Methodist University	G001663-7500		39,998
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Stanford University	61311386-124387	19,821	26,951
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853 93.853	University of California, Davis University of California. San Francisco	A15-0409-S003 10594SC	-	5,008 5,169
Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco University of Cincinnati	011337-133488	—	38,220
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	012043-133488		2.116
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Michigan	SUBK10404CSPE-002		51,548
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Michigan	SUBK10404CSPR-002	_	4,168
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Montana	PG20-61098-03	_	30,994
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pennsylvania	572825	_	3,750
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pittsburgh	0050115	_	1,376
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	State University of New York at Buffalo	R1250365	_	17,184
Subtotal Assistance listing 93.853				19,821	563,486
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	01061408	_	313,751
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	01061410	_	7,319
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	01061412	_	_
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	01061420	_	(9,276)
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	01062294 PO 2200017614	—	353,363
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	01062297	—	40,868
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	01062306 PO 2200017615	_	818,151
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	01063320	_	18,478
Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.855 93.855	Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center	01063321 PO 2200017614 01063322	_	28,421 6,973
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	01063323	_	152.661
Allergy and Infectious Diseases Research	93.855	Boston Children's Hospital	GENFD0001509963	_	187.518
Allergy and Infectious Diseases Research	93.855	Case Western Reserve University	RES513356	_	3.902
Allergy and Infectious Diseases Research	93.855	Duke University	A032384	_	106,032
Allergy and Infectious Diseases Research	93.855	Duke University	A032960	_	55
Allergy and Infectious Diseases Research	93.855	Emory University	A294224	_	57,705
Allergy and Infectious Diseases Research	93.855	Emory University	A539519	_	39,870
Allergy and Infectious Diseases Research	93.855	GoDX, Inc.	SRA-20-013	_	(564)
Allergy and Infectious Diseases Research	93.855	Icahn School of Medicine Mount Sinai	0255-D341-4609	_	129,602

Schedule of Expenditures of Federal Awards Year ended June 30, 2021

Addigs with findings Distance Distance<	Federal grantor/pass-through grantor/program or cluster title	Assistance listing number	Pass-through entity name	Pass-through entity identifying number	Passed through to subrecipients	Total federal expenditures
Alborg of the function Decress Research 19.500 Index Junch Teal Prof. — 19.520 Addrey of the function Decress Research 2000 (Fight Address Addres Address Address Address Address Address Address Addr						
Alborg of Indicas Desses Research 91356 National Jensini Partial Part Institution (Partial Part Institution (Part Part Part Part Institution (Part Part Part Part Part Part Part Part					Ŷ	
Albig on the function lines are based in the stand in the st						
Adding and Indicato Descers Based in Advance Relation 19233 — 12333 Adding and Indicato Descers Based in Advance Relation 000000 000000 000000 Adding and Indicato Descers Based in Advance Relation 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 0000000 000000 0000000 0000000 0000000 0000000 0000000 0000000 0000000 00000000 00000000 000000000 000000000 000000000 000000000 0000000000 0000000000 0000000000 0000000000 0000000000 0000000000 0000000000 0000000000 0000000000 0000000000 0000000000 00000000000 0000000000 0000000000 0000000000 0000000000 0000000000 0000000000 0000000000 00000000000 00000000000 00000000000 00000000000 00000000000 00000000000 000000000000 000000000000 000000000000 00000000000000000 000000000000000000000000000000000000						
Aller of bic/bits Dist Prior Handback Backs / Bassimi Import Prior Bassimi <thimport bassimi<="" prior="" th=""> <thimport bassimi<="" prior="" td=""><td></td><td></td><td></td><td></td><td>_</td><td></td></thimport></thimport>					_	
Adags of Indicate Desser Resert BalassedISCS PORES00 LPERS00 - 38.48 Adags of Indicate Desser Resert BalassedISCS PORES00 LPERS00 - 64.00 Adags of Indicate Desser Resert BalassedISCS PORES00 LPERS00 - 64.00 Adags of Indicate Desser Resert BBA Filter Desser Resert 64.00 - 64.00 Adags of Indicate Desser Resert BBA Filter Desser Resert BBA - 64.00 Adags of Indicate Desser Resert BBA Filter Desser Resert BBA - 64.00 Adags of Indicate Desser Resert BBA Enclosition Internation Internatinternatinternation Internation Internation Internation Internati					_	
Adags of Indicate Desser Resert BalassedISCS PORES00 LPERS00 - 38.48 Adags of Indicate Desser Resert BalassedISCS PORES00 LPERS00 - 64.00 Adags of Indicate Desser Resert BalassedISCS PORES00 LPERS00 - 64.00 Adags of Indicate Desser Resert BBA Filter Desser Resert 64.00 - 64.00 Adags of Indicate Desser Resert BBA Filter Desser Resert BBA - 64.00 Adags of Indicate Desser Resert BBA Filter Desser Resert BBA - 64.00 Adags of Indicate Desser Resert BBA Enclosition Internation Internatinternatinternation Internation Internation Internation Internati					_	
Albrig and Indicatos Diseases Research B36.25 Matter of Microsov Research Handbalo B54.21-007 — 6.6.60 Albrig and Indicatos Diseases Research B38.85 Matter of Microsov Research Handbalo B38.85 B38.85 <td></td> <td>93.855</td> <td></td> <td>Subaward#5326 PO#996565 HJF#64385</td> <td>_</td> <td></td>		93.855		Subaward#5326 PO#996565 HJF#64385	_	
Altering and Indicators Diseases Research 0.165 Perturbition Streams (Name) 1.6 9.170 Altering and Indicators Diseases Research 0.185 Tensebb Instance 1.02038 - 9.170 Altering and Indicators Diseases Research 0.185 Tensebb Instance 9.170 9.170 Altering and Indicators Diseases Research 0.185 Tensebb Instance 9.170 9.170 Altering and Indicators Diseases Research 0.185 Tensebb Instance 9.170 9.160 Altering and Indicators Diseases Research 0.185 University of Calciman, Intre 200.1724 - 4.69.318 Altering and Indicators Diseases Research 0.186 University of Calciman, Intre 200.1724 - 4.69.318 Altering and Indicators Diseases Research 0.186 University of Calciman, Intre 200.1724 - 4.69.318 Altering and Indicators Diseases Research 0.186 University of Calciman, Intre 200.177 - 4.69.318 Altering and Indicators Diseases Research 0.186 University of Calciman, Intre 1.65.688 Altering and Indicators Diseases Resear	Allergy and Infectious Diseases Research	93.855	Joan & Sanford I Weill Medical College	212095-10/P01AI129859-02	_	
Altery and Medican Diseases Research 1028518 — 936.47 Arbyr and Medican Diseases Research 1028528 — 936.427 Arbyr and Medican Diseases Research 1028528 — 1028528 Arbyr and Medican Diseases Research 1028528 University of Privitian 1028528 Arbyr and Medican Diseases Research 10285 University of Privitian 1028528 1028528 Arbyr and Medican Diseases Research 10285 University of Privitian 1028528 1028528 1028528 1028528 1028528 1028528 1028528 1028528 1028528 1028528 1028528					_	
Alergy and Indicates Diseases Research 9.3.8.5 Setting Disease Research 205.00 — 301.200 Alory and Indicates Diseases Research 9.3.8.5 University of Alaram at Birmingfunn 00000014-000 — 103.8.6 Alory and Indicates Diseases Research 9.3.8.5 University of Alaram at Birmingfunn 00000014-000 — 8.3.8.5 Alory and Indicates Diseases Research 9.3.8.5 University of Alaram at Birmingfunn 00000014-000 — 8.3.8.5 Alory and Indicates Diseases Research 9.3.8.5 University of Charlam Search 9.3.8.5 Marry and Indicates Diseases Research — 4.3.7.8.1 Alory and Indicates Diseases Research 9.3.8.5 University of Charlam Charge Hill 9.3.8.6.5 4.3.7.8.1 - 4.3.7.8.1 Alory and Indicates Diseases Research 9.3.8.5 University of Marca 9.3.8.6.5 - 4.3.7.8.1 Alory and Indicates Diseases Research 9.3.8.5 University of Marca 9.3.8.6.5 - 4.3.6.5 Alory and Indicates Diseases Research 9.3.8.5 University of Marca 9.3.8.6.5 - 4.3.6.7					_	
Allergy and Indicates Diseases Research 91.855 Trendegine in Comparison in Allergy and Indicates Diseases Research 93.850 Unregine in Comparison in C					_	
Altery and Indicato Diseases Research 91.865 Tunky and Indicato Diseases Research 97.800 — 17.22.80 Altery and Indicato Diseases Research 91.865 University of Alternator States and States and Strands — 17.67.693 Altery and Indicato Diseases Research 91.865 University of California, San Francisco 957se — 4.87.711 Altery and Indicato Diseases Research 91.865 University of California, San Francisco 957se — 4.87.711 Altery and Indicato Diseases Research 91.865 University of Mindpan Participan Partitipan Paritipan Participan					_	
Allerg and Interbasis Diseases Research 9.8.55 University of Califorms, Inter weight of Alasama all Biningham 0052025-005 - 1.074,625 Allerg and Interbasis Diseases Research 9.8.55 University of Califorms, Inter weight of Califorms, Inter Parabases 2027,126 - - 1.074,625 Allerg and Interbasis Diseases Research 9.8.55 University of Califorms, Inter Parabases 2027,126 - - 4.9.731 Allerg and Interbasis Diseases Research 9.8.55 University of Califorms, Inter Parabases SUBDOILT70 - - 4.9.731 Allerg and Interbasis Diseases Research 9.8.55 University of Multiconia - Multiconia SUBDOILT70 - 1.9.542 Allerg and Interbasis Diseases Research 9.8.55 University of Multiconia - Multiconia 9.155010 - 1.9.542 Allerg and Interbasis Diseases Research 9.8.55 University of Multiconia - Multiconia 9.8.5501 - 1.9.542 Allerg and Interbasis Diseases Research 9.8.550 University of Multiconia - Multiconia 9.8.5501 - 1.9.542 Biomediad Research and Research Taining 9.8.50 Partial Mili					_	
Allergy and Indexina Diseases Research 93.855 University of Califorms, Inter ² 2025-1294 — 645.518 Allergy and Indexina Diseases Research 93.855 University of Califorms, Inter ² 2025-1294 — 165.528 Allergy and Indexina Diseases Research 93.855 University of Charge — 452.381 Allergy and Indexina Diseases Research 93.855 University of Charge 93.856 93.856 Allergy and Indexina Diseases Research 93.855 University of National Science 93.856 93.856 Allergy and Indexina Diseases Research 93.856 University of National Science 93.856 — 4.83.83 Allergy and Indexina Diseases Research 93.856 University of National Science 93.850 — 4.83.83 Allergy and Indexina Disease Research 93.850 University of National Science — 4.83.83 Allergy and Indexina Disease Research 93.850 Vinconin - Madean 83.95.000 — 4.84.93 Allergy and Indexina Disease Research 93.856 Vinconin - Madean 83.95.000 — - 1.95.95.000					_	
Allergy and Indicatos Diseases Research 9.855 University of Caldrom, San Francisco 9756 — 1.95,278 Allergy and Indicatos Diseases Research 9.855 University of Pixola 9000000000000000000000000000000000000					_	
Allergy and Indicatos Diseases Research 9.855 University of Caldoms, San Francisco 9786: - 24,021 Allergy and Indicatos Diseases Research 9.855 University of Tockag W0100707 - 4402 Allergy and Indicatos Diseases Research 9.855 University of Tockag 9.000007198 - 4.000 Allergy and Indicatos Diseases Research 9.855 University of Tockag 9.000007198 - 1.000007 Allergy and Indicatos Diseases Research 9.0000000000 9.000000000000000000000000000000000000					_	
Along and Indextona Diseases Research 98.85 University of Finding SUB0001770 - 49.237 Along and Indicationa Diseases Research 98.85 University of Finding SUB000171098 - 49.237 Along and Indicationa Diseases Research 98.85 University of Finding SUB000171098 - 49.237 Along and Indicationa Diseases Research 98.85 University of Watchington SUB0001700 - 49.237 Along and Indicationa Diseases Research 98.85 University of Watchington Bio Statu - 10.588 Along and Indicationa Diseases Research 98.85 University of Watchington Bio Statu - 10.588 Subdata Research Training 98.65 University of Watchington Bio Statu - 6.312 Bio medical Research Training 98.65 University of Watchington 10.551 - 6.312 Bio medical Research Training 98.65 University of Watchington 10.512 - 10.512 Bio medical Research Training 98.65 University of Watchington - 6.332						
Allergy and Indicatos Dessess Research 92.855 University of Kindia SUB00001700 - 4.143 Allergy and Indicatos Dessess Research 92.855 University of Kindia SUB00001706 - 4.53 Allergy and Indicatos Dessess Research 92.855 University of Kundia SUB0001710 - 156.843 Allergy and Indicatos Dessess Research 92.855 University of Watchington BURK (22.0007166 - 156.843 Allergy and Indicatos Dessess Research 92.855 University of Watchington University of Watchington - 6.10.623 Bornedical Research and Research Training 92.855 Vincentinon BURK (22.0182) - 3.418 Biomedical Research and Research Training 92.859 Vincentinon Matchington - 6.10.623 Biomedical Research and Research Training 92.859 Vincentinon Matchington - 6.2.367 Biomedical Research and Research Training 92.859 University of Watchington University of Watchington - 6.2.367 Biomedical Research and Research Training 92.859 University of Watchi						
Altergrand Infectiona Diseases Research 9.0650 — 4.0310 Altergrand Infectiona Diseases Research 9.3655 University of Wachscraim at Chargel Hill 5116866 — 4.0310 Altergrand Infectiona Diseases Research 9.3555 University of Wachscraim at Chargel Hill 5116866 — 151.554 Altergrand Infectiona Diseases Research 9.3555 University of Wachscraim at Chargel Hill 5116866 — 151.554 Substant Seasorch 9.3555 University of Wachscraim at Chargel Hill 510.551.551.551.551.551.551.551.551.551.					_	
Allergy and Infectious Diseases Research 93.656 University of Watcomin 511896 — 156.648 Allergy and Infectious Diseases Research 93.955 University of Watcomin 6159010 — 151.83 Allergy and Infectious Diseases Research 93.955 University of Watcomin MARCINE Constraints Diseases Research — 105.84 Allergy and Infectious Diseases Research 93.955 University of Watcomin MARCINE Constraints Diseases — 105.84 Biomedical Research Training 93.955 Watcomin Marcine Constraints Disease — 83.432 Biomedical Research Training 93.955 Watership of Marcine Disease — 103.852 Biomedical Research Training 93.555 University of PhEudry Marcine Disease — 103.852 Biomedical Research Training 93.555 University of Marcine Disease — 103.852 Biomedical Research Training 93.555 University of Marcine Disease — 103.852 Biomedical Research Training 93.555 University of Marcine Disease — 103.852 Biomedical Research and Re					—	
Allergy and Infectious Dessase Research 93.85 University of Wisconsin - Madison 915010 — 10.548 Allergy and Infectious Dessase Research 93.855 University of Wisconsin - Madison 944/72 — 10.548 Allergy and Infectious Dessase Research 93.855 University of Wischrighton UNIX67(1220) GPO No.51822 — 10.558 Subtola Assistance Dessare Research 93.855 Johas Hopkins University 2003723463 — 6.819.044 Bornedical Research Taining 93.899 Johas Hopkins University 2003723463 — 3.418 Bornedical Research Taining 93.899 Johas Hopkins University 100201 — 3.418 Bornedical Research Taining 93.890 University of Wisconsin - Madison 00000000666 — 6.2387 Bornedical Research Taining 93.890 University of Wisconsin - Madison 00000000666 — 6.2387 Bornedical Research Taining 93.890 University of Wisconsin - Madison 00000000666 — 6.2387 Bornedical Research Taining 93.890 University of Wisconsin - Madison <					_	
Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research Biomedical Research Research Biomedical Research Training Biomedical Research Training Biomedical Research Training Biomedical Research Training Biomedical Research and Research Training Biomedical Research Training Biomedical Research and Research Training Biomedical Research Training <br< td=""><td></td><td></td><td></td><td></td><td>_</td><td></td></br<>					_	
Allergy and Infectious Diseases Research 9.3.55 University of Washington UNIVES/12200 JEPO Nos 51822 - 17.523 Subtodal Assistance listing 93.855 - - 68.090.044 Biomedical Research Training 93.355 Vorgennicis Biologues - 84.342 Biomedical Research Training 93.355 Vorgennicis Biologues 100201 - 93.436 Biomedical Research Training 93.355 Vorgennicis Biologues - 40.432 Biomedical Research and Research Training 93.356 University of Plastorgh AVD00000919 (133.432.52) - 106.832 Biomedical Research and Research Training 93.356 University of Washington UNISC1246 UPIS UNISC1246 - 40.233 Biomedical Research and Research Training 93.356 University of Washington UNISC1244 UPIS UNISC1244 - 40.230 Biomedical Research and Research Training 93.559 University of Washington UNISC1244 - 40.230 Biomedical Research and Research Training 93.559 University of Washington UNISC1244 - 40.230 Bio					_	
Allerging and Infectious Diseases Research					_	
Biomedical Research and Research Training 93.869 Johns Hadpins Linkersity 200723480 – 84.942 Biomedical Research and Research Training 93.869 Portinat Site Linkersity 100201 - 23.947 Biomedical Research and Research Training 93.869 University of Plasburgh PM000000866 - 62.337 Biomedical Research and Research Training 93.859 University of Washington UWSC10441 BP030866 - 104.852 Biomedical Research Training 93.859 University of Washington UWSC10441 BP030866 - 113.440 Biomedical Research Training 93.859 University of Washington UWSC10441 BP030866 - 113.440 Biomedical Research Training 93.869 Olive Wew-UCA Education & Research Institute (ER 19.05 - 12.05 Child Health and Human Development Extramural Research 93.860 Olive Wew-UCA Education & Research Institute (ER 19.05 - 12.03 Child Health and Human Development Extramural Research 93.860 Columbia University 20.07 - 20.07 Child Health and Human Development Extramural Research					_	
Biomedial Research Training 93.859 Portland Sinte University' 10201 - 3.418 Biomedial Research and Research Training 93.859 Wilanett University Richard Sinte University - 104.832 Biomedial Research and Research Training 93.859 University of Wisconin - Madison 000000059 (13343-2) - 104.832 Biomedial Research and Research Training 93.859 University of Wiscingin - Madison 00000059 (13343-2) - 104.832 Biomedial Research and Research Training 93.859 University of Wiscingin - Madison 0000059 (13343-2) - 113.1440 Biomedial Research and Research Training 93.859 University of Wiscingin - Madison 0000059 (15930-00000000000000000000000000000000000	Subtotal Assistance listing 93.855					8,191,064
Biomedial Research Training 93.859 Portland Sinte University' 10201 - 3.418 Biomedial Research and Research Training 93.859 Wilanett University Richard Sinte University - 104.832 Biomedial Research and Research Training 93.859 University of Wisconin - Madison 000000059 (13343-2) - 104.832 Biomedial Research and Research Training 93.859 University of Wiscingin - Madison 00000059 (13343-2) - 104.832 Biomedial Research and Research Training 93.859 University of Wiscingin - Madison 0000059 (13343-2) - 113.1440 Biomedial Research and Research Training 93.859 University of Wiscingin - Madison 0000059 (15930-00000000000000000000000000000000000	Biomedical Research and Research Training	93.859	Johns Hopkins University	2003723463	_	84.342
Biomedical Research and Research Training 93.859 University of Pittaburgh AW000000519 (13334.2) - 104.832 Biomedical Research and Research Training 93.859 University of Washington UWSC10441 BP0.00569 - 62.387 Biomedical Research and Research Training 93.859 University of Washington UWSC10441 BP0.00569 - 113.440 Biomedical Research and Research Training 93.859 University of Washington UWSC10441 BP0.00569 - 113.440 Biomedical Research and Research Training 93.850 Olive View-VCLA Education & Research Institute (ER 19-05 - 11,550 Child Health and Human Development Extramural Research 93.865 Cale Poly Corporation K&827.047 - 20.479 Child Health and Human Development Extramural Research 93.865 Cale Poly Corporation K&823.00450 - 41,102 Child Health and Human Development Extramural Research 93.865 Cale Poly Corporation K&823.00450 - 56.52 Child Health and Human Development Extramural Research 93.865 Cale Poly Corporation Cale S0.55 Cale Poly Corporation K<823.004					_	
Biomedical Research and Research Training 93.899 University of Waschington 000000656 - 62.387 Biomedical Research and Research Training 93.899 University of Washington UWSC10441 BP030956 - 113.140 Biomedical Research and Research Training 93.899 University of Washington UWSC10441 BP030956 - 113.140 Biomedical Research and Research Training 93.899 University of Washington - 409.149 Emerging Infections Sentinel Networks 93.800 Olive-UCLA Education & Research Institute (ER 19-05 - 25.251 Child Health and Human Development Extramural Research 93.865 21st Century Medicine SR42-1047 - 20.479 Child Health and Human Development Extramural Research 93.865 Callerloy Corporation K54.220-07450 - 455.652 Child Health and Human Development Extramural Research 93.865 Curators of the University of Missouri C00009012-2 - 65.652 Child Health and Human Development Extramural Research 93.865 Curators of the University of Missouri C00009012-2 - 65.652 Child	Biomedical Research and Research Training	93.859	Willamette University	R15GM132845-OHSU	_	23,847
Biomedical Research Training 93.859 University of Washington UWSC10411 — (1.230) Biomedical Research Training 93.859 University of Washington UWSC10414 BPO303656 — 113 Biomedical Research Training 93.859 University of Washington UWSC10414 BPO303656 — 400,140 Biomedical Research and Research Institute (ER 19.05 — 400,140 — 400,140 … 52,531 … … 11550 … … 11,550 … … 11,550 … … 11,550 … … 11,550 … … 11,550 … … 11,550 … … 11,610 … 12,613 … … 14,620 … 14,102 … 14,102 … 14,102 … 14,102 … 14,102 … 14,102 … 14,102 … 16,102 … 16,102 … 16,102 … 16,102 … 16,102 … 16,102 16,102	Biomedical Research and Research Training	93.859	University of Pittsburgh	AWD00000919 (133343-2)	_	104,832
Biomedical Research and Research Training 93.859 University of Washington UWSC1044 BPG30896	Biomedical Research and Research Training	93.859	University of Wisconsin - Madison	000000856	_	62,387
Biomedical Research rand Research and Research ranking 93.859 University of Washington — 113 Subtola Assistance listing 93.859 — — 409.149 Emerging Infections Sentinel Networks 0 0live View-UCLA Education & Research Institute (ER 19-05 — 11.550 Child Heath and Human Development Extramural Research 93.865 Beckman Research Institute of the City of Hope 62876.2008391.669301 — 2.5,531 Child Heath and Human Development Extramural Research 93.865 Cal Fordy Corporation K.82-20-OHSU — 14.102 Child Heath and Human Development Extramural Research 93.865 Cal Intell Heath and Human Development Extramural Research 85.652 Child Heath and Human Development Extramural Research 93.865 California Research Institute 30005847.477 — 85.652 Child Heath and Human Development Extramural Research 93.865 Curators of the University of Missouri C00089012.2 — 6.1680 Child Heath and Human Development Extramural Research 93.865 Curators of the University of Missouri C00089012.2 — 6.1680 Child Heath and Human Development Extramural Research 93.865 Curators of the University of Missouri C00089012.2 — 6.662 Child Heath and Human Development Extramural Research 93.865	Biomedical Research and Research Training				_	(1,230)
Subtolal Assistance listing 93.859 — — — — — 409.149 Emerging Infections Sentinel Networks 93.860 Olive View-UCLA Education & Research Institute (ER 19-05 — — 11,550 Child Heath and Human Development Extramural Research 93.865 Beckman Research Institute of the City of Hope 62876.201.0471 — 25,331 Child Heath and Human Development Extramural Research 93.865 Child Heath and Human Development Extramural Research — 40,479 Child Heath and Human Development Extramural Research 93.865 Calurbia Chuiversity of Missouri C00009012-3 — 85,562 Child Heath and Human Development Extramural Research 93.865 Curators of the University of Missouri C00009012-3 — 6,862 Child Heath and Human Development Extramural Research 93.865 Curators of the University of Missouri C00009012-3 — 6,8100 Child Heath and Human Development Extramural Research 93.865 Dartnouth-Hitchcock Clinic GC100750-20-11 — 42.050 Child Heath and Human Development Extramural Research 93.865 Dartnouth-Hitchcock Clinic GC100750-20-11 — 42.050 Child Heath and H						
Emerging Infections Sentinel Networks93.860Olive View-UCLA Education & Research Institute (ER19-05-11,550Child Health and Human Development Extramural Research93.865Beckman Research Institute of the City of Hope62876.2008391.669301-52,531Child Health and Human Development Extramural Research93.86521st Century MedicineSRA-21-047-20,479Child Health and Human Development Extramural Research93.865Cal Poly CorporationK82230-OHSU-14,102Child Health and Human Development Extramural Research93.865Columbia University of Missouri2006547-07-85,052Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-3-(8,180)Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-3-(8,180)Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-3-(8,180)Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-3-(8,100)Child Health and Human Development Extramural Research93.865Iprime Stramural Research-7,5600Child Health and Human Development Extramural Research93.865Iprime Stramural Research-7,5500Child Health and Human Development Extramural Research93.865Iprime Stramural Research-7,5500Child Health an	5	93.859	University of Washington	UWSC9495		
Child Health and Human Development Extramural Research93.865Beckman Research Institute of the City of Hope62876.2008391.669301—52.51Child Health and Human Development Extramural Research93.865Cal Poly CorporationKRA21-047—20.47Child Health and Human Development Extramural Research93.865Cal Poly CorporationK.88230-CHSU—14.102Child Health and Human Development Extramural Research93.865Columbia University3000547+07—85.652Child Health and Human Development Extramural Research93.865Columbia University200069012-2—65.852Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-3—45.862Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-3—45.652Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-3—45.605Child Health and Human Development Extramural Research93.865Dartmourh-Hitchcock ClinicSRA-16.00-D—45.605Child Health and Human Development Extramural Research93.865Indiana UniversityNone Given—45.695Child Health and Human Development Extramural Research93.865Indiana UniversityNone Given—45.695Child Health and Human Development Extramural Research93.865Indiana UniversityNone Given—45.695Child Health and H	•			10.05		
Child Health and Human Development Extramural Research93.86521st Century MedicineSRA-21-047—20,479Child Health and Human Development Extramural Research93.865Cal Poly CorporationK-58230-OHSU—41,102Child Health and Human Development Extramural Research93.865Cal Poly CorporationK-58230-OHSU—81,602Child Health and Human Development Extramural Research93.865Columbia University2(GO14633-01)—65,652Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-2—6,652Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-3—42,050Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069114-4—76,600Child Health and Human Development Extramural Research93.865Dartmouth-Hitchcock ClinicGC10075-02-01—42,050Child Health and Human Development Extramural Research93.865Iportal State University of MissouriR000002706—46,695Child Health and Human Development Extramural Research93.865Iportal State UniversityNon Given—45,690Child Health and Human Development Extramural Research93.865Iportal State UniversityNon Given—46,695Child Health and Human Development Extramural Research93.865Iportal State UniversityNon Given—46,695Child Health	Emerging Intections Sentinel Networks				_	
Child Health and Human Development Extramural Research93.865Cal Poly CorporationK-8203-OHSU14,102Child Health and Human Development Extramural Research93.865Children's Research Institute30005547-0785.622Child Health and Human Development Extramural Research93.865Curators of the University of Missouri20(Go1 H633-01)65.622Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-36.163Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC0006911-037.600Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC0006911-034.6,605Child Health and Human Development Extramural Research93.865Dartors of the University of MissouriC0006901-234.6,605Child Health and Human Development Extramural Research93.865Dartors of the University of MissouriC0006901-234.6,605Child Health and Human Development Extramural Research93.865Indiana UniversityNon Given4.6,605Child Health and Human Development Extramural Research93.865Indiana UniversityNon Given4.6,655Child Health and Human Development Extramural Research93.865Indiana UniversityNon Given4.6,656Child Health and Human Development Extramural Research93.865Joan & Sanford I Weill Medical College2019.0006 P0					_	
Child Health and Human Development Extramural Research93.865Children's Research Institute900557-07—85.652Child Health and Human Development Extramural Research93.865Courators of the University of MissouriC00069012-2—5.652Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-3—6.163Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-3—6.163Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-3—4.6160Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069014-4—4.610Child Health and Human Development Extramural Research93.865Dartmouth-Hildcock ClinicSRA.1600-D—4.6695Child Health and Human Development Extramural Research93.865Indiana UniversityMisouri—4.6695Child Health and Human Development Extramural Research93.865Joan & Sanford I Weill Medical College2015.000F PO#P054137—4.6695<					_	
Child Health and Human Development Extramural Research93.865Curduros fib University of MissouriC00069012.2-5.652Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012.3-(8.180)Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC0006911.4-75.600Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC0006917.3-42.050Child Health and Human Development Extramural Research93.865Dartor of the University of MissouriC0006917.02-01-46.051Child Health and Human Development Extramural Research93.865Eppin Pharma IncR00002706-46.055Child Health and Human Development Extramural Research93.865Indiana UniversityNone Giveen-7.750Child Health and Human Development Extramural Research93.865Indiana UniversityNone Giveen-45.058Child Health and Human Development Extramural Research93.865Joan & Sanford I Weill Medical College2019.0006 PO/#P054137-201Child Health and Human Development Extramural Research93.865Joan & Sanford I Weill Medical College203535-463.582Child Health and Human Development Extramural Research93.865Medical University of South Carolina262463.582Child Health and Human Development Extramural Research93.865Medical University of South Carolina2662463.582 <td></td> <td></td> <td></td> <td></td> <td>_</td> <td></td>					_	
Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-2-558Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-4-75.600Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-4-75.600Child Health and Human Development Extramural Research93.865Dartmouth-Hitchcock ClinicC01075-02-01-42.050Child Health and Human Development Extramural Research93.865Epin Pharma IncSRA.16-009-D-42.050Child Health and Human Development Extramural Research93.865Indiana UniversityNone Given-45.695Child Health and Human Development Extramural Research93.865Indiana UniversityNone Given-45.695Child Health and Human Development Extramural Research93.865Indiana University2019.0006 PO#P054137-5.598Child Health and Human Development Extramural Research93.865Joan & Sanford I Weill Medical College203535-6.666Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation2.062.05137-4.848Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation2.052.558-4.848Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation-4.848 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069012-3(8,180)Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC0006911-442,050Child Health and Human Development Extramural Research93.865Dartmouth-Hitchocok ClinicGC10075-02-0142,050Child Health and Human Development Extramural Research93.865Eppin Pharma IncSRA060-09-D48,051Child Health and Human Development Extramural Research93.865Florida State UniversityNon Given46,055Child Health and Human Development Extramural Research93.865Indiana UniversityNon Given7,750Child Health and Human Development Extramural Research93.865Indiana UniversityNon Given45,059Child Health and Human Development Extramural Research93.865Joan & Sanford I Weill Medical College2019.000 F0/#P054137463,582Child Health and Human Development Extramural Research93.865Joan & Sanford I Weill Medical College203535463,582Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation262463,582Child Health and Human Development Extramural Research93.865Medical University of South Carolina262463,582Child Health and Human Development Extramural Research93.865Medical University of South Carolina2624						
Child Health and Human Development Extramural Research93.865Curators of the University of MissouriC00069141-475.600Child Health and Human Development Extramural Research93.865Dartmouth-Hickhock ClinicGC10075-02-0142.050Child Health and Human Development Extramural Research93.865Eppin Pharma Inc87.41-60-09-D42.050Child Health and Human Development Extramural Research93.865Indita State UniversityNone Given47.600Child Health and Human Development Extramural Research93.865Indita UniversityNone Given47.690Child Health and Human Development Extramural Research93.865Institute for Systems Biology2019.0006 PO#P0541375.598Child Health and Human Development Extramural Research93.865Joan & Sanford I Weill Medical College203536.666Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation26248.3582Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation46.3582Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation48.3582Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation48.3582Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation48.3582						
Child Health and Human Development Extramural Research93.865Dartmouth-Hilchcock ClinicG10075-02-0142.050Child Health and Human Development Extramural Research93.865Eppin Pharma IncSRA-16-009-D46.051Child Health and Human Development Extramural Research93.865Florida State UniversityR0000270646.052Child Health and Human Development Extramural Research93.865Indiana UniversityR0000270645.059Child Health and Human Development Extramural Research93.865Indiana University2019.0006 P0/#P0541375.598Child Health and Human Development Extramural Research93.865Joan & Sanford I Weill Medical College20353546.056Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation262463.582Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation2662463.582Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation262463.582Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation2624.284Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation2624.284Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation2624						
Child Health and Human Development Extramural Research 93.865 Eprin Pharma Inc SRA 16-009-D 81.012 Child Health and Human Development Extramural Research 93.865 Florid State University R000002706 64.695 Child Health and Human Development Extramural Research 93.865 Indiana University R000002706 7.750 Child Health and Human Development Extramural Research 93.865 Institute for Systems Biology 2019.0006 P0#054137 5.598 Child Health and Human Development Extramural Research 93.865 Joan & Sanford I Weill Medical College 16081197-01 463.662 Child Health and Human Development Extramural Research 93.865 Joan & Sanford I Weill Medical College 16081197-01 463.662 Child Health and Human Development Extramural Research 93.865 Magee-Woment Steasearch Institute & Foundation 262 463.562 Child Health and Human Development Extramural Research 93.865 Madee-Woment Research Institute & Foundation 262 463.562 Child Health and Human Development Extramural Research 93.865 Micro Lindervisity of South Caroli						
Child Health and Human Development Extramural Research93.865Florida State UniversityR0000270646.895Child Health and Human Development Extramural Research93.865Indiana UniversityNone Given7,500Child Health and Human Development Extramural Research93.865Institute for Systems Biology2019.0006 PO#P0541375,598Child Health and Human Development Extramural Research93.865Joan & Sanford I Weill Medical College2035356,666Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation262463,582Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation2040-\$013463,582Child Health and Human Development Extramural Research93.865Magee-Womens Research Institute & Foundation2062484Child Health and Human Development Extramural Research93.865Medical University of South CarolinaA00-2240-\$0134.274Child Health and Human Development Extramural Research93.865Magne-Womens Research Institute & Foundation205354.274Child Health and Human Development Extramural Research93.865Magne-Womens Research Institute & Foundation4.274Child Health and Human Development Extramural Research93.865Seattle Children's Research Institute & Foundation6.354Child Health and Human Development Extramural Research93.865Seattle Children's Research Institute<					_	
Child Health and Human Development Extramural Research 93.865 Indiana University Non Given 7.750 Child Health and Human Development Extramural Research 93.865 Indiana University 2019.000 Pol#054137 5.989 Child Health and Human Development Extramural Research 93.865 Joan & Sanford I Weill Medical College 2019.000 Pol#054137 4221 Child Health and Human Development Extramural Research 93.865 Joan & Sanford I Weill Medical College 203535 60.666 Child Health and Human Development Extramural Research 93.865 Magee-Womens Research Institute & Foundation 262 63.562 463.562 Child Health and Human Development Extramural Research 93.865 Magee-Womens Research Institute & Foundation 2662 463.562 Child Health and Human Development Extramural Research 93.865 Medical University of South Carolina 2062.70.50.3 4.848 Child Health and Human Development Extramural Research 93.865 Seattle Children's Research Institute 50.505.05.05.05.05.05.05.05.05.05.05.05.					—	
Child Health and Human Development Extramural Research 93.865 Institute for Systems Biology 201.0006 PO#P054137 5.598 Child Health and Human Development Extramural Research 93.865 Joan & Sanford I Weill Medical College 6081197-01 221 Child Health and Human Development Extramural Research 93.865 Joan & Sanford I Weill Medical College 20353 60,666 Child Health and Human Development Extramural Research 93.865 Magee-Womens Research Institute & Foundation 262 483,582 Child Health and Human Development Extramural Research 93.865 Medical University of South Carolina A00-2240-S013 484,842 Child Health and Human Development Extramural Research 93.865 Michigan State University RC1106770HSU 4,3542 Child Health and Human Development Extramural Research 93.865 Seattle Children's Research Institute 500.002 6,354 Child Health and Human Development Extramural Research 93.865 Seattle Children's Research Institute 500.002 6,354 Child Health and Human Development Extramural Research 93.865 Seattle Chi					_	
Child Health and Human Development Extramural Research 93.865 Joan & Sanford I Weill Medical College 1001 197-01 — 221 Child Health and Human Development Extramural Research 93.865 Joan & Sanford I Weill Medical College 203535 — 60.666 Child Health and Human Development Extramural Research 93.865 Magee-Womens Research Institute & Foundation 262 — 463.582 Child Health and Human Development Extramural Research 93.865 Magee-Womens Research Institute & Foundation 262 — 463.582 Child Health and Human Development Extramural Research 93.865 Medical University of South Carolina A02.204.500.33 — 4.848 Child Health and Human Development Extramural Research 93.865 Micro Base Micro B					_	
Child Health and Human Development Extramural Research 93.865 Joan & Sanford I Weill Medical College 203535 — 60.666 Child Health and Human Development Extramural Research 93.865 Megee-Womens Research Institute & Foundation 2662 — 463.582 Child Health and Human Development Extramural Research 93.865 Medical University of South Carolina A00-2240-S013 — 4.848 Child Health and Human Development Extramural Research 93.865 Michigan State University RC1106770HSU — 12.574 Child Health and Human Development Extramural Research 93.865 Seattle Children's Research Institute 12536SUB — 6.354 Child Health and Human Development Extramural Research 93.865 Seattle Children's Research Institute 26464861-130123 — 0.6,354						
Child Health and Human Development Extramural Research 93.865 Magee-Womens Research Institute & Foundation 2602 — 463.882 Child Health and Human Development Extramural Research 93.865 Medical University of South Carolina 2602 — 4848 Child Health and Human Development Extramural Research 93.865 Michigan State University RC1106770HSU — 12.574 Child Health and Human Development Extramural Research 93.865 Seattle Children's Research Institute 2565UB — 6.354 Child Health and Human Development Extramural Research 93.865 Seattle Children's Research Institute 26464861130123 — 26,784						
Child Health and Human Development Extramural Research 93.865 Medical University of South Carolina A00-2240-S013 — 4,848 Child Health and Human Development Extramural Research 93.865 Michigan State University RC108/TOHSU — 12,574 Child Health and Human Development Extramural Research 93.865 Seattle Children's Research Institute 12536SUB — 6,354 Child Health and Human Development Extramural Research 93.865 Stanford University 62464861-130123 — 206,764						
Child Health and Human Development Extramural Research 93.865 Michigan State University RC1 106770HSU — 12,574 Child Health and Human Development Extramural Research 93.865 Seattle Children's Research Institute 12536SUB — 6,354 Child Health and Human Development Extramural Research 93.865 Statiford University 62464861-130123 — 06,784					=	
Child Health and Human Development Extramural Research 93.865 Seattle Children's Research Institute 12536SUB — 6,354 Child Health and Human Development Extramural Research 93.865 Stanford University 62464861-130123 — 206,784					_	
					_	
Child Health and Human Development Extramural Research 93.865 University of California, Los Angeles 0865 G XA999 — 190,470	Child Health and Human Development Extramural Research		Stanford University	62464861-130123	_	
	Child Health and Human Development Extramural Research	93.865	University of California, Los Angeles	0865 G XA999	_	190,470

Schedule of Expenditures of Federal Awards Year ended June 30, 2021

Federal grantor/pass-through grantor/program or cluster title	Assistance listing number	Pass-through entity name	Pass-through entity identifying number	Passed through to subrecipients	Total federal expenditures
Child Health and Human Development Extramural Research	93.865	University of California, Riverside	S-000960	s —	1,475
Child Health and Human Development Extramural Research	93.865	University of North Carolina at Chapel Hill	5110333	· _	16,085
Child Health and Human Development Extramural Research	93.865	University of Pittsburgh	CNVA00048860 (126873-19)	_	13,523
Child Health and Human Development Extramural Research	93.865	University of Texas at Austin	UTA20-000198	_	10,704
Child Health and Human Development Extramural Research	93.865	University of Virginia	GB10318 PO#2120208		5,770
Subtotal Assistance listing 93.865					1,421,955
Aging Research	93.866	APDM Inc	RSA-02-NIH007	-	76,750
Aging Research	93.866	APDM Inc	RSA-02-NIH005-P2	1,837	151,059
Aging Research	93.866	Brown University	00001178	_	42,452
Aging Research	93.866	Brown University	00001355 00001357	-	75,779
Aging Research Aging Research	93.866 93.866	Brown University Brown University	00001357	_	42.830
Aging Research	93.866	Brown University	00001584	—	18.284
Aging Research	93.866	Brown University	00001585	_	90.146
Aging Research	93.866	Brown University	00001592		45,936
Aging Research	93.866	Brown University	0001357	_	20.879
Aging Research	93.866	California Pacific Medical Center Research Institute	280201018-S243 PO 28000007733	2.098.334	2.479.427
Aging Research	93.866	California Pacific Medical Center Research Institute	280201018-S276	2,000,004	166.049
Aging Research	93.866	California Pacific Medical Center Research Institute	280201023-S254 PO 28000007049	_	207.973
Aging Research	93.866	California Pacific Medical Center Research Institute	280201024-S283	_	106.830
Aging Research	93.866	Cleveland Clinic Lerner College of Medicine/CWRU	1341-SUB	_	166,470
Aging Research	93.866	Duke University	A030518	_	8,014
Aging Research	93.866	Emory University	A261099	_	17,153
Aging Research	93.866	Icahn School of Medicine Mount Sinai	0255-E311-4609	_	18,469
Aging Research	93.866	Northwestern University	60047610 OHSU	_	134,214
Aging Research	93.866	Northwestern University	60048332 OHSU	_	29,338
Aging Research	93.866	Oregon State University	P0486A-A	_	11,955
Aging Research	93.866	Pennsylvania State University	5974-OHSU-DHHS-0408	_	41,316
Aging Research	93.866	Regents of the University of Minnesota	N006909401	_	229,566
Aging Research	93.866	Seattle Institute for Biomedical and Clinical Rese	BW218-OHSU-1	—	265,090
Aging Research	93.866	University of California, San Diego	92311838 PO#S9001796	—	31,415
Aging Research	93.866	University of Illinois at Chicago	18240	—	29,796
Aging Research	93.866	University of Kentucky Research Foundation	3200002468-19-276	_	68,522
Aging Research	93.866	University of Nevada, Reno	UNR-20-41	_	158,257
Aging Research	93.866	University of Oregon	217320A	-	25,835
Aging Research	93.866 93.866	University of Pennsylvania	577437 PO 4326025	-	83,552 4.941
Aging Research Aging Research	93.866	University of Pittsburgh University of Southern California	AWD00002717 (134965-1) 105584954	_	287,210
	93.866	University of Washington	UWSC10151	_	68.666
Aging Research Aging Research	93.866	University of Washington	UWSC10151	—	8,890
Aging Research	93.866	University of Washington	UWSC7729 / BPO32893		26,515
Aging Research	93.866	University of Washington	UWSC7729, BPO32893 Line 1	_	(1,759)
Aging Research	93.866	University of Wisconsin – Madison	738K824	_	(1,735) (6)
Aging Research	93.866	Yale University	GR104097		18,201
Subtotal Assistance listing 93.866				2,100,171	5,256,022
Vision Research	93.867	Jaeb Center for Health Research Inc	None	_	42,028
Vision Research	93.867	Jaeb Center for Health Research Inc	Protocol W	_	18,627
Vision Research	93.867	Jaeb Center for Health Research Inc	Site 89, protocol K	_	85
Vision Research	93.867	Legacy Emanuel Hosp & Hith Ctr	2021-SLM-04	_	953
Vision Research	93.867	New York University School of Medicine	ZEDS	_	6,821
Vision Research	93.867	Oregon State University	P0521A-A	_	75,525
Vision Research	93.867	Pennsylvania State University	OHSEY023533	-	1,988
Vision Research	93.867	Portland State University	100512	-	42,863
Vision Research	93.867	Ted's Brain Science, Inc.	SRA-20-043	_	44,277
Vision Research	93.867	University of Alabama at Birmingham	000514548-002	_	35,246
Vision Research	93.867	University of Alabama at Birmingham	000517548-002	_	228,753
Vision Research	93.867	University of California, Riverside	S-000947	_	89,394
Vision Research	93.867	University of Miami	OS00000469 PO SPC-001666	_	74,628
Vision Research	93.867	University of Miami	OS00000469 PO SPC-001758	-	47,208

Schedule of Expenditures of Federal Awards

Naion Research 93.87 University of Wascomin - Madison 000000303	Federal grantor/pass-through grantor/program or cluster title	Assistance listing number	Pass-through entity name	Pass-through entity identifying number	Passe through subrecipi	to federal
Vision Research 93.867 University of Wiscontin – Madisian 612/161 — _	Vision Research	93.867	University of Southern California	129212702	\$	- 48,641
Vision Research Vision Research Matisan P12/161	Vision Research			000000030		- 81,651
Medical Library Assistance 50.879 University of Elifocia 16021	Vision Research	93.867		612K161		— 14,344
Subtotal Assistance Isting 93.879	Subtotal Assistance listing 93.867					- 853,032
National Bioteronism Hospital Preparances Program 93.889 University of California, San Francisco 11608ac — 44.85 Subbital Assistance listing 93.889 KAND Corporation 9520160337 — 622 Opportunity, Measure Development for the Quality Payment Program 93.886 RAND Corporation 9520160337 — 622 Opportunity, Measure Development for the Quality Payment Program 93.886 RAND Corporation 9520160337 — 622 Subbital Assistance listing 93.986 The Subbital Assistance listing 93.986 The Subbital Assistance listing 93.986 — 636.51 DHHS Programs 93.UNK ANA Associates, Inc. 49183 — 630.62 DHHS Programs 93.UNK Children't Hospital I ca Angeles Mol 1801 — 5000 DHHS Programs 93.UNK Children't Hospital I ca Angeles Mol 1801 — 454.82 DHHS Programs 93.UNK Dub Interviny 277.87 CHildren's Hospital I Ca Angeles Mol 181.92 — 454.22 DHHS Programs 93.UNK National Natrow Oncer Program DMI 181.92 —	Medical Library Assistance	93.879	University of Illinois at Chicago	16021		84
Subtitul Assistance listing 93.889	Subtotal Assistance listing 93.879					84
Medicare Access and CHIP Peak-britication Act (MACRA) Frynking 53.986 RAND Corporation 920190037 (22 Opportunity, Measure Development for the Quality Payment Program 93.986 RAND Corporation SCON-00000173 / SCON-00000329 (32 Difference Access and CHIP Readubricitation Act (MACRA) Funding 93.986 RAND Corporation 4983 (500 Difference Access and CHIP Readubricitation Act (MACRA) Funding 93.UNK Ant Associates, Inc. 4983 (500 DHHS Programs 93.UNK Ant Associates, Inc. 4983 (500 DHHS Programs 93.UNK Ant Associates, Inc. 4983 (500 DHHS Programs 93.UNK Ant Associates, Inc. 4983 (22 DHHS Programs 93.UNK Nate Foundation Research Institute 500001370 (24 DHHS Programs 93.UNK Nate University 257786 TORX State656499 154.22 DHHS Programs 93.UNK Massochustetts General Hosp 237165 46.14 DHHS	National Bioterrorism Hospital Preparedness Program	93.889	University of California, San Francisco	11608sc		- 44,857
Opportunity: Measure Development for the Quality Payment Program 93.986 RAND Corporation 920190037 C22 Medicare Access and CHIP Result/Payment Program 93.986 RAND Corporation 50.000 36.74 Subbital Assistance listing 33.986 36.74 36.74 DHHS Programs 93.UNK Abit Associates, Inc. 49183 5.00 DHHS Programs 93.UNK Abit Associates, Inc. 49183 2.16 DHHS Programs 93.UNK Abit Associates, Inc. 49183 2.16 DHHS Programs 93.UNK Abit Associates, Inc. 49183 2.16 DHHS Programs 93.UNK Kaine Foundation Programs 2.0001376 2.16 DHHS Programs 93.UNK Kaine Foundation Research Institute 0.00034147.0HSU 14.42 DHHS Programs 93.UNK National Network Dior Program BMT CTN Protocol #802 45.42 DHHS Programs 93.UNK National Network Dior Program BMT	Subtotal Assistance listing 93.889					- 44,857
Opportunity. Measure Development for the Quality Payment Program 93.886 RAND Corporation 920190037 C22 Opportunity. Measure Development for the Quality Payment Program 93.886 RAND Corporation 500000173 / SCON-00000299 86.74 Subotal Assistance listing 93.986 93.UNK Abt Associates, Inc. 41983 50.00 DHHS Programs 93.UNK Abt Associates, Inc. 41983 50.00 DHHS Programs 93.UNK Abt Associates, Inc. 41983 50.00 DHHS Programs 93.UNK Abt Associates, Inc. 41983 51.00 DHHS Programs 93.UNK Abt Associates, Inc. 41983 51.00 DHHS Programs 93.UNK Abt Associates, Inc. 40183 51.00 DHHS Programs 93.UNK Macine Foundation Research Institute OOS03047.OHSU 154.22 DHHS Programs 93.UNK Maional Mexon'or Ultraines of Medicine, BP/04.67672 63.55 DHHS Programs 93.UNK Na	Medicare Access and CHIP Reauthorization Act (MACRA) Funding					
Opportunity: Weasure Development for the Quality Payment Program 93.986 RAND Corporation SCON-00000173 / SCON-00000329	Opportunity: Measure Development for the Quality Payment Program	93.986	RAND Corporation	9920190037		— (229)
DHHS Programs 93.UNK Abf Associates, Inc. 49183 – 5.00 DHHS Programs 93.UNK Ann & Robert H. Lurie Children's Hospital of Chicago A20-001378 – 21.86 DHHS Programs 93.UNK Ann & Robert H. Lurie Children's Hospital of Chicago A20-001378 – 21.86 DHHS Programs 93.UNK Children's Hospital Los Angeles NMD 1801 – 11.86 DHHS Programs 93.UNK Children's Hospital Los Angeles NMD 1801 – 11.86 DHHS Programs 93.UNK Children's Hospital Los Angeles NMD 1801 – 14.22 DHHS Programs 93.UNK Children's Hospital Of Philadelphia GRT10000058/20213002-RSUB – 14.22 DHHS Programs 93.UNK Children's Hospital Of Philadelphia GRT7000058/20213002-RSUB – 14.22 DHHS Programs 93.UNK National Network Donor Infora BMT 57 Children's Hospital 64.72 DHHS Programs 93.UNK National Network Donor Infora BMT 57 Children's Hospital 64.72 DHHS Programs		93.986	RAND Corporation	SCON-00000173 / SCON-00000329		- 36,740
DHHS Programs 93 UNK Abt Associates, Inc. 4913 – 500 DHHS Programs 93 UNK Ann & Abort H. Lufe Children's Hospital of Chicago A20013-S01 – 21.86 DHHS Programs 93 UNK Ann & Abort H. Lufe Children's Hospital of Chicago A20013-S01 – 21.86 DHHS Programs 93 UNK Children's Hospital Los Angeles NMD 1801 – 11.86 DHHS Programs 93 UNK Children's Hospital Los Angeles NMD 1801 – 11.86 DHHS Programs 93 UNK Children's Hospital Los Angeles NMD 1801 – 14.22 DHHS Programs 93 UNK Children's Hospital Consecution Institute 20758 TOM2 Steed/349 – 14.22 DHHS Programs 93 UNK Matter Foundation Research Institute 20758 TOM2 Steed/349 – 42.22 DHHS Programs 93 UNK Matter Matter Dong Hospital 20758 TOM2 Steed/349 – 42.22 DHHS Programs 93 UNK Matter Dong Hospital 20758 TOM2 Steed/349 – 42.22 DHHS Programs 93 UNK <td>Subtotal Assistance listing 93.986</td> <td></td> <td>·</td> <td></td> <td></td> <td>— 36,511</td>	Subtotal Assistance listing 93.986		·			— 36,511
DHHS Programs 93.UNK An Robert H, Lurie Children's Hospital of Chicago A20.013-5001 — 12169 DHHS Programs 93.UNK Broad Institute, Inc. 500821-550001376 — 21.959 DHHS Programs 93.UNK Children's Hospital Los Angeles NUM 1801 — 43.46 DHHS Programs 93.UNK Children's Hospital of Philadelphia GRT.0000657/0213002-RSUB — 43.46 DHHS Programs 93.UNK Children's Hospital of Philadelphia GRT.0000657/0213002-RSUB — 43.46 DHHS Programs 93.UNK Kater Foundation Research Institute 006330447-OHSU — 176.97 DHHS Programs 93.UNK National Network of Libraries of Medicine. BMT CTN Protocol #1802 — 42.32 DHHS Programs 93.UNK National Network of Libraries of Medicine. BP045972 — 45.92 DHHS Programs 93.UNK National Network of Libraries of Medicine. BP045972 — 4.53 DHHS Programs 93.UNK National Network of Libraries of Medicine. 9.9045972 — 4.37 <	DHHS Programs	93.UNK	Abt Associates, Inc.	49183		
DHHS Programs 93.UNK Brand Institute, Inc. 5000821-550001376 — 2195 DHHS Programs 93.UNK Children's Hospital OX Angeles NM 0801 — 1188 DHHS Programs 93.UNK Children's Hospital OX Angeles NM 0801 — 94.44 DHHS Programs 93.UNK Duke University 257756 TOM2 Sike/05490 — 94.42 DHHS Programs 93.UNK Maiser Foundation Research Institute OOS030447-OHSU — 164.22 DHHS Programs 93.UNK Maiser Aubertis General Hosp 237165 — 49.14 DHHS Programs 93.UNK National Marrow Donor Program BMT CTN Protocol #1802 — 6.655 DHHS Programs 93.UNK National Marrow Portrad Meal Indepeid C18-03 — 4.54 DHHS Programs 93.UNK National Mealth Board C18-03 — 9.323 DHHS Programs 93.UNK National Mealth Board C18-03 — 9.323 DHHS Programs 93.UNK RAID Corporation 920190053 — 9.344 DHHS Programs 93.UNK Satubinke Seattle Dh						
DHHS Programs93.UNKChildren's Hospital Los AngelesNMD 1801—11.88DHHS Programs93.UNKChildren's Hospital dPhiladelphiaGRT 00000567/021302-RSUB—34.44DHHS Programs93.UNKKaiser Fondation Research InstituteODS30447-0HSU—154.22DHHS Programs93.UNKKaiser Fondation Research InstituteODS30447-0HSU—4.914DHHS Programs93.UNKNational Marrow Doner ProgramBMT CTN Protocol #1602—2.23DHHS Programs93.UNKNational Marrow Doner ProgramBMT CTN Protocol #1602—2.23DHHS Programs93.UNKNational Marrow Doner ProgramBMT CTN Protocol #1602—2.62DHHS Programs93.UNKNotTweet Portland Area Indian Health BoardC16-03—4.54DHHS Programs93.UNKNotTweet Portland Area Indian Health BoardC16-03—4.54DHHS Programs93.UNKNotTweet Portland Area Indian Health BoardC16-032.33.76DHHS Programs93.UNKRND Corporation99201900532.33.76DHHS Programs93.UNKRND Corporation8.312-0214743-65893L11.94DHHS Programs93.UNKSattle Enimedical Research Institute1.25002.33.76DHHS Programs93.UNKUniversity of Michigan30063463332.24DHHS Programs93.UNKUniversity of Michigan30063463332.846 <t< td=""><td></td><td></td><td></td><td></td><td></td><td>- 21,956</td></t<>						- 21,956
DHHS Programs 93.UNK Chitter's Hospital of Philadelphia GRT-00000569/0213002-RSUB — 94.46 DHHS Programs 93.UNK Duku Unversity 27758 To402 Street06499 — 154.22 DHHS Programs 93.UNK Masser Foundation Research Institute 00503047/20HSU — 176.97 DHHS Programs 93.UNK Masser/buest General Hostitute 237165 — 4.94.1 DHHS Programs 93.UNK National Marrow Donor Program BMT CTN Protocol #1802 — 2.23 DHHS Programs 93.UNK National Network of Libraries of Medicine, BPC#45972 — 6.95 DHHS Programs 93.UNK Northwest Portland Area Indian Health Board C11-03 — 4.94 DHHS Programs 93.UNK Northwest Portland Area Indian Health Board C12-03 — 37.95 DHHS Programs 93.UNK RAND Corporation 920190053 — 37.95 DHHS Programs 93.UNK Seattle Biomedical Research Institute 122.03 (77.86 — 4.43.73 DHHS Programs 93.UNK		93.UNK		NMD 1801		- 11,882
DHHS Programs 93 UNK Duke University 25778 T0#02 Stee#05499 — 1642 DHHS Programs 93 UNK Kasser Condation Research Institute 005030447-0HSU — 176.97 DHHS Programs 93 UNK Massachusetts General Hosp 237165 — 49.14 DHHS Programs 93 UNK Mational Marrow Donor Program BMT CTN Protocol #1802 — 2.23 DHHS Programs 93 UNK National Marrow Donor Program BMT CTN Protocol #1802 — 6.85 DHHS Programs 93 UNK National Marrow Donor Program DPI45907 — 6.85 DHHS Programs 93 UNK Northwest Portiand Area Indian Health Board C18-03 — 4.54 DHHS Programs 93 UNK Rate Indian Health Board C18-03 — 4.54 DHHS Programs 93 UNK Rate Indian Health Board C18-03 — 4.54 DHHS Programs 93 UNK Rate Indian Health Board C18-03 — 6.31.02 DHHS Programs 93 UNK Rate Indian Health Board C18-03 — 4.54.37 DHHS Programs 93 UNK				GRT-00000659/20213002-RSUB		
DHHS Programs93 UNKMassachusetis General Hosp237165—49.44DHHS Programs93 UNKNational Marcow Dono ProgramBMT CTN Protoci #1802—2.23DHHS Programs93 UNKNational Network of Libraries of Medicine,BPO/#5972—6.95DHHS Programs93 UNKNorthwest Portland Area Indian Health BoardC18-03—4.45DHHS Programs93 UNKNorthwest Portland Area Indian Health BoardC18-03—4.54DHHS Programs93 UNKRAND Corporation9920190053—3.735DHHS Programs93 UNKSeattle Biomedical Research Institute12250—4.44DHHS Programs93 UNKSeattle Biomedical Research Institute12250—4.443DHHS Programs93 UNKSeattle Biomedical Research Institute12450SUB—1.283,76DHHS Programs93 UNKUniversity of Maryland3001767 Ref No 4311—6.20DHHS Programs93 UNKUniversity of WashingtonUWSC11752 BPO#46809—150.31DHHS Programs93.UNKUniversity of WashingtonUWSC11752 BPO#46809—150.31DHHS Programs94.01Lioko Biomedical Re						
DHNS Programs93 UNKNational Marrow Donor ProgramBMT CTN Protocol #1802-2.23DHNS Programs93. UNKNational Network of Libraries of Medicine, BPO#45972BPO#45972-6,695DHNS Programs93. UNKNorthwest Portiand Area Indian Health BoardC18-03-4,54DHNS Programs93. UNKOregon State UniversityV0858A-A/19X077Q-23.76DHNS Programs93. UNKRAND Corporation920190053-37.95DHNS Programs93. UNKRTI International8.312-0214743-658931161.94DHNS Programs93. UNKSeattle Biomedical Research Institute75N03019C00070 / 12250-4.434,73DHNS Programs93. UNKSeattle Biomedical Research Institute75N03019C00070 / 12250-4.434,73DHNS Programs93. UNKSeattle Children's Research Institute124605UB-1.263,75DHNS Programs93. UNKSeattle Children's Research Institute124605UB-1.263,75DHNS Programs93. UNKUniversity of Maryland3006344533-2.84DHNS Programs93. UNKUniversity of Maryland3006344533-2.86DHNS Programs93. UNKUniversity of Maryland3006344533-2.86DHNS Programs93. UNKUniversity of Maryland0005030545-OHSU-2.86DHNS Programs97. UNKKaiser Foundation Research InstituteOOS030545-OHSU-3.065UHSAID Foreign Assistance for P						
DHNS Programs93.UNKNational Network of Libraries of Medicine, 93.UNKBPC/449726.95DHNS Programs93.UNKNorthwest Portland Area Indian Health BoardC18-034.54DHNS Programs93.UNKOregon State UniversityV0858A-A119X077Q233,76DHNS Programs93.UNKRAND Corporation992019005337,95DHNS Programs93.UNKRTI International8-312-021743-65893L59,34DHNS Programs93.UNKSeattle Biomedical Research Institute75N03019C00070 / 122504,444,73DHNS Programs93.UNKSeattle Biomedical Research Institute75N03019C00070 / 122504,444,73DHNS Programs93.UNKSeattle Biomedical Research Institute75N03019C00070 / 122504,245DHNS Programs93.UNKUniversity of Maryland3001767 Ref No 43116,20DHNS Programs93.UNKUniversity of Maryland3001767 Ref No 431128,46DHNS Programs93.UNKUniversity of Maryland30063450328,66DHNS Programs93.UNKUniversity of Maryland30063450328,66DHNS Programs91.UNKKaiser Foundation Research InstituteOOS030545-OHSU28,66DHNS Programs97.UNKKaiser Foundation Research Institute005030545-OHSU28,66DHNS Programs97.UNKLeidos Biomedical Research Institute005030545-OHSU28,66USAID F	DHHS Programs	93.UNK	Massachusetts General Hosp	237165		- 49,149
DHHS Programs93.UNKNorthwest Portland Area Indian Health BoardC18-03—4 54DHHS Programs93.UNKOregon State UniversityV0858A-A19X077Q—233,76DHHS Programs93.UNKRAND Corporation9920190053—37,95DHHS Programs93.UNKRTI International8-312-0214743-65893L—161,94DHHS Programs93.UNKSeattle Biomedical Research Institute12250—59,34DHHS Programs93.UNKSeattle Biomedical Research Institute75N03019C00070,12250—4,434,73DHHS Programs93.UNKSeattle Biomedical Research Institute75N03019C00070,12250—4,634,73DHHS Programs93.UNKSeattle Biomedical Research Institute1260,503—6,200DHHS Programs93.UNKUniversity of Maryland3001767 Ref No 4311—6,200DHHS Programs93.UNKUniversity of Maryland3006344533—28,66DHHS Programs93.UNKUniversity of Maryland3006344533—28,66DHHS Programs93.UNKUniversity of Maryland3005355-OHSU—22,66DHHS Programs97.UNKKalser Foundation Research InstituteOS030545-OHSU—22,66DHHS Programs98.001Eastern Virginia Medical SchoolUCS-20-004—31,65USAID Foreign Assistance for Programs Overseas98.001Eastern Virginia Medical SchoolUCS-20-004—31,65USAID Foreign Assistance for Heatth and Human Ser	DHHS Programs	93.UNK	National Marrow Donor Program	BMT CTN Protocol #1802		- 2,237
DHHS Programs93.UNKOregon State UniversityV0858A-/19X077Q—233.76DHHS Programs93.UNKRAND Corporation9920190053—33.76DHHS Programs93.UNKRTI International&312.0214743-65893L—161.94DHHS Programs93.UNKSeattle Biomedical Research Institute12250—593.43DHHS Programs93.UNKSeattle Biomedical Research Institute12250—4.943.73DHHS Programs93.UNKSeattle Biomedical Research Institute12450SUB—1.263.75DHHS Programs93.UNKSeattle Children's Research Institute12450SUB—1.263.75DHHS Programs93.UNKUniversity of Maryland3001767 Ret No 4311—6.200DHHS Programs93.UNKUniversity of WashingtonUWSC11752 BPO#46909—150.31Subtotal Assistance listing 93.UNKVashingtonUWSC11752 BPO#46909—150.31DHHS Programs97.UNKKaiser Foundation Research InstituteOOS030545-OHSU—2.264DHHS Programs97.UNKLeidos Biomedical Research InstituteOOS030545-OHSU—3.76USAID Foreign Assistance for Programs Overseas98.001Eastern Virginia Medical SchoolUCS-20.004—13.65Subtotal Department of Health and Human Services (HHS)	DHHS Programs	93.UNK	National Network of Libraries of Medicine,	BPO#45972		- 6,957
DHHS Programs93.UNKRAND Corporation9920190053—37.95DHHS Programs93.UNKRTI International8-312-0214743-65893L—161.94DHHS Programs93.UNKSeattle Biomedical Research Institute12250—4.434.73DHHS Programs93.UNKSeattle Biomedical Research Institute75N03019C00070 / 12250—4.434.73DHHS Programs93.UNKSeattle Children's Research Institute12450SUB—1.263.75DHHS Programs93.UNKUniversity of Maryland3001767 Ref No 4311—6.200DHHS Programs93.UNKUniversity of Michigan3006344533—28.46DHHS Programs93.UNKUniversity of MarylandUNSC11752 BPO#46909—150.31Subtotal Assistance listing 93.UNKVuniversity of MarylandOOS030545-OHSU—2.666.53DHHS Programs97.UNKKaiser Foundation Research InstituteSA20010—3.76USAID Foreign Assistance for Programs Overseas98.001Eastern Virginia Medical Research InstituteSA20010—3.666.945USAID Foreign Assistance for Programs Overseas98.001Eastern Virginia Medical SchoolUCS-20-004	DHHS Programs	93.UNK	Northwest Portland Area Indian Health Board	C18-03		- 4,549
DHHS Programs93.UNKRTI International8-312-0214743-65893L161.94DHHS Programs93.UNKSeattle Biomedical Research Institute125059.34DHHS Programs93.UNKSeattle Biomedical Research Institute12504.434.73DHHS Programs93.UNKSeattle Children's Research Institute12450SUB1.263.75DHHS Programs93.UNKUniversity of Maryland300163445336.20DHHS Programs93.UNKUniversity of Maryland30063445336.20DHHS Programs93.UNKUniversity of WashingtonUWSC11752 BPO#46909150.31Subtotal Assistance listing 93.UNKVIniversity of WashingtonUWSC11752 BPO#469092.26.46DHHS Programs97.UNKKaiser Foundation Research InstituteOOS030545-OHSU2.26.46DHHS Programs97.UNKLeidos Biomedical Research InstituteOOS030545-OHSU3.07.66DHHS Programs97.UNKLeidos Biomedical Research InstituteCOS030545-OHSU3.06DHHS Programs97.UNKLeidos Biomedical Research InstituteCOS030545-OHSU3.06DHHS Programs97.UNKLeidos Biomedical Research InstituteCOS030545-OHSU		93.UNK	Oregon State University	V0858A-A/19X077Q		- 233,764
DHHS Programs93.UNKSeattle Biomedical Research Institute12250—59.34DHHS Programs93.UNKSeattle Biomedical Research Institute75/03019C00070 / 12250—4.434.73DHHS Programs93.UNKSeattle Biomedical Research Institute75/03019C00070 / 12250—4.634.73DHHS Programs93.UNKSeattle Children's Research Institute12450SUB—1.263.75DHHS Programs93.UNKUniversity of Maryland3001767 Ref No 4311—6.20DHHS Programs93.UNKUniversity of Michigan3006344533—2.84.6DHHS Programs93.UNKUniversity of MashingtonUWSC11752 BPO#46909—150.31Subtotal Assistance listing 93.UNK97.UNKKaiser Foundation Research InstituteOOS030545-OHSU—2.26.4DHHS Programs97.UNKKaiser Foundation Research Institute00S030545-OHSU—3.3.65DHHS Programs Overseas98.001Eastern Virginia Medical SchoolUCS-20-004—13.65Subtotal Department of Health and Human Services (HHS)Eastern Virginia Medical SchoolUCS-20.04—13.65Total Research and Development Cluster – Indirect Programs2.881.51342.384.36	DHHS Programs	93.UNK	RAND Corporation	9920190053		- 37,950
DHHS Programs93.UNKSeattle Biomedical Research Institute75N03019C00070 / 122504,434,73DHHS Programs93.UNKSeattle Children's Research Institute12450SUB1,263,75DHHS Programs93.UNKUniversity of Maryland300634453328,46DHHS Programs93.UNKUniversity of Michigan300634453328,46DHHS Programs93.UNKUniversity of Michigan300634453328,46DHHS Programs93.UNKUniversity of Michigan300634453328,46DHHS Programs93.UNKUniversity of MarylandUWSC11752 BPO#46909150,31Subtotal Assistance listing 93.UNKUniversity of Maryland00S030545-OHSU22,64DHHS Programs97.UNKKaiser Foundation Research Institute00S030545-OHSU3,76DHHS Programs97.UNKLeidos Biomedical Research Institute02S-0043,76USAID Foreign Assistance for Programs Overseas98.001Eastern Virginia Medical SchoolUCS-20.0043,85Subtotal Department of Health and Human Services (HHS)2,866,94540,110,752,881,51342,384,36Total Research and Development Cluster - Indirect Programs2,881,51342,384,3642,384,36	DHHS Programs	93.UNK	RTI International	8-312-0214743-65893L		— 161,946
DHHS Programs93.UNKSeattle Children's Research Institute12450SUB—1,263,75DHHS Programs93.UNKUniversity of Maryland3006344533—6,20DHHS Programs93.UNKUniversity of Maryland3006344533—6,20DHHS Programs93.UNKUniversity of WashingtonUWSC11752 BPO#46909—150,31Subtotal Assistance listing 93.UNKUniversity of WashingtonUWSC11752 BPO#46909—22,64DHHS Programs97.UNKKaiser Foundation Research InstituteOOS030545-OHSU—22,64DHHS Programs97.UNKLeidos Biomedical Research InstituteSA20010—3,76USAID Foreign Assistance for Programs Overseas98.001Eastern Virginia Medical SchoolUCS-2004—13,65Subtotal Department of Health and Human Services (HHS)						00,040
DHHS Programs93.UNKUniversity of Maryland3001767 Ref No 43116.20DHHS Programs93.UNKUniversity of Michigan300634453328.46DHHS Programs93.UNKUniversity of Maryland300634453328.66DHHS Programs93.UNKUniversity of WashingtonUWSC11752 BP0#46909150.31Subtotal Assistance listing 93.UNK97.UNKKaiser Foundation Research InstituteOOS030545-OHSU22.64DHHS Programs97.UNKLeidos Biomedical Research InstituteOOS030545-OHSU3.76USAID Foreign Assistance for Programs Overseas98.001Eastern Virginia Medical SchoolUCS-20.00413.65Subtotal Department of Health and Human Services (HHS)5.266.94540.110.752.861.51342.384.363Total Research and Development Cluster – Indirect Programs2.881.51342.384.36342.384.363						.,
DHHS Programs 93.UNK University of Michigan 3006344533 28,46 DHHS Programs 93.UNK University of Michigan UWSC11752 BPO#46909 150,31 Subtoal Assistance listing 93.UNK University of Washington UWSC11752 BPO#46909 6,865,53 DHHS Programs 97.UNK Kaiser Foundation Research Institute OOS030545-OHSU 22,64 DHHS Programs 97.UNK Leidos Biomedical Research Institute OOS030545-OHSU 3,76 DHHS Programs 97.UNK Leidos Biomedical Research Inc S420010 3,86 USAID Foreign Assistance for Programs Overseas 98.001 Eastern Virginia Medical School UCS-20.004 3,86 Subtotal Department of Health and Human Services (HHS) 2,866,945 40,110,75 2,866,945 40,110,75 Total Research and Development Cluster - Indirect Programs 2,881,513 42,384,362 42,384,362						1,200,100
DHHS Programs 93.UNK University of Washington UWSC11752 BPO#46909 — 150.31 Subtotal Assistance listing 93.UNK Subtotal Assistance listing 93.UNK Immediate the second se						0,200
Subtotal Assistance listing 93.UNK — 6,865,53 DHHS Programs 97.UNK Kaiser Foundation Research Institute OOS030545-OHSU — 22,64 DHHS Programs 97.UNK Leidos Biomedical Research Inst SA20010 — 3,76 USAID Foreign Assistance for Programs Overseas 98.001 Eastern Virginia Medical School UCS-20-004 — 13,65 Subtotal Department of Health and Human Services (HHS) — 2,666,945 40,110,75 Total Research and Development Cluster – Indirect Programs — 2,881,513 42,384,363						20,101
DHHS Programs 97.UNK Kaiser Foundation Research Institute OOS030545-OHSU - 22,64 DHHS Programs 97.UNK Leidos Biomedical Research Institute SA2001 - 3,76 USAID Foreign Assistance for Programs Overseas 98.001 Eastern Virginia Medical School UCS-20-004 - 13,65 Subtotal Department of Health and Human Services (HHS) - 2,666,945 40,110,75 Total Research and Development Cluster - Indirect Programs - 2,881,513 42,384,367	DHHS Programs	93.UNK	University of Washington	UWSC11752 BPO#46909		100,011
DHHS Programs 97.UNK Leidos Biomedical Research Inc SA20010 — 3,760 USAID Foreign Assistance for Programs Overseas 98.001 Eastern Virginia Medical School UCS-20-004 — 13,65 Subtotal Department of Health and Human Services (HHS) 2,666,945 40,110,75 Total Research and Development Cluster – Indirect Programs 2,881,513 42,384,360	Subtotal Assistance listing 93.UNK					- 6,865,533
USAID Foreign Assistance for Programs Overseas 98.001 Eastern Virginia Medical School UCS-20-004 13,65 Subtotal Department of Health and Human Services (HHS) 2,666,945 40,110,75 Total Research and Development Cluster – Indirect Programs 2,881,513 42,384,366	DHHS Programs	97.UNK	Kaiser Foundation Research Institute	OOS030545-OHSU		- 22,648
Subtotal Department of Health and Human Services (HHS) 2,666,945 40,110,75 Total Research and Development Cluster – Indirect Programs 2,881,513 42,384,36	DHHS Programs	97.UNK	Leidos Biomedical Research Inc	SA20010		- 3,762
Total Research and Development Cluster – Indirect Programs 2,881,513 42,384,36	USAID Foreign Assistance for Programs Overseas	98.001	Eastern Virginia Medical School	UCS-20-004		— 13,657
	Subtotal Department of Health and Human Services (HHS)				2,666	,945 40,110,753
	Total Research and Development Cluster – Indirect Programs				2,881	,513 42,384,363
Total Research and Development \$	Total Research and Development				\$ 59,814	,044 334,656,558

Schedule of Expenditures of Federal Awards

Federal grantor/pass-through grantor	Program or cluster title	Additional Award Identification	Assistance listing number	Passed through to subrecipients	Total federal expenditures
Other awards – Direct Programs:					
U.S. Department of Defense (DOD): U.S. Army Medical Research Acquisition Activity	Military Medical Research and Development		12.420	\$ 125,690	566,505
Department of the Navy: DOD Office of Naval Research DOD Office of Naval Research	Military Medical Research and Development Defense Programs	DODIPA - BW	12.420 12.UNK	_	61,137 58,306
Subtotal U.S. Department of Defense (DOD)				125,690	685,948
Federal Communications Commission Federal Communications Commission	Communication Information and Assistance and Investigation of Complaints		32.001		372,757
Subtotal Federal Communications Commission					372,757
National Science Foundation (NSF) National Science Foundation LOC	Biological Sciences		47.074	_	(114)
Subtotal National Science Foundation (NSF)					(114)
U.S. Department of Veterans Affairs (VA) U.S. Dept of Veterans Affairs DVA U.S. Dept of Veterans Affairs DVA	VA Programs VA Programs	36C26020P0893 36C26021N0379 Obligation # 648-C15241	64.UNK 64.UNK		202,140 58
Subtotal U.S. Dept of Veterans Affairs (VA)					202,198
U.S. Department of Education: COVID-19 – Education Stabilization fund COVID-19 – Education Stabilization fund	Higher Education Emergency Relief Fund – Student aid portion Higher Education Emergency Relief Fund – Institutional portion		84.425E 84.425F	_	506,097 1.091.885
Subtotal COVID-19 – Education Stabilization fund	····g····				1,597,982
Subtotal U.S. Department of Education					1,597,982
U.S. Department of Health and Human Services (HHS): Administration for Children and Families: DHHS Administration for Children and Families – Office of Refugee					
Resettlement DHHS Administration on Developmental Disabilities	Assistance for Torture Victims University Centers for Excellence in Developmental		93.604	_	494,512
·	Disabilities Education, Research, and Service		93.632		574,500
Subtotal Administration for Children and Families					1,069,012
Centers for Disease Control and Prevention: DHHS CDCP	Disabilities Prevention				10.1.100
DHHS CDCP National Center on Birth Defects & Developmental Disabilities DHHS CDCP	Disabilities retwention Rare Disorders: Research, Surveillance, Health Promotion, and Education Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs		93.184 93.315 93.946		464,428 60,549 263.794
DHHS CDCP National Center for Injury Prevention & Control DHHS CDCP National Center for Injury Prevention & Control DHHS CDCP National Center for Injury Prevention & Control	DHIS Programs DHIS Programs DHIS Programs	16IPA1605223 20IPA2014109 20IPA2009426	93.UNK 93.UNK 93.UNK		3,124 17,295 10,570
Subtotal for Centers for Disease Control and Prevention	-			89,398	819,760
Subtolal for Centers for Disease Control and Prevention Health Resources and Services Administration (HRSA): DHHS HRSA Bureau of Health Professions	Training in General, Pediatric, and Public Health Dentistry		93.059	89,398	819,760
DHHS HRSA Bureau of Health Professions DHHS HRSA Maternal and Child Health Bureau DHHS HRSA Maternal and Child Health Bureau DHHS HRSA Dflice of Rural Hith Policy DHHS HRSA Dereau of Health Professions DHHS HRSA Bureau of Health Professions DHHS HRSA Bureau of Health Professions DHHS HRSA Office of Rural Health Policy DHHS HRSA Office of Rural Health Policy DHHS HRSA Dereau of Hith Professions DHHS HRSA Bureau of Hith Professions DHHS HRSA Bureau of Health Professions DHHS HRSA Bureau of Health Professions	Area Health Education Centers Maternal and Child Health Federal Consolidated Programs Emergency Medical Services for Children Rural Health Research Centers Grants to States for Loan Repayment Program Nursing Workforce Diversity Health Center Program Cluster State Rural Hospital Flexibility Program Advanced Education Nursing Grant Program Geriatric Academic Career Awards Department of Health and Human Services		93.107 93.110 93.127 93.155 93.165 93.178 93.224 93.241 93.241 93.247 93.252	547,120 402,892 82,917 45,744 — — — — — —	654,667 1,310,984 241,726 159,086 157,209 486,079 2,730,664 667,531 666,910 75,355 407,132
DHHS Health Resources and Services Administration DHHS HRSA Office of Rural Health Policy DHHS Health Resources and Services Administration	Poison Center Support and Enhancement Grant Program Small Rural Hospital Improvement Grant Program Nurse Education, Practice Quality and Retention Grants		93.253 93.301 93.359	1,122,244 —	407,126 1,222,260 62,502

Schedule of Expenditures of Federal Awards

Federal grantor/pass-through grantor	Program or cluster title	Additional Award Identification	Assistance listing number	Passed through to subrecipients	Total federal expenditures
DHHS Health Resources and Services Administration	COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured		93.461	s —	618,804
Provider Relief Fund Provider Relief Fund Provider Relief Fund	Tuality Healthcare dba OHSU Health Hillsboro Medical Center — General distribution OHSU General Distribution OHSU Targeted Funds		93.498 93.498 93.498		5,497,237 36,820,947 439,848
Assistance listing 93.498 Sub-total					42,758,032
DHHS HRSA Maternal and Child Health Bureau	Family to Family Health Information Centers		93.504	_	73,932
DHHS HRSA Office of Rural Health Policy DHHS HRSA Office of Rural Health Policy	Rural Health Care Services Outreach, Rural Health Network Development and Small Health Care Provider Quality Improvement Program Grants to States for Operation of State Offices of Rural Health		93.912 93.913	_	(37) 4,858
DHHS HRSA HIV/AIDS Bureau	Ryan White HIV/AIDS Dental Reimbursement and Community Based Dental Partnership Grants		93.924	38,618	377,685
Subtotal Health Resources and Services Administration				2,239,535	52,675,553
Office of the Assistant Secretary for Preparedness and Response National Bioterrorism Hospital Preparedness Program	COVID-19 supplemental funding		93.889		41,442
Subtotal U.S. Department of Health and Human Services				2,328,933	54,605,767
U.S. Department of Homeland Security (DHS): Federal Emergency Management Agency (FEMA)	DHS Cooperating Technical Partners		97.045		(1,997)
Subtotal U.S. Department of Homeland Security (DHS)					(1,997)
Total Other awards – Direct Programs				\$ 2,454,623	57,462,541

Schedule of Expenditures of Federal Awards

Federal grantor/pass-through grantor/program or cluster title Other awards – Indirect Programs: U.S. Department of Justice (DOJ): Crime Victim Assistance Criminal and Juvenile Justice and Mental Health Collaboration Program Subtotal U.S. Department of Justice (DOJ) U.S. Dept of the Treasury Coronavirus Relief Fund Coronavirus Relief Fund Subtotal U.S. Dept of the Treasury U.S. Department of Transportation (DOT): National Priority Safety Programs Subtotal U.S. Department of Transportation (DOT) – Highway Safety Cluster U.S. Department of Defense (DOD):	16.575 16.745 21.019 21.019 20.616 12.UNK 12.UNK	Pass-through entity name Oregon Department of Justice Deschutes County Health Services City of Portland Oregon Health Authority Oregon Department of Transportation CytoSorbents, Inc. Mid-Atlantic Epilepsy and Sleep Center	identifying number VOCA-FI-2018-OHSU-00070 DC-2019-001 30007596 167760 M1CPS-20-45-01 SRA-18-081 W81XWH-15-2-0069		expenditures 231,028 7,804 238,832 45,000 388,493 433,493 102,859 102,859 (0)
Crime Victim Assistance Criminal and Juvenile Justice and Mental Health Collaboration Program Subtotal U.S. Department of Justice (DOJ) U.S. Dept of the Treasury Coronavirus Relief Fund Coronavirus Relief Fund Subtotal U.S. Dept of the Treasury U.S. Department of Transportation (DOT): National Priority Safety Programs Subtotal U.S. Department of Transportation (DOT) – Highway Safety Cluster	16.745 21.019 21.019 20.616 12.UNK	Deschutes County Health Services City of Portland Oregon Health Authority Oregon Department of Transportation CytoSorbents, Inc.	DC-2019-001 30007596 167760 M1CPS-20-45-01 SRA-18-081		7,804 238,832 45,000 388,493 433,493 102,859 102,859
Criminal and Juvenile Justice and Mental Health Collaboration Program Subtotal U.S. Department of Justice (DOJ) U.S. Dept of the Treasury Coronavirus Relief Fund Coronavirus Relief Fund Subtotal U.S. Dept of the Treasury U.S. Department of Transportation (DOT): National Priority Safety Programs Subtotal U.S. Department of Transportation (DOT) – Highway Safety Cluster	16.745 21.019 21.019 20.616 12.UNK	Deschutes County Health Services City of Portland Oregon Health Authority Oregon Department of Transportation CytoSorbents, Inc.	DC-2019-001 30007596 167760 M1CPS-20-45-01 SRA-18-081		7,804 238,832 45,000 388,493 433,493 102,859 102,859
U.S. Dept of the Treasury Coronavirus Relief Fund Coronavirus Relief Fund Subtotal U.S. Dept of the Treasury U.S. Department of Transportation (DOT): National Priority Safety Programs Subtotal U.S. Department of Transportation (DOT) – Highway Safety Cluster	21.019 20.616 12.UNK	Oregon Health Authority Oregon Department of Transportation CytoSorbents, Inc.	167760 M1CPS-20-45-01 SRA-18-081		45,000 388,493 433,493 102,859 102,859
Coronavirus Relief Fund Coronavirus Relief Fund Subtotal U.S. Dept of the Treasury U.S. Department of Transportation (DOT): National Priority Safety Programs Subtotal U.S. Department of Transportation (DOT) – Highway Safety Cluster	21.019 20.616 12.UNK	Oregon Health Authority Oregon Department of Transportation CytoSorbents, Inc.	167760 M1CPS-20-45-01 SRA-18-081		<u>388,493</u> <u>433,493</u> <u>102,859</u> <u>102,859</u>
Coronavirus Relief Fund Subtotal U.S. Dept of the Treasury U.S. Department of Transportation (DOT): National Priority Safety Programs Subtotal U.S. Department of Transportation (DOT) – Highway Safety Cluster	21.019 20.616 12.UNK	Oregon Health Authority Oregon Department of Transportation CytoSorbents, Inc.	167760 M1CPS-20-45-01 SRA-18-081		388,493 433,493 102,859 102,859
Subtotal U.S. Dept of the Treasury U.S. Department of Transportation (DOT): National Priority Safety Programs Subtotal U.S. Department of Transportation (DOT) – Highway Safety Cluster	20.616 12.UNK	Oregon Department of Transportation	M1CPS-20-45-01 SRA-18-081		433,493 102,859 102,859
U.S. Department of Transportation (DOT): National Priority Safety Programs Subtotal U.S. Department of Transportation (DOT) – Highway Safety Cluster	12.UNK	CytoSorbents, Inc.	SRA-18-081		102,859 102,859
National Priority Safety Programs Subtotal U.S. Department of Transportation (DOT) – Highway Safety Cluster	12.UNK	CytoSorbents, Inc.	SRA-18-081		102,859
U.S. Department of Defense (DOD):				_	(0)
				_	
Defense Programs Defense Programs				_	(8) 730
Subtotal U.S. Department of Defense (DOD)					722
U.S. Department of Health and Human Services (HHS):					
Public Health Emergency Preparedness	93.069	Oregon Health Authority, HIth Svcs Div, Public Hea	168656	-	20,099
Blood Disorder Program: Prevention, Surveillance, and Research Blood Disorder Program: Prevention, Surveillance, and Research	93.080 93.080	American Thrombosis and Hemostasis Network American Thrombosis and Hemostasis Network	ATHN2015001-X-5 ATHN2020CDC-X-01	201,508 28,354	210,305 84,715
Subtotal Assistance listing 93.080				229,862	295,020
Affordable Care Act (ACA) Personal Responsibility Education Program	93.092	Oregon Health Authority	163785	_	134,041
Food and Drug Administration Research	93.103	Children's Hospital Los Angeles	RGF011721-A	_	30,305
Maternal and Child Health Federal Consolidated Programs	93.110	Boston University Medical Campus (BUMC)	4500003304	—	37,952
Maternal and Child Health Federal Consolidated Programs Maternal and Child Health Federal Consolidated Programs	93.110 93.110	Boston University Medical Campus (BUMC) Family Voices	4500002753 2020-442		104,193 7,500
Subtotal Assistance listing 93.110					149,645
Emergency Medical Services for Children	93.127	State University of New York at Buffalo	R1192439		14,430
Emergency Medical Services for Children	93.127	Univ. of Texas at Austin	UTA20-001233		49,954
Subtotal Assistance listing 93.184					64,384
Injury Prevention and Control Research and State and Community Based Programs	93.136	Oregon Health Authority	167851	—	66,512
Disabilities Prevention	93.184	Univ. of Alabama at Birmingham	000512145-SC008	24,463	28,156
Grants to States to Support Oral Health Workforce Activities	93.236	Oregon Health Authority	143021-2	6,500	170,290
Substance Abuse and Mental Health Services: Projects of Regional and National Significance	93.243	Oregon Health Authority	159428	_	33.151
Projects of Regional and National Significance	93.243	Oregon Health Authority	159428		7,985
Subtotal Assistance listing 93.243					41,136
Sickle Cell Treatment Demonstration Program	93.365	Center for Comprehensive Care & Diagnosis of Inherited Blood Disorders	CIBDIX2014HRSA-OHSU-07	_	23,256
Sickle Cell Treatment Demonstration Program	93.365	Center for Comprehensive Care & Diagnosis of Inherited Blood Disorders	CIBDX2014HRSA-OHSU-06		2,740
Subtotal Assistance listing 93.365					25,996

Schedule of Expenditures of Federal Awards

Federal grantor/pass-through grantor/program or cluster title	Assistance listing number	Pass-through entity name	Pass-through entity identifying number	Passed through to subrecipients	Total federal expenditures
Integrated Care for Kids Model	93.378	Oregon Health Authority	164167	\$ 110,100	856,539
Native American Programs	93.612	Northwest Portland Area Indian Health Board	C18-22	_	11,635
Opioid STR Opioid STR Opioid STR Opioid STR Opioid STR Opioid STR Opioid STR	93.788 93.788 93.788 93.788 93.788 93.788 93.788 93.788	Oregon Health Authority Oregon Health Authority Oregon Health Authority Oregon Health Authority Oregon Health Authority Oregon Health Authority Oregon Health Authority	#157416 158613 162151 166100 166329 167939 Agreement# 157416		(57) 50,160 402,842 399,940 144,464 30,584 (109)
Subtotal Assistance listing 93.788				16,031	1,027,824
National Bioterrorism Hospital Preparedness Program	93.889	Oregon Health Authority	161611	-	12,375
HIV Emergency Relief Project Grants HIV Emergency Relief Project Grants HIV Emergency Relief Project Grants HIV Emergency Relief Project Grants HIV Emergency Relief Project Grants	93.914 93.914 93.914 93.914 93.914 93.914	Multnomah County Health Department Multnomah County Health Department Multnomah County Health Department Multnomah County Health Department Multnomah County Health Department	HD-IGA-E-10999-21019 HD-IGA-E-12022-2020 HD-IGA-E-12023-2020 HD-IGA-E-12025-2020 TBD	 90,091	(1,512) 9,053 263,373 676,845 23,419
Subtotal Assistance listing 93.914				90,091	971,178
HIV Care Formula Grants HIV Care Formula Grants	93.917 93.917	Multnomah County Health Department Multnomah County Health Department	HD-IGA-E-10839-2019 HD-IGA-E-12041-2020		(564) 242,525
Subtotal Assistance listing 93.917					241,961
Block Grants for Community Mental Health Services Block Grants for Community Mental Health Services	93.958 93.958	Oregon Health Authority, Health Services Division Oregon Health Authority	159409 159412		690,231 643,606
Subtotal Assistance listing 93.958					1,333,837
Maternal and Child Health Services Block Grant to the States Maternal and Child Health Services Block Grant to the States Maternal and Child Health Services Block Grant to the States	93.994 93.994 93.994	Oregon Health Authority Oregon Health Authority Oregon Health Authority	143021 143021 143021-2	(12,000) — 681,303	(12,000) (578) 1,674,789
Subtotal Assistance listing 93.994				669,303	1,662,211
DHHS Programs DHHS Programs DHHS Programs DHHS Programs	93.UNK 93.UNK 93.UNK 93.UNK	American Academy of Family Physicians Foundation Lewin Group Lewin Group Vanderbilt Univ.	None TLG17008-5645.08 TLG17010-5645.08 VUMC89536		623 231,903 193,636 5,722
Subtotal Assistance listing 93.UNK					431,884
Subtotal U.S. Department of Health and Human Services (HHS)				1,146,350	7,575,028
Total Other awards – Indirect Programs				1,146,350	8,350,934
Total Other Awards				\$3,600,973	65,813,475

Schedule of Expenditures of Federal Awards

Year ended June 30, 2021

Federal grantor/pass-through grantor/program or cluster title	Assistance listing number	Program title	 Passed through to subrecipients	Total Federal expenditures
Student Financial Assistance – Direct Programs:				
U.S. Department of Education	84.007	Federal Supplemental Educational Opportunity Grants (FSEOG)	\$ s —	81,725
U.S. Department of Education	84.033	Federal Work-Study Program (FWS)	-	6,920
U.S. Department of Education	84.038	Federal Perkins Loan Program (FPL) (note 4)	-	4,565,718
U.S. Department of Education	84.063	Federal Pell Grant Program (PELL)	-	1,114,025
U.S. Department of Education	84.268	Federal Direct Student Loans – Subsidized	—	2,434,236
U.S. Department of Education	84.268	Federal Direct Student Loans – Unsubsidized	—	38,971,052
U.S. Department of Education	84.268	Federal Direct Parent Loans	_	668,742
U.S. Department of Education	84.268	Federal Direct Grad PLUS Loan		24,575,361
Assistance listing 84.268 Sub-total				66,649,391
U.S. Department of Education Total				72,417,779
U.S. Department of Health and Human Services (DHHS)	93.264	Nurse Faculty Loan Program (NFLP) (note 4)	_	886,439
U.S. Department of Health and Human Services (DHHS)	93.342	Health Professions Student Loan – Dental (note 4)	_	6.112.055
U.S. Department of Health and Human Services (DHHS)	93.342	Health Professions Student Loan – Primary Care Medical (note 4)	_	186,149
Assistance listing 93.342 Sub-total				6,298,204
				0 700 057
U.S. Department of Health and Human Services (DHHS)	93.364	Nursing Student Loan – Undergraduate (note 4)	—	2,798,657
U.S. Department of Health and Human Services (DHHS)	93.364	Nursing Student Loan – Nursing Graduate (note 4)		187,819
Assistance listing 93.364 Sub-total				2,986,476
U.S. Department of Health and Human Services (DHHS)	93.925	Scholarships for Health Professions Students from Disadvantaged Backgrounds		649,340
U.S. Department of Health and Human Services (DHHS) Total				10,820,459
Student Financial Assistance – Direct Programs Total				83,238,238
Federal Awards Total			\$ 63,415,017	483,708,271

See accompanying notes to schedule of expenditures of federal awards and independent auditors' report on compliance for each major federal program; report on internal control over compliance; and report on schedule of expenditures of federal awards required by the Uniform Guidance.

Notes to Schedule of Expenditures of Federal Awards

Year ended June 30, 2021

(1) Basis of Presentation

The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of Oregon Health & Science University (OHSU) under programs of the federal government for the year ended June 30, 2021. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200 (2 CFR 200), *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of OHSU, it is not intended to and does not present the financial position, changes in its financial position, or cash flows of OHSU.

(2) Summary of Significant Accounting Policies

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

(3) Indirect Cost Rate

OHSU has elected not to use the 10% de minimis indirect cost rate allowed under the Uniform Guidance.

(4) Federal Student Loan Programs

The federal student loan programs listed below are administered directly by OHSU, and balances and transactions relating to these programs are included in OHSU's financial statements. The basis used to determine loans expended shown on the Schedule is the amount of new loans made or received during the fiscal year plus the balance of loans from previous years for which the federal government imposes continuing compliance requirements, plus any interest subsidy, cash, or administrative cost allowance received.

	Assistance listing number		Loans outstanding at the beginning of the fiscal year	New loans processed during the fiscal year	Administrative cost	Total loans on the schedule of expenditures of federal awards	Outstanding balance at June 30, 2021
Perkins loans	84.038	\$	4,565,718	_	_	4,565,718	3,425,586
Nursing faculty loans	93.264		552,831	333,608	_	886,439	783,792
Health professional loans – Dental	93.342		4,802,357	1,309,698	_	6,112,055	5,427,207
Health professional loans – Primary care	93.342		186,149	_	_	186,149	112,893
Nursing student loans – Undergraduate	93.364		2,195,822	602,835	_	2,798,657	2,386,889
Nursing student loans – Graduate	93.364	_	155,027	32,792		187,819	168,832
		\$_	12,457,904	2,278,933		14,736,837	12,305,199

Notes to Schedule of Expenditures of Federal Awards

Year ended June 30, 2021

(5) Student Financial Aid Expenditures and Administrative Costs

Student financial aid program expenditures represent payments to students, which include each program's cost sharing or matching amount. The student financial aid program expenditures include amounts representing administrative allowances. Administrative allowances totaling \$4,548 were claimed in the fiscal year ended June 30, 2021.

(6) Personal Protective Equipment Receipts (Unaudited)

OHSU has not received any donated personal protective equipment (PPE).

(7) Provider Relief Funds

During the year ended June 30, 2020, OHSU was the recipient of funds under the CARES Act Provider Relief Fund program. In accordance with guidance provided in the OMB 2 CFR 200 Part 200 Compliance Supplement, such amounts are reflected, to the extent utilized, in the Schedule of Expenditure of Federal Awards for the year ended June 30, 2021.

Schedule of Findings and Questioned Costs Year ended June 30, 2021

(1) Summary of Auditors' Results

- (a) The type of report issued on whether the financial statements were prepared in accordance with generally accepted accounting principles: **Unmodified**
- (b) Internal control deficiencies over financial reporting disclosed by the audit of the financial statements:
 - Material weaknesses: No
 - Significant deficiencies: None Reported
- (c) Noncompliance that is material to the financial statements: No
- (d) Internal control deficiencies over the major programs disclosed by the audit:
 - Material weaknesses: No
 - Significant deficiencies: None reported
- (e) Type of report issued on compliance for the major programs: Unmodified
- (f) Audit findings that are required to be reported in accordance with 2 CFR 200.516(a): No
- (g) The major programs:
 - Provider Relief Fund Assistance listing number 93.498
 - Research and Development Cluster Assistance listing number 10.310, 11.012, 12.351, 12.420, 12.750, 12.800, 12.910, 16.560, 16.838, 43.001, 43.003, 47.041, 47.049, 47.070, 47.074, 47.075, 47.076, 66.716, 81.049, 84.324, 93.059, 93.073, 93.077, 93.080, 93.103, 93.110, 93.113, 93.121, 93.127, 93.136, 93.155, 93.157, 93.172, 93.173, 93.191, 93.213, 93.226, 93.233, 93.236, 93.242, 93.243, 93.247, 93.262, 93.273, 93.279, 93.286, 93.307, 93.310, 93.343, 93.350, 93.351, 93.352, 93.353, 93.359, 93.360, 93.361, 93.365, 93.393, 93.394, 93.395, 93.396, 93.397, 93.398, 93.399, 93.433, 93.650, 93.732, 93.837, 93.838, 93.839, 93.846, 93.847, 93.853, 93.855, 93.859, 93.860, 93.865, 93.866, 93.867, 93.879, 93.889, 93.913, 93.945, 93.953, 93.970, 93.974, 93.986, 97.044, 98.001, 12.Unknown, 64.Unknown, 81.Unknown, 93.Unknown, 97.Unknown
- (h) Dollar threshold used to distinguish between Type A and Type B programs: \$3,000,000
- (i) Auditee qualified as a low-risk auditee: Yes
- (2) Findings Relating to the Financial Statements Reported in Accordance with *Government Auditing Standards*

None.

(3) Findings and Questioned Costs Relating to Federal Awards

None.